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Abstract	  Bacterial	   infections	   have	   a	   large	   impact	   on	   the	   health	   of	   the	   general	   public,	  however	   individuals	   with	   cystic	   fibrosis	   (CF)	   are	   immensely	   susceptible	   to	  acquire	   pulmonary	   infections	   with	   environmental	   bacteria,	   viruses	   and	   fungal	  species.	  Ultimately	  pulmonary	   infections	   are	   the	  major	   cause	  of	  morbidity	   and	  mortality	  in	  CF	  patients.	  The	  genetic	  defect	  of	  CF	  patients	  alters	  the	  environment	  of	   the	   airways	   aiding	  P.	   aeruginosa	   to	   persist	   and	   establish	   chronic	   infections.	  Chronic	  P.	  aeruginosa	   infections	   in	  CF	  patients	  are	  characterized	  by	  conversion	  to	   a	   mucoid	   and	   intensive	   biofilm	   formation.	   Different	   microenvironments	  within	   the	   airways	   of	   the	   patients	   lead	   to	   phenotypic	   and	   genotypic	  diversification,	  sculpting	  the	  bacteria	  to	  become	  an	  efficient	  colonizer	  despite	  the	  environmental	   niche	   in	   the	   CF	   airways.	   Despite	   intensive	   antibiotic	   treatment	  and	   a	   profound	   immunologic	   response,	   the	   infections	   persist.	   The	   ongoing	  polymorphonuclear	   leukocyte	   (PMN)	   immune	   response	   contributes	   to	   the	  generation	  of	  oxygen	  changes	  in	  the	  CF	  airway	  environments	  in	  a	  major	  way.	  P.	  
aeruginosa	  is	  capable	  of	  growing	  in	  anoxic	  environments	  which	  makes	  it	  capable	  of	   adapting	   to	   different	   niches	   of	   the	   airways,	   while	   the	   ongoing	   immune	  response	   gradually	   leads	   to	   pulmonary	   deterioration.	   Physiologically	   different	  oxygen	   environments	   are	   present	   in	   the	   different	   compartments	   of	   the	   CF	  airways	   and	   this	   has	   a	   profound	   impact	   on	   bacterial	   growth	   and	   the	   effect	   of	  chemotherapeutics	  to	  eradicate	  the	  bacteria.	  	  	   Several	   in	   vivo	   and	   in	   vitro	   model	   systems	   are	   available	   to	   study	   CF	  associated	  bacterial	  infections.	  In	  vivo	  systems	  like	  the	  widely	  used	  mouse	  model	  primarily	   lack	   essential	   CF	   related	   traits	   as	   the	   development	   of	   the	   significant	  spontaneous	   lung	  disease.	  In	  vitro	  systems	  like	  the	  flow	  cell	  system	  has	  proven	  essential	   aspects	   on	   biofilm	   formations,	   however	   generates	   highly	   artificial	  biofilms	  that	  lack	  several	  CF	  airway	  scenarios.	  	  	  The	  driving	  force	  and	  the	  heart	  of	  this	  project	  has	  its	  origin	  in	  the	  study	  of	  the	  role	  played	  by	  P.	  aeruginosa	  in	  the	  CF	  airways.	  One	  of	  the	  aims	  of	  this	  thesis	  was	   to	  develop	  an	  accurate	   tool	   for	  growing	  biofilms	   that	  can	  mimic	   the	  cystic	  fibrosis	   airways,	   emulating	   one	   of	   the	   most	   important	   characteristics	   of	   the	  
	   viii	  
human	   airways,	   the	   oxygen	   environments.	   Microfluidic	   approaches	   that	   allow	  biofilm	   formation	   under	   controllable	   oxygen	   concentrations,	   and	   furthermore	  enable	   migration	   between	   the	   individual	   compartments,	   are	   proposed	   in	   this	  thesis.	  An	  approach	  to	  mimic	  the	  accumulation	  of	  thickened	  mucus	  that	  supports	  biofilm	  growth	  in	  a	  3D	  matrix	  within	  the	  CF	  airways	  is	  furthermore	  proposed.	  	  The	   use	   of	   our	   already	   set	   flow	   cell	   systems	   was	   extended	   to	   another	  biofilm	   forming	   S.	   cerevisiae.	   The	   potential	   positive	   impact	   that	   the	   flow	   cell	  system	   can	   have	   on	   studies	   with	   other	   fugal	   species	   as	   the	   opportunistic	  pathogens,	  A.	  fumigatus	  or	  C.	  albicans,	  is	  without	  a	  doubt	  highly	  relevant.	  	  	   The	   presented	   microfluidic	   systems	   are	   in	   line	   with	   the	   thought	   of	  developing	  in	  vitro	  systems	  to	  obtain	  optimal	  conditions	  for	  CF	  research,	  replace	  animal	  models	  and	  reduce	  chemicals	  used.	  
	  
	   	  ix	  
Resume	  Bakterielle	   infektioner	   kan	   have	   en	   stor	   indvirkning	   på	   helbredstilstanden	   for	  normalt	   raske	   mennesker,	   men	   personer	   med	   cystisk	   fibrose	   (CF)	   er	   utroligt	  modtagelige	   for	   at	   erhverve	   sig	   lungeinfektioner	   med	   bakterier	   fra	   de	   nære	  omgivelser,	   vira	   og	   svampearter.	   Pulmonære	   infektioner	   er	   den	   væsentligste	  årsag	   til	  morbiditet	  og	  dødsfald	  hos	  CF	  patienter.	  Den	  genetiske	  defekt	  hos	  CF-­‐patienter	  medfører	  et	  ændret	  miljø	  i	  luftvejene	  og	  medvirker	  til,	  at	  P.	  aeruginosa	  vedbliver	   og	   etablerer	   kroniske	   infektioner.	  Kroniske	  P.	   aeruginosa	   infektioner	  hos	   CF-­‐patienter	   er	   kendetegnet	   ved	   omdannelse	   til	   en	   mucoid	   fænotype	   og	  intensiv	   biofilmdannelse.	   Forskellige	  mikromiljøer	   i	   luftvejene	   hos	   patienterne	  fører	   til	   fænotypisk	   og	   genotypisk	   diversificering,	   modellerer	   bakterierne	   til	  effektivt	  at	  kunne	  kolonisere	  de	  forskellige	  nicher	  i	  CF	  luftvejene.	  Trods	  intensiv	  antibiotika	   behandling	   og	   kraftige	   immunologiske	   reaktioner,	   fortsætter	   de	  bakterielle	   infektioner.	   Det	   vedvarende	   polymorphonucleære	   neutrophile	  granulocyt	   (PMN)	   immunrespons	   bidrager	   til	   dannelsen	   af	   ændringer	   i	  luftvejenes	  oxygen	  miljøer	  hos	  CF	  patienter.	  P.	  aeruginosa	  er	  i	  stand	  til	  at	  vokse	  i	  iltfattige	   miljøer,	   der	   gør	   dem	   i	   stand	   til	   at	   tilpasse	   sig	   forskellige	   nicher	   i	  luftvejene,	  mens	   det	   igangværende	   immunrespons	   gradvist	   fører	   til	   pulmonær	  ødelæggelse.	   Fysiologiske	   forskelligheder	   i	   oxygen	   miljøerne	   er	   tilstede	   i	  forskellige	   dele	   af	   CF	   luftvejene,	   og	   har	   stor	   indflydelse	   på	   bakteriel	   vækst	   og	  effekt	  af	  den	  kemoterapeutiske	  behandling	  af	  infektionerne.	  Adskillige	  in	  vivo	  og	  in	  vitro	  modelsystemer	  er	  tilgængelige	  for	  studier	  af	  CF	  relaterede	  bakterielle	   infektioner.	  In	  vivo	  systemer,	  som	  den	  bredt	  anvendte	  musemodel	  mangler	  primært	  essentielle	  CF	  relaterede	  træk,	  som	  udviklingen	  af	  spontan	   lungesygdom.	   In	   vitro	   systemer,	   som	   flowcelle	   systemet,	   har	   givet	  væsentlige	   informationer	   om	   aspekter	   af	   biofilm	   dannelse,	   men	   tillader	   kun	  dannelse	   af	   meget	   kunstige	   biofilm	   med	   mangel	   af	   adskillige	   CF	   luftvejs	  scenarier.	  Hovedpunkterne	   i	   dette	   projekt	   er	   inspireret	   af	   luftvejene	   hos	   CF	  patienter	   og	   den	   rolle	   som	  P.	   aeruginosa	  har	   i	   respiratoriske	   infektioner.	   Et	   af	  formålene	  med	  denne	  afhandling	  var	  at	  udvikle	  et	  præcist	  redskab	  til	  dyrkning	  af	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biofilm,	   som	   kan	   efterligne	   cystisk	   fibrose	   luftvejene	   og	   disses	   ændrede	   ilt	  miljøer.	   Mikrofluide	   tilgangsvinkler,	   der	   tillader	   biofilmformation	   under	  kontrollerbare	   iltkoncentrationer	   og	   endvidere	   tillader	   migration	   mellem	   de	  enkelte	   rum,	   er	   foreslået	   i	   denne	   afhandling.	   En	   tilgang	   til	   at	   efterligne	  akkumulering	  af	   fortykket	   slim,	  der	  understøtter	  biofilmvækst	   i	   en	  3D	  matrix	   i	  CF	  luftvejene,	  er	  ydermere	  præsenteret.	  Brugen	   af	   vores	   allerede	   etablerede	   flow	   cellesystem	   blev	   udvidet	   til	  biofilmdannelse	  med	  S.	   cerevisiae.	  Den	  potentielle	  positive	  effekt	   som	   flowcelle	  systemet	   kan	   have	   på	   andre	   studier	   med	   svampearter	   af	   opportunistiske	  patogener	  som	  f.eks.	  A.	  fumigatus	  eller	  C.	  albicans,	  er	  utvivlsomt	  af	  stor	  relevans.	  	  De	  præsenterede	  mikrofluide	  systemer	  er	  i	  overensstemmelse	  med	  tanken	  om	  at	  udvikle	   in	   vitro	   systemer	   til	   at	   opnå	   optimale	   betingelser	   for	   CF	   forskning,	  erstatte	  dyremodeller	  og	  reducere	  mængden	  af	  benyttede	  kemikalier.	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   1	  
Introduction	  
1 Cystic	  fibrosis	  
1.1 Disease	  characteristics	  	  Cystic	  fibrosis	  (CF)	  is	  one	  of	  the	  most	  common	  recessive	  genetic	  disorders	  in	  the	  Caucasian	   population	   [8].	   	   CF	   is	   a	   deadly	   disease	   that	   leads	   to	   a	   slow	  deterioration	   of	   the	   patient’s	   health	   despite	   massive	   efforts	   to	   circumvent	  disease-­‐derived	  characteristics.	  	  	  	  
Woe to that child which when kissed on the forehead tastes salty. He is bewitched 
and soon must die [9]. This	   old	   folklore	   describes	   one	   of	   the	   implications	   and	   ways	   in	   which	  children	   with	   possible	   CF	   are	   diagnosed.	   Sweat	   tests	   that	   are	   consistently	  positive	   for	   high	   salt	   concentrations	   give	   indications	   of	   a	   CF	   diagnosis.	   Such	  indications	  do	  however	  need	  to	  be	  correlated	  with	  other	  tests	  and	  family	  history	  in	  order	  to	  ascertain	  the	  diagnosis,	  as	  other	  conditions	  can	  lead	  to	  elevated	  sweat	  electrolytes	   [10,	   11].	   The	   genetic	  match	   of	   two	   parental	  malfunctioning	   genes	  leads	   to	  a	  25%	  risk	  of	  a	  CF	  child.	  Approximately	  70.000	  people	  are	  affected	  by	  the	   disease	   worldwide,	   with	   the	   late	   30’es	   as	   an	   estimated	   predicted	   age	   of	  survival	   	  (American	  cystic	  fibrosis	  patients,	  2009)	  (www.cff.org).	  The	  disease	  is	  established	   through	   a	   deficiency	   in	   the	   cystic	   fibrosis	   transmembrane	  conductance	  regulator	  protein	  (CFTR)	  [12].	  Approximately	  1900	  mutations	  have	  been	   found	   in	   the	   CFTR	   gene,	   which	   have	   been	   classified	   according	   to	   defect	  (listed	  at	  the	  Cystic	  Fibrosis	  Mutation	  Database	  [13]).	  Approximately	  70%	  of	  the	  mutations	   observed	   in	   CF	   patients	   result	   from	   a	   deletion	   mutation	   of	   a	  phenylalanine	  residue	  at	  position	  508,	  the	  ΔF508	  mutation	  [14].	  The	  effect	  of	  the	  deletion	   is	   manifested	   by	   a	   misfolding	   of	   the	   maturing	   proteins	   in	   the	  endoplasmic	   reticulum,	   resulting	   in	   an	   ubiquitin	   mediated	   degradation	   of	   the	  CFTR	  proteins	   [15].	  The	  direct	  effect	   is	   that	  very	   few	   functional	  proteins	  reach	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the	  plasma	  membrane	  [16].	  Several	  other	  consequences	  of	  CFTR	  mutations	  are	  possible,	   such	   as	   frame	   shifts,	   truncation	   of	   the	   protein	   and	   instability	   of	   the	  mRNA	   with	   outcomes	   of	   e.g.	   incorporation	   of	   simply	   functionally	   impaired	  proteins	  [15,	  16].	  
1.2 The	  CFTR	  protein	  CFTR	  is	  a	  glycoprotein	  located	  on	  the	  apical	  side	  of	  predominantly	  epithelial	  cells	  and	   is	   ordinarily	   expressed	   in	   gland-­‐rich	   organs	   such	   as	   the	   airways,	   colonic,	  pancreas,	   reproductive	   tract,	   sweat	   glands	   and	   hepatic	   bile	   ducts,	   where	   it	  functions	  as	  a	  cAMP-­‐regulated	  chloride	  channel	  [17].	  The	  1480	  amino	  acid	  CFTR	  protein	   is	   a	   member	   of	   the	   ATP-­‐binding	   cassette	   (ABC)	   superfamily.	   It	   is	  assembled	   with	   two	   membrane-­‐spanning	   protein	   domains,	   two	   nucleotide-­‐binding	  domains	  and	  a	  regulatory	  domain	  [18,	  19].	  Phosphorylation	   of	   the	   regulatory	   domain	   by	   the	   cAMP-­‐dependent	   protein	  kinase	  (PKA)	  is	  essential	   for	  opening	  of	  the	  chloride	  channel.	   It	   is	  believed	  that	  the	  importance	  of	  the	  CFTR	  protein	  is	  not	  only	  restricted	  to	  chloride	  transport,	  but	  also	  due	  to	   its	   interaction	  with	  other	   transporters,	  by	  either	  obstructing	  or	  strengthening	  their	  ion	  transportation	  [17,	  20].	  	  
1.3 CF	  epithelia	  Epithelial	   cells	   of	   several	   organs	   are	   affected	   by	   CFTR	   deficiencies,	   causing	   a	  range	  of	  clinical	  problems	  for	  the	  CF	  patients.	  The	  defective	  CFTR	  proteins	  lead	  to	  failure	  in	  absorption	  of	  hypertonic	  NaCl	  in	  the	  sweat	  glands	  [21].	  In	  the	  lungs	  of	  CF	  patients,	   there	   is	   a	  dysfunctional	   regulation	  of	   isotonic	   volume	   transport	  [22].	  Dysfunction	   in	  CFTR	   leads	   to	  a	  decrease	   in	   chloride	   ion	   transport	   and	  an	  accelerated	  uptake	  of	  Na+	  on	  the	  apical	  membrane	  side	  of	   the	  airway	  epithelial	  cells	  [23].	  	  Hyperabsorption	  of	  Na+	  results	  in	  a	  dehydration	  of	  the	  airway	  surface	  liquid.	  
1.4 Clinical	  manifestations	  of	  CF	  CF	   related	   disorders	   range	   from	   the	   male	   reproductive	   tract	   to	   multi-­‐organ	  deficiencies	   in	   the	   gastrointestinal	   tract,	   exocrine	   pancreas,	   intestine,	   exocrine	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sweat	   glands,	   hepatobiliary	   system	   and	   respiratory	   deficiencies	   that	   is	   the	  primary	  course	  of	  morbidity	  and	  mortality	  in	  CF	  patients	  [23,	  24].	  	  Exocrine	   pancreatic	   insufficiency	   is	   characterized	   by	   deficiencies	   in	  production	   of	   digestive	   enzymes	   leading	   to	   malabsorption	   of	   fat	   with	  manifesting	   steatorrhea,	   fat	   soluble	   vitamins,	   nutrients	   and	   poor	   growth	  capabilities	   [24].	   The	   main	   treatment	   for	   pancreatic	   insufficiency	   include	  additive	   pancreatic	   enzymes,	   vitamins	   and	   a	   high	   calorie	   diet	   [25].	  Approximately	  3-­‐10%	  of	  CF	  patients	  develop	  severe	  liver	  disease	  characterized	  by	   cirrhosis.	   Fatal	   liver	   disease	   is	   reported	   in	   around	   2-­‐3%	   and	   is	   the	   second	  most	  frequent	  cause	  of	  CF	  related	  deaths	  [26].	  Intestinal	  obstruction	  syndromes	  are	  frequent	  problems	  in	  CF	  patients.	  	  Intestinal	  obstruction	  can	  be	  treated	  with	  laxatives,	  intestinal	  lavage	  or	  intestinal	  surgery	  in	  very	  complicated	  cases.	  Other	  consequences	  are	  male	  infertility	  by	  obstruction	  of	  the	  vas	  deferens	  and	  female	  patients	   show	   fertility	   problems	   due	   to	   severe	   obstruction	   of	   the	   cervix	   by	  accumulation	   of	   viscous	   mucus	   [24].	   	   Despite	   multi	   organ	   deficiencies,	   the	  primary	  clinical	  problems	  arise	  with	  severe	  chronic	  infections	  of	  the	  airways.	  	  	  
1.5 Correlated	  implications	  in	  the	  airways	  An	   array	   of	   events	   leads	   to	   maintenance	   of	   the	   airway	   surface	   liquid	   	   (ASL)	  within	  the	  airways	  of	  healthy	  individuals.	  Defective	  CFTR	  leads	  to	  a	  dehydrating	  scenario	  of	   the	  airway	  surfaces	  due	   to	   the	  defective	  chloride	   ion	   transport	   [27,	  28].	  The	   importance	  of	  ASL	   is	   connected	   to	   the	   function	  of	   the	  airway	  clearing	  mechanism	   that	   rely	   on	   the	   production	   of	   mucin	   glycoprotein	   molecules	   that	  constitute	  the	  main	  component	  of	  airway	  mucus	  [29,	  30].	  The	  upper	  parts	  of	  the	  human	  airways	  rely	  on	  goblet	  cells	  as	  the	  principal	  secretory	  cells,	  whereas	  the	  Clara	   cells	   dominate	   in	   the	   terminal	   bronchioles	   with	   diameters	   below	  approximately	   2	  mm	   [30].	   In	   this	   part	   of	   the	   airways	   the	   epithelia	   are	   ciliated	  whereas	  the	  respiratory	  zones	  lack	  cilia.	  	  	  The	  mucus	   layer	  of	   the	  human	  airways	  serves	  as	  a	  mechanical	   trap	   for	   inhaled	  materials	   and	   microbes	   [23].	   Efficient	   clearing	   employ	   a	   feature	   in	   which	  entrapment	   of	   inhaled	   particles	   is	   aided	   by	   turbulent	  movement	   of	   the	  mucus	  [5].	  Sufficient	  ASL	  levels	  are	  required	  in	  order	  for	  efficient	  mucus	  transport,	  cilia	  movement.	  The	  periciliary	  liquid	  (PCL)	  fraction	  of	  ASL	  is	  regulated	  by	  Na+	  and	  Cl-­‐	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transport	   and	   is	   the	   basis	   for	   functional	   cilia	   movement,	   which	   requires	   an	  approximately	  7µm	  of	  PCL	  in	  height	  at	  steady-­‐state,	  figure	  1.	  It	  has	  been	  shown	  with	   CF	   epithelia	   cultures	   that	   PCL	   dehydration	   impede	   the	   ciliary	  movement.	  Optimal	   functions	   rely	   on	   coordination	   of	   Na+	   absorption	   and	   Cl-­‐	   secretion	   by	  epithelial	  ion	  transport	  processes	  [31].	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   1.	   	   Electron	   micrograph	   of	   human	   airway	   epithelia.	   Left	   side	   shows	   epithelia	  from	   normal	   subjects	   and	   right	   side	   epithelia	   from	   CF	   subjects.	   Note	   the	   mucus	  deposited	  on	  the	  CF	  fallen	  cilia	  [31].	  	  The	   importance	   of	   the	   liquid	   volume	   is	   portrayed	   by	   the	   capability	   of	   normal	  airway	  epithelia	  to	  reach	  a	  steady	  state	  of	  volume	  absorption	  when	  subjected	  to	  small	   amounts	   of	   excess	   liquid,	   whereas	   CF	   airway	   epithelia	   fail	   to	   halt	  absorption	   at	   a	   physiological	   appropriate	   volume	   [28,	   31].	  Dehydrating	   events	  lead	   to	   physiological	   changes	   of	   the	   airway	  mucus	   layer,	   inflicting	   the	   cilia	   to	  collapse	  towards	  the	  airway	  surfaces,	  Figure	  1.	  The	  CF	  airways	  will	  in	  contrast	  to	  a	   normal	   “sterile”	   environment	   of	   healthy	   humans	   represent	   an	   environment	  prone	  to	  infections	  by	  inhaled	  microorganisms	  due	  to	  the	  impaired	  mucociliary	  clearing	  [27,	  32,	  33].	  	  	  
1.6 Colonization	  of	  the	  CF	  airways	  –	  the	  usual	  suspects	  Several	   aspects	   of	   CF	   pathology	   emphasize	   the	   implications	   generated	   by	   the	  effect	  of	  the	  altered	  mucosal	  surfaces	  in	  the	  CF	  airways.	  From	  the	  early	  years,	  CF	  patients	  suffer	   from	  recurrent	   infections	  by	  an	  array	  of	  microbial	  pathogens	  as	  (i)	  respiratory	  viruses	  (ii)	  bacterial	  species	  from	  the	  normal	  human	  flora	  of	  the	  skin	  and	  respiratory	  tract	  and	  (iii)	  environmental	   fungal-­‐	  and	  bacterial	  species.	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The	  most	   frequently	   involved	   bacteria	   in	   CF	   related	   pulmonary	   infections	   are	  
Pseudomonas	  aeruginosa,	  Candida	  albicans,	  Staphylococcus	  aureus,	  Haemophilus	  
influenza	  and	  Burkholderia	  cepacia	  [34,	  35],	  see	  figure	  2.	  	  The	   colonization	  pattern	   seems	   to	  be	  age	   related,	   as	  S.	   aureus	   and	  H.	   influenza	  have	   most	   frequently	   been	   found	   as	   the	   dominant	   species	   in	   the	   youngest	  patients	   [3].	   P.	   aeruginosa	   eventually	   alters	   the	   colonization	   scenario	   by	  becoming	  the	  dominating	  pathogen	  in	  the	  older	  patients.	  Up	  to	  a	  staggering	  80%	  of	  young	  CF	  adults	  will	  become	  chronically	  infected	  with	  P.	  aeruginosa	  by	  the	  age	  of	  20	  [36-­‐38].	  	  
	  Early	  infections	  are	  typically	  intermittent	  but	  turn	  chronic	  if	  the	  initial	  infection	  remains	  unresolved,	  leaving	  a	  timespan	  of	  approximately	  12	  months	  for	  clearing	  the	   infection	   [39].	   Intermittent	   colonization	   was	   defined	   by	   Høiby	   et	   al.	   as	  continuous	  presence	  of	  P.	  aeruginosa	  in	  the	  lower	  respiratory	  tract	  secretions	  for	  <6	   months	   with	   normal	   levels	   of	   antibodies	   against	   P.	   aeruginosa,	   whereas	   a	  chronic	  infection	  was	  set	  as	  >6	  months	  and/or	  2	  precipitating	  antibodies	  against	  
P.	  aeruginosa	   [40].	  Chronic	   infections	  predominately	  coincides	  with	  conversion	  
	  
Figure	   2.	   Showing	   the	   prevalence	   of	   respiratory	   infections	   in	   CF	   patients	   by	   age.	  Colonization	  and	  infection	  rates	  follow	  an	  age-­‐specific	  trend	  with	  respect	  to	  specific	  bacterial	  pathogens.	  Figure	  adapted	  from	  Goldberg[3]	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of	  P.	  aeruginosa	   from	  a	  nonmucoid	  to	  a	  mucoid	  phenotype,	  which	   is	  associated	  with	  a	  profound	  decline	   in	   the	   lung	   function	   in	  CF	  patients.	   (section	  3.6.1)	   [41,	  42].	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2 Pseudomonas	  aeruginosa	  The	   bacteria	   P.	   aeruginosa	   is	   a	   Gram-­‐negative	   rod-­‐shaped	   bacterium	   that	  belonging	   to	   the	   family	   of	   Pseudomonadaceae	   and	   is	   commonly	   found	   in	  different	   environments	   as	   terrestrial	   and	   aquatic	   [43].	   It	   is	   a	   very	   ubiquitous	  bacterium	   capable	   of	   colonizing	   a	   wide	   range	   of	   kingdoms,	   from	   animals	   to	  plants	  and	  furthermore	  utilize	  a	  wide	  rage	  of	  organic	  compounds	  as	  nutritional	  sources	   [43].	  P.	   aeruginosa	   is,	   unlike	  most	   other	   Pseudomonas	   spp.	   capable	   of	  growing	   at	   temperatures	   up	   to	   42°C,	   with	   an	   optimal	   temperature	   of	   37°C.	  P.	  
aeruginosa	   is	   an	   opportunistic	   pathogen	   capable	   of	   causing	   severe	   nosocomial	  infections	  [44].	  With	  a	   large	  genome	  of	  ∼	  6.3	  Mbp	  (PAO1	  WT	  strain)	  its	  genetic	  makeup	  permits	  flexibility	  making	  it	  a	  highly	  versatile	  settler	  [45].	  
P.	   aeruginosa	   is	   considered	   a	   notorious	   pathogen	   for	   immunocompromised	  patients	   with	   predisposing	   conditions	   as	   leukemia,	   diffuse	   panbronchiolitis,	  AIDS,	  burn	  wounds	  and	  in	  cystic	  fibrosis	  patients	  [46].	  Once	  P.	  aeruginosa	  infects	  a	  patient	  it	  elicits	  ways	  to	  evade	  eradication	  by	  administered	  antibiotic	  and	  the	  immunological	  defense	  systems	  of	  the	  host.	  The	  protective	  battery	  includes	  e.g.	  expression	  and	  secretion	  of	   several	  virulence	   factors	  and	  overproduction	  of	  an	  exopolysaccharide	  alginate	  [41,	  47]	  (see	  section	  3.6.1).	  
2.1 Pseudomonas	  aeruginosa	  in	  CF	  
P.	  aeruginosa	  has	  a	  highly	  versatile	  genetic	  makeup	  allowing	  it	  to	  adapt	  and	  cope	  with	  changes	  in	  its	  environments	  [45].	  Many	  CF	  patients	  become	  colonized	  with	  
P.	  aeruginosa	  early	  in	  their	  childhood	  and	  carry	  this	  infectious	  strain	  for	  the	  rest	  of	   their	   lifetime	   [3].	   So	   what	   makes	   this	   bacterium	   so	   successful	   in	   being	   the	  dominant	  colonizer	  of	  the	  CF	  environment?	  	  
P.	   aeruginosa	   produces	   an	   intricate	   variety	   of	   extracellular	   and	   cellular	   bound	  virulence	   factors	   that	   contribute	   to	   the	   initial	   step	  of	   colonization	   and	   thereby	  achieving	  the	  foundation	  for	  the	  establishment	  of	  enduring	  infections	  [48].	  	  	  
2.2 P.	  aeruginosa	  cell	  associated	  virulence	  factors	  Cell-­‐associated	  virulence	  factors	  include	  adhesion	  structures	  as	  pili	  and	  flagella.	  These	   motility	   driving	   protein	   appendages	   have	   been	   proven	   important	   in	  
	   8	  
adherence	   of	   P.	   aeruginosa	   to	   surface	   moieties.	   Several	   flagella	   genes,	   as	   the	  flagella	  cap	  encoding	  fliD,	  have	  been	  shown	  to	  contribute	  to	  the	  adherence	  to	  e.g.	  respiratory	  mucin	  [49-­‐51].	  This	  might	  actually	   impede	  bacterial	  colonization	  of	  the	  healthy	  airways	  by	  aiding	  to	  the	  mucociliary	  clearing	  mechanism.	  	  Type	   IV	   pili	   driven	   twitching	   motility	   has	   been	   shown	   to	   promote	  attachment	  to	  epithelial	  cells	  [52,	  53].	  Twitching	  motility	  mediated	  by	  type	  IV	  pili	  has	   been	   proven	   important	   in	   the	   formation	   of	   distinctive	   structures	   of	   P.	  
aeruginosa	  biofilms	  [54,	  55].	  Type	  IV	  pili	  act	  as	  a	  major	  virulence	  factor	  in	  acute	  pulmonary	   infections,	   seen	   by	   the	   influence	   of	   pili	   structures	   in	   causing	   an	  inflammatory	  response	  in	  the	  murine	  test	  model	  [56].	  	  	  The	   major	   cell	   wall	   surface	   component	   of	   gram-­‐negative	   bacteria,	  lipopolysaccharide	   (LPS),	   is	   a	   dominating	   contributor	   to	   mediating	   host	  responses	   to	  P.	  aeruginosa	   infections	   [57].	   Interestingly	  environmental	   isolates	  express	  a	  “smooth”	  LPS	  phenotype	  with	  long	  O-­‐polysaccharide	  side	  chains	  while	  strains	  that	  have	  adapted	  to	  the	  CF	  lung	  environment,	  have	  lost	  these	  side	  chains	  (rough	   phenotype)	   [57,	   58].	   Ernst	   and	   co-­‐workers	   have	   shown	   that	   LPS	  structures	   from	   different	   CF	   P.	   aeruginosa	   isolates	   have	   specific	   lipid	   A	  structures,	   characterized	   by	   penta-­‐	   and	   hexa-­‐acylation	   that	   is	   associated	   with	  increased	   immunogenicity	   [58].	   Although	   increasing	   the	   sensitivity	   towards	  P.	  
aeruginosa	  LPS	  structures,	  they	  do	  not	  stimulate	  as	  potent	  macrophage	  cytokine	  responses	  as	  E.	  coli	  or	  Salmonella	  LPS	  [58].	  The	  characteristics	  of	  the	  negatively	  charged	  LPS	  structures	  correlate	  with	  the	  use	  of	  cationic	  antimicrobial	  peptides	  in	  the	  treatment	  of	  infected	  patients.	  Genetic	  modifications	  of	  the	  lipid	  A	  moieties	  of	   the	   LPS	   structures	   has	   been	   shown	   as	   an	   underlying	   mechanism	   for	   the	  adaptive	   resistance	   induction	   towards	   cationic	   antimicrobial	   peptides	   as	   the	  polymyxins	  (see	  section	  7).	  	  
2.3 P.	  aeruginosa	  extracellular	  virulence	  factors	  
P.	   aeruginosa	   produces	   an	   array	   of	   secreted	   virulence	   factors	   that	   following	  initial	   colonization	  can	  cause	  extensive	  damage	   to	   the	  host	   tissue,	  bloodstream	  invasion	  and	  spreading	  of	  the	  infection.	  	  Exoenzyme	   S	   and	   Exotoxin	   A	   are	   two	   secreted	   exotoxins,	   with	   Exotoxin	   A	  causing	   local	   tissue	   damage	   and	   bacterial	   invasion.	   This	   is	   effectuated	   by	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inhibition	  of	  protein	  synthesis	  due	  to	  inactivation	  of	  elongation	  factor	  2	  resulting	  in	   cell	   death	   [59,	   60].	   Exoenzyme	  S	  may	  be	   responsible	   for	  direct	   damage	   and	  bacterial	   propagation,	   as	   well	   as	   disruption	   of	   eukaryotic	   signal	   transduction	  [61].	   In	   addition,	   P.	   aeruginosa	   produce	   proteases	   and	   hemolysins	   that	  furthermore	  contribute	   to	   the	   invasive	  strategy.	  The	  elastases	   (LasA	  and	  LasB)	  are	   members	   of	   the	   zinc	   metalloprotease	   family	   and	   are	   responsible	   for	   the	  degradation	  of	  host	  elastin,	  which	  is	  important	  in	  the	  expansion	  and	  contraction	  of	  the	  lungs	  [62].	  The	  elastases	  interfere	  with	  several	  components	  of	  the	  immune	  system,	   as	   inactivation	   of	   human	   immunoglobulins	   IgG,	   IgA	   as	   well	   as	  components	   of	   the	   complement	   system	   [63,	   64].	   The	   additional	   proteases,	  alkaline	   protease	   and	   protease	   IV	   are	   important	   contributors	   to	   pathogenesis	  and	  have	  been	  found	  in	  sputum	  samples	  from	  CF	  patients	  [65-­‐67].	  Rhamnolipid	  and	  phospholipase	  C	  are	   two	  hemolysins	  with	   the	   capability	  of	  breaking	  down	  lipids	  and	  lectins	  structures.	  Phospholipase	  C	  decreases	  the	  respiratory	  burst	  of	  neutrophils	  and	  induces	  local	  production	  of	  cytokines	  as	  tumor	  necrosis	  factor	  α	  (TNF-­‐α),	  macrophage	  inflammatory	  protein	  1α	  and	  2	  (MIP-­‐1α	  and	  MIP-­‐2),	  IL-­‐1β	  in	   addition	   to	   stimulating	   neutrophil	   infiltration,	   thereby	   contributing	   to	   the	  inflammatory	  response	   in	   the	  CF	  airways	  [68].	  Rhamnolipids	  have	  equivalently	  been	   found	   in	   sputum	   samples	   from	  P.	   aeruginosa	   infected	   CF	   patients	  where	  they	   are	   found	   in	   exceptionally	   high	   concentrations	   [69].	   Rhamnolipids	   have	  detergent	   like	   properties	   that	   break	   down	   the	   phospholipid	   surfactant	   of	   the	  lungs	  as	  well	  as	   inhibiting	  ciliary	   function	  of	   the	  human	  respiratory	  epithelium	  [70,	  71].	  The	  direct	  effects	  of	  rhamnolipids	  on	  mammalian	  cells	  have	  been	  shown	  by	   the	   interference	   of	   the	   chemotactic	   responses	   by	   polymorphonuclear	  leukocytes	   (PMNs1),	   inhibition	   of	   normal	   macrophage	   function	   as	   well	   as	  stimulation	  of	  cytokine	  release	  from	  epithelial	  cells	  [72,	  73].	  It	  has	  recently	  been	  shown	   that	   rhamnolipids	   are	   important	   components	   in	   causing	   persistent	  infections	   directed	   by	   a	   coordinated	   intercellular	   bacterial	   communication	  system	  called	  quorum	  sensing	  (QS)	  [74].	  The	  QS	  system	  upregulate	  rhamnolipid	  production	   and	   several	   other	   virulence	   factors.	   The	   protective	   properties	   of	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  PMNs	  are	  granulocytes:	  neutrophils,	  eosinophils	  and	  basophils,	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rhamnolipids	  produced	  P.	  aeruginosa	  biofilms	   lead	  to	  a	  direct	  PMN	  elimination	  [74-­‐76].	  
2.4 Type	  III	  secretion	  system	  	  The	   Pseudomonas	   aeruginosa	   type	   III	   secretion	   system	   (T3SS)	   is	   a	   complex	  export	  machinery	   of	   effector	  molecules.	   The	  T3SS	   requires	   direct	   contact	  with	  the	   host	   cells	   to	   which	   effector	   molecules	   are	   actively	   translocated	   into	   the	  cytosol	   of	   the	   eukaryotic	   cell	   [77].	   More	   than	   80%	   of	   acute	   P.	   aeruginosa	  infections	   express	   the	   T3SS	   machinery,	   but	   are	   expressed	   to	   a	   much	   lesser	  degree	   in	   chronic	   CF	   respiratory	   infections	   [78].	   A	   needle	   apparatus	   creates	   a	  translocation	   channel	   that	   allows	  molecular	   transport	   from	   the	  bacterium	   into	  the	   host	   cell.	   Four	   T3SS	   effector	   enzymes	   have	   been	   identified	   until	   now;	   the	  exoenzymes	  S,	  T,	  Y	  and	  U	  (ExoS,	  ExoT,	  ExoY	  and	  ExoU)	  [77].	  	  The	   expression	   of	   the	   T3SS	   plays	   an	   important	   role	   in	   the	   initial	   colonization	  steps	  by	   contributing	   to	   epithelial	   cell	   damage	   and	  killing	  of	  macrophages	   and	  PMNs	  [79].	  Chronic	  P.	  aeruginosa	  infections	  are	  often	  correlated	  with	  conversion	  to	  a	  mucoid	  phenotype	  [41,	  42].	  It	  was	  shown	  by	  Wu	  et	  al.,	  2004	  that	  mucoid	  P.	  
aeruginosa	   down-­‐regulate	   the	   T3SS	   system	   during	   up-­‐regulation	   of	   genes	  involved	  in	  alginate	  biosynthesis	  [80].	  The	  switch	  indicates	  a	  need	  for	  the	  T3SS	  system	  during	   initial	  colonization	  however	  shutting	  down	  the	  secretion	  system	  in	  order	  to	  save	  energy	  during	  alginate	  production.	  	  	  	  
2.5 P.	  aeruginosa	  communication	  –	  quorum	  sensing	  
P.	   aeruginosa	  will	   as	  mentioned	   reach	   high	   cell	   densities	   in	   the	   airways	   of	   CF	  patients,	   which	   correlate	  with	   the	   induction	   of	   the	   QS	   communication	   system.	  Bacterial	   communication	  generates	  a	   specific	   environment	  of	   a	  bacterial	   group	  related	  behavioral	  pattern.	  Group	  behavior	  can	  be	  subscribed	  to	  features	  as	  the	  QS	   communication	   system,	   dynamics	   of	   biofilm	   formation,	   production	   of	  virulence	   factors,	   extracellular	   DNA	   release	   and	   iron	   siderophore	   production	  [81,	   82].	   QS	   relies	   on	   the	   production	   and	   local	   concentrations	   of	   autoinducer	  molecules.	  Gram-­‐negative	  bacteria	  typically	  accomplish	  communication	  through	  produced	  acylated	  homoserine	  lactones	  (AHLs)	  whereas	  gram-­‐positive	  bacteria	  utilize	  small	  peptide	  molecules	  [83].	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P.	   aeruginosa	   employ	   at	   least	   two	  major	   interrelated	   quorum	   sensing	   systems	  [84].	   Each	   of	   these	   systems	   consists	   of	   an	   auto-­‐inducer	   and	   its	   transcriptional	  regulator	  protein.	  As	  the	  local	  accumulation	  of	  the	  auto-­‐inducer	  molecules	  reach	  a	   threshold	   concentration,	   the	   transcriptional	   regulators	   coordinate	   with	   the	  auto-­‐inducers	  which	  in	  turn	  leads	  to	  activation	  [85].	  	  One	  system	  leads	  to	  the	  activation	  of	  the	  transcriptional	  activator	  LasR	  through	  its	   autoinducer	   molecule	   N-­‐(3-­‐oxododecanoyl)-­‐L-­‐homoserine	   lactone	  (3OC12HSL)	  produced	  by	  the	  signal	  synthase	  LasI.	  	  The	  second	  system	  responds	  to	   and	   produces	   N-­‐(buytryl)-­‐L-­‐homoserine-­‐lactone	   (C4-­‐HSL)	   with	   the	   signal	  synthase	  RhlI	  and	  transcription	  activator	  RhlR	  [84].	  	  Reaching	   threshold	   concentrations	  will	   induce	   transcription	   of	   target	   genes	   in	  the	   respective	  Rhl	  and	  Las	   regulons.	  Transcription	   leads	   to	  an	  enhancement	  of	  activating	  events,	  as	  transcription	  of	  the	  AHL	  synthease	  genes	  that	  push	  forward	  a	   positive	   feedback	   loop	   encompassing	   an	   up-­‐regulation	   of	   transcription	  regulators.	  The	  overlapping	  regulation	  of	  the	  system	  is	  seen	  by	  the	  ability	  of	  the	  Las	  systems	  to	  activate	  the	  Rhl	  system,	  figure	  3.	  	  Another	   integrated	   component	   in	   the	   QS	   system	   of	   P.	   aeruginosa	   is	   the	   pqs	  system[86-­‐88].	   The	   Pseudomonas	   quinolone	   signal	   molecule	   2-­‐heptyl-­‐3-­‐hydroxy-­‐4-­‐quinolone	   (PQS)	   is	   under	   regulation	   of	   the	   las	   and	   rhl	   systems[86].	  PQS	   is	   intertwined	   between	   the	   las	   and	   rhl	   systems	   as	   PQS	   production	   is	  positively	  regulated	  by	  the	  las	  quorum	  sensing	  system	  and	  PQS	  strongly	  induce	  
rhlI	  [87,	  88].	  The	  QS	  systems	  undertake	  the	  induction	  of	  a	  wide	  range	  of	  essential	  components	   that	   style	   P.	   aeruginosa	   to	   become	   a	   successful	   colonizer.	   QS	   has	  been	   shown	   to	   be	   essential	   for	   induction	   of	   virulence	   in	   animal	   models.	   The	  predominant	   reduction	   in	   virulence	   was	   seen	   with	   mutant	   strain	   defective	   in	  both	   lasI	  and	  rhlI	  [89].	  Several	  animal	  studies	  have	  shown	  QS	  mutants	  to	  cause	  less	  tissue	  destruction,	  reduced	  pneumonia,	  disseminated	  infections	  and	  reduced	  number	  of	  mortalities	  [89-­‐93].	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Figure	  3.	  Pseudomonas	  aeruginosa	  quorum-­‐sensing	  systems.	  P.	  aeruginosa	  uses	  the	  two	  quorum-­‐sensing	   systems:	   LasI	   and	  LasR	   (blue),	  RhlI	   and	  RhlR	   (purple).	   LasI	  produces	  the	  auto-­‐inducer	  3OC12HSL	   (homoserine	   lactone;	  blue	  pentagons),	   and	  RhlI	  makes	   the	  auto-­‐inducer	  C4-­‐HSL	  (purple	  pentagons)	  and	  RhlR	  bind	  to	   their	  cognate	  auto-­‐inducers	  and	   induce	   gene	   expression.	   The	   systems	   control	   partially	   overlapping	   sets	   of	   genes.	  (Henke	  and	  Bassler,	  2004[85])	  
	  Davies	   et	   al.	   showed	   that	   the	   impact	   of	   the	   rhl-­‐las	   system	   was	   set	   to	   the	  developmental	  stages,	  following	  initial	  attachment	  and	  proliferation,	  directed	  by	  the	  density	  of	   the	  population	   [94].	   Furthermore	   they	   showed	   that	   the	  mutants	  formed	   flat	   and	   undifferentiated	   biofilms	   susceptible	   to	   treatment	   with	   the	  detergent	   sodium	   dodecyl	   sulfate	   (SDS)	   [94].	   QS	   regulated	   rhamnolipids	   have	  proven	  important	  in	  the	  development	  of	  channel-­‐separated	  macrocolony	  biofilm	  structures	   as	  well	   as	   aid	   in	   the	   detachment	   of	   the	   biofilms	   [95].	   PQS	  has	   been	  shown	  to	  be	  necessary	   for	  extracellular	  DNA	  production,	  which	  might	   facilitate	  cap	   formation	  of	   the	  mushroom	  structures2.	  This	   is	  due	  to	  the	   fact	   that	   type	  IV	  pili	   bind	   with	   high	   affinity	   to	   DNA	   present	   in	   higher	   concentrations	   on	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Mushroom	  structures,	  macro	  colonies	  that	  take	  the	  shape	  of	  mushrooms	  with	  stalk	  and	  cap	  formations.	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microcolonies	   in	   P.	   aeruginosa	   biofilms	   [55].	   A	   recent	   study	   has	   shown	   the	  absolute	   dependency	   of	   oxygen	   in	   the	   final	   step	   of	   PQS	   synthesis	   from	   HHQ3	  catalyzed	  reaction	  by	  PqsH.	  They	  propose	  that	  PqsH	  could	  function	  as	  regulator	  in	   P.	   aeruginosa	   by	   controlling	   PQS	   controlled	   traits	   in	   response	   to	   different	  environments	  [96].	  	  	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  2-­‐heptyl-­‐4-­‐quinolone	  (HHQ)	  is	  a	  precursor	  for	  PQS	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3 P.	  aeruginosa	  and	  biofilms	  -­‐	  CF	  a	  biofilm	  associated	  
infectious	  disease	  	  
3.1 P.	  aeruginosa	  and	  biofilms	  in	  the	  CF	  airways	  A	  major	  constituent	   in	  the	  cystic	   fibrosis	  pathology	  is	  the	   lifelong	  P.	  aeruginosa	  infections	   in	   the	  airways	  of	   the	  patients,	  which	  has	  been	  accepted	  as	  a	  biofilm-­‐associated	  mode	  of	  growth	  [97].	  	  With	  increasing	  age,	  P.	  aeruginosa	  infecting	  CF	  patients	   undertake	   a	   phenotypic	   switch	   to	   a	   mucoid	   alginate	   overproducing	  phenotype	  [41].	  The	  mucoid	  phenotype	  corresponds	  with	  declining	  therapeutic	  possibilities	   to	   treat	   the	   P.	   aeruginosa	   infection	   as	   the	   mucoid	   phenotype	  corresponds	  with	   high	   resistance	   to	   antibiotics	   [98].	   The	  mucoid	   phenotype	   is	  recognized	   as	   a	   poor	   prognostic	   indicator	   and	   once	   a	   biofilm	   infection	   is	  established,	  these	  bacteria	  are	  seldom	  eradicated	  [41,	  99,	  100].	  
3.2 Biofilm	  definition	  The	  classic	  way	  of	  observing	  bacteria	  has	  been	  in	  cultures	  of	  planktonic	  bacteria,	  however	  it	  has	  become	  evident	  that	  many	  microbes	  predominantly	  live	  in	  more	  sessile	  communities	  called	  biofilms.	  –	  Surface	  associated	  communities	  encased	  in	  a	   self-­‐produced	   extracellular	   produced	   matrix	   –	   is	   the	   general	   definition	   of	  microbial	   biofilms	   [101].	   Biofilms	   are	   involved	   in	   a	   remarkable	   number	   of	  chronic	  and	  acute	  infections,	  a	  regime	  consisting	  of	  a	  single	  species	  or	  assembled	  by	   a	  mixture	   of	   bacterial	   or	   fungal	   species	   [101].	   The	  populations	   of	   cells	   that	  establish	   biofilms	   demonstrate	   distinct	   features	   compared	   to	   planktonic	   cell	  populations	  as	  these	  communities	  adapt	  to	  a	  highly	  construction	  driven	  lifestyle.	  	  In	   nature,	   the	   presence	   of	   a	   purely	   planktonic	   culture	   very	   seldom	   exists,	  however	   the	   biofilm	   lifestyle	   of	   microbes	   is	   seen	   in	   more	   or	   less	   all	   aquatic	  sediments,	  and	  cause	  extreme	  problems	  with	  costly	  contamination	  of	  industrial	  production	   lines,	   dental	   plaques	   and	   complications	   with	   indwelled	   medical	  devices	  [102].	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3.3 Biofilm	  formation	  The	   history	   of	   biofilm	   formations	   goes	   back	   about	   3	   billion	   years	  with	   similar	  biofilm	  formations	  in	  modern	  day	  environments.	  The	  fact	  that	  biofilms	  are	  dated	  this	  many	   years	   back	   shows	   great	   adaptation	   to	   fluctuating	   environments	   and	  the	  need	  to	  evolve	  into	  a	  complex	  societies	  [103].	  	  The	  development	   in	  biofilm	   formation	  encompasses	  a	   five-­‐stage	  differentiation	  process	   initiated	   by	   the	   attachment	   of	   freely	   swimming	   (planktonic)	   cells	   to	   a	  surface	   (i).	   The	   attachment	   step	   is	   a	   reversible	   process	   (ii)	   followed	   by	   an	  irreversible	  attachment,	  where	  the	  cells	  at	  the	  surface	  start	  to	  produce	  EPS4	  (iii)	  formation	   of	   micro-­‐colonies	   by	   cell	   proliferation	   or	   further	   adherence	   of	  planktonic	   bacteria	   and	   (iv)	   the	   development	   of	   the	   biofilm	   in	   construction	   of	  macro-­‐colonies	   and	   finally	   (v)	   seeding	   dispersal,	   where	   detaching	   cells	   from	  macro-­‐colonies	  exit	  the	  biofilm	  community	  to	  occupy	  new	  surfaces,	  figure	  4.	  
	  
Figure	  4.	  Representation	  of	  biofilm	  development.	  The	  process	  is	  separated	  in	  5	  different	  scenarios.	   (i)	   reversible	   attachment	   (ii)	   irreversible	   attachment	   (iii)	   formation	   of	  developing	   micro-­‐colonies	   (iv)	   maturating	   macro-­‐colonies	   (v)	   dispersal.	   Black	   lines	  representing	  bacterial	  movement,	  blue	  lines	  illustrating	  flow	  of	  liquids.	  (modified	  from,	  Monroe,	  2007[104])	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  EPS:	  extracellular	  polymeric	  substances	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In	   the	   process	   of	   initial	   attachment	   to	   various	   surfaces,	   the	   cells	   become	  irreversibly	  attached	  through	  surface	  structures	  as	  LPS,	  type	  IV	  pili	  fimbriae	  and	  flagella.	   Type	   IV	   pili	   are	   important	   in	   the	   development	   of	   mushroom	   shaped	  macro-­‐colonies,	  as	  type	  IV	  pili	  mutants	  of	  P.	  aeruginosa	  show	  distinctive	  traits	  to	  the	  stalk	  formation,	  whereas	  the	  motile	  population	  migrate	  to	  form	  the	  cap	  of	  the	  mushroom	   [54].	   	   Mutants	   incapable	   of	   producing	   biosurfactant	   rhamnolipids	  (rhlA	   mutants)	   are	   deficient	   in	   producing	   biofilms	   with	   characteristic	  architecture	  of	  “water	  channels”	  and	  unable	  to	  establish	  strong	  cell-­‐cell	  and	  cell-­‐surface	  interactions	  [95,	  105].	   	   In	  an	  analysis	  of	  CF	  sputum	  samples,	  QS	  system	  signaling	  molecules	   indicate	   that	  P.	   aeruginosa	   convert	   to	   a	   biofilm	   lifestyle	   in	  the	   CF	   lung	   environment	   [97].	   As	   several	   factors	   controlled	   by	   QS	   facilitate	  biofilm	  sustainability	  and	  protection,	  biofilm	  formation	  must	  essentially	  provide	  beneficial	  advantages	  to	  the	  community.	  
3.4 	  The	  biofilm	  lifestyle	  Many	  questions	  come	  to	  mind	  when	  considering	  this	  community	  driven	  lifestyle.	  One	  of	  them	  being:	  Why	  is	  this	  a	  preferable	  form	  of	  community	  living?	  There	  are	  several	  aspects	  that	  need	  to	  be	  taken	  into	  consideration	  when	  trying	  to	  answer	  this	  question.	  	  First	  of	  all,	  going	  back	  in	  time	  it	  was	  not	  until	  the	  late	  1970’es	  that	  Costerton	  and	  co-­‐workers	  published	  their	  work	  that	  defines	  “the	  biofilm	  way	  of	   life”	  as	  a	  rule	  more	  than	  an	  exception	  [106].	  So	  what	  are	  the	  advantages	  for	  bacteria	  to	  “settle	  down”	  in	  such	  a	  structured	  society?	  Speculating	  on	  the	  general	  “purpose	  of	  life”	  for	  a	  bacterium	   is	   for	   the	  species	   to	  persist.	  Settling	   in	  a	  habitat	  with	  plenty	  of	  nutrients	   and	   solid	   surfaces	   to	   attach	   to,	   enables	   bacteria	   to	   vividly	   found	   a	  community.	  Having	  neighbors	  close	  by	  can	  be	  beneficial	  in	  several	  aspects,	  as	  cooperating	  on	  the	   production	   of	   common	   goods	   and	   genetic	   variability	   through	   exchange	   of	  genetic	   elements	   [107,	   108].	   Within	   biofilms,	   cells	   are	   tightly	   packed	   against	  each	   other	   and	   share	   a	   wide	   range	   of	   secreted	   molecules	   as	   enzymes,	   iron	  scavenging	   siderophores,	   community	   enzymatic	   defense	   systems	   as	   well	   as	  extracellular	  polymers	  for	  shielding	  purposes	  (section	  3.5).	  Within	  the	  proximity	  of	   others	   the	   evolutionary	  expansion	  of	   cheating	  phenotypes	   are	   also	  prone	   to	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evolve	   [107].	   This	   is	   unambiguously	   seen	   in	   mixed	   regimes	   where	   conflicts	  prevail	   over	   contribution	   to	   the	   shared	   resources	   of	   the	   group	   [109].	  Competition	   can	   be	   both	   between	   relatives	   or	   non-­‐relatives	   in	   the	   local	  environment,	  where	  resources	  may	  be	  scarce	  [109,	  110].	  	  It	  has	  been	  shown	  with	  siderosphore	  production,	   that	  bacteria	   living	  with	  other	  highly	  related	  bacteria	  evolve	   to	   produce	   more	   siderosphores	   than	   bacteria	   living	   with	   unrelated	  individuals	   [110].	   	   Cooperation	   for	   the	   production	   of	   extracellular	   polymeric	  substances	   (EPS)	   can	   in	   the	   same	   sense	   provide	   a	   shielding	   factor	   for	   non-­‐producers	  within	  the	  biofilm.	  	  In	   response	   to	   environmental	   factors	   as	   starvation	   and	   oxygen	   depletion,	   the	  biofilm	   community	  may	   respond	  by	   reorganizing	   the	   structures	   and	  dissolving	  the	  biofilm	  in	  a	  possible	  search	  for	  more	  nutrient	  rich	  environments	  [111].	  	  
3.5 The	  extracellular	  polymeric	  matrix	  	  One	  of	  the	  early	  observations	  of	  biofilm	  characteristics	  was	  the	  slimy	  nature	  of	  these	   surface	   associated	   communities.	   A	   characteristic	   feature	   of	   surface	  attached	  micro-­‐organisms	  is	   the	  production	  of	  a	  polymeric	  matrix	  that	  anchors	  the	   micro-­‐organisms	   together	   and	   furthermore	   fosters	   important	   shielding	  properties	   [112,	  113].	  The	  polymeric	  matrix	  structurally	  stabilizes	   the	  growing	  biofilm	   and	   provides	   a	   shield	   for	   antibacterial	   factors	   as	   constituents	   of	   the	  immune	  system	  and	  antimicrobial	  components	  [101,	  114].	  However	  suggestions	  that	  the	  biofilm	  matrix	  bring	  a	  low	  diffusion	  of	  antibiotics	  have	  been	  a	  matter	  of	  controversy	   (see	  section	  7).	  The	  extracellular	  polymeric	  matrix	   is	   composed	  of	  several	   different	   factors	   that	   differ	   in	   ratio,	   but	   the	   solids	   are	   primarily	  composed	   of	   polysaccharides	   40-­‐95%,	   <1-­‐60%	   protein,	   <1-­‐10%	   nucleic	   acids,	  <1-­‐40%	  lipids	  (numbers	  direct	  from	  table	  1[112])	  [112,	  114].	  As	   stated,	   polysaccharides	   account	   for	   a	   large	   proportion	   of	   the	  matrix	  that	  encases	  the	  bacteria	  of	  the	  biofilm.	  The	  initial	  colonization	  of	  the	  CF	  airways	  by	  P.	  aeruginosa	  typically	  renders	  an	  intermittent	  colonization,	  an	  acute	  infection	  that	   in	  time	  turns	  chronic	   if	   the	   initial	  acute	   infection	   is	  unsolved	  [40].	  Chronic	  infections	   generally	   correspond	   with	   P.	   aeruginosa	   converting	   to	   the	   mucoid	  phenotype,	   a	   state	   that	   can	   be	   measured	   in	   the	   antibody	   titer	   towards	   P.	  
aeruginosa	  produced	  alginate	  [42].	  However	  these	  antibodies	  do	  not	  work	  in	  an	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opsonizing	  manner	   to	   eradicate	   the	   bacteria	   as	   they	   are	   directed	   towards	   this	  inert	  material	  encapsulating	  the	  bacteria	  [42].	  	  
3.6 Alginate	  and	  essential	  matrix	  components	  by	  P.	  aeruginosa	  
3.6.1 Alginate	  production	  A	  seminal	  feature	  of	  P.	  aeruginosa	  is	  that	  it	  is	  frequently	  found	  in	  the	  airways	  of	  CF	  patients	  as	  a	  mucoid	  phenotype,	  which	  is	  an	  infection	  hallmark	  that	  appears	  over	  the	  course	  of	  the	  infection.	  	  	  Alginates	   are	   co-­‐polymers	   of	   β-­‐D-­‐mannuronic	   and	   α-­‐L-­‐guluronic	   acids	  generated	  from	  the	  biosynthesis	  starting	  material	  fructose-­‐6-­‐phosphate.	  Initially,	  alginate	   production	   is	   considered	   one	   of	   the	   virulence	   factors	   produced	   by	   P.	  
aeruginosa	  in	  the	  CF	  airways	  [42].	  The	  conversion	  to	  an	  alginate	  overproducing	  phenotype	  is	  one	  of	  the	  traits	  going	  from	  an	  intermittent	  to	  chronic	  colonization	  in	   the	   CF	   airways	   [42,	   115].	   This	   phenomenon	   takes	   place	   in	   the	   inner	  membrane	   where	   the	   anti-­‐sigma	   factor	   MucA	   binds	   to	   the	   sigma	   factor	   AlgU	  (alternatively	   called	   AglT	   or	   σ22)	   [41].	   Mutations	   in	   MucA	   lead	   to	   a	   strong	  activation	  of	  AlgD	  transcription,	  as	  the	  alginate	  operon	  is	  under	  the	  control	  of	  the	  AlgD	  promoter.	  AlgD	  is	  essential	  for	  alginate	  synthesis	  as	  the	  AlgD	  gene	  product	  catalyzes	  the	  first	  step	  in	  the	  synthesis	  process	  [41,	  115].	  It	  has	  been	  shown	  that	  
P.	   aeruginosa	   in	   the	   airways	   of	   chronically	   infected	   CF	   patients	   produce	   large	  quantities	  of	  alginate,	  however	  in	  wild	  type	  P.	  aeruginosa	  strains	  PAO1	  and	  PA14	  alginate	  has	  been	  shown	  not	  to	  be	  a	  be	  a	  major	  constituent	  of	  the	  extra-­‐cellular	  matrix	  in	  the	  vitro	  biofilm	  formation	  [116].	  	  	  
3.6.2 Psl	  and	  Pel	  polysaccharides	  matrix	  components	  Two	   additional	   polysaccharides	   are	   essential	   components	   of	   the	   EPS	  matrix	  produced	  by	  P.	  aeruginosa.	  The	  pel	  genes	  (pelA-­‐F)	  encode	  polysaccharides	  shown	  to	  be	  essential	  for	  the	  pellicle	  formation	  at	  the	  air-­‐liquid	  interface	  [117].	  
Pel	  mutants	   are	   defective	   in	   the	   formation	   of	   solid	   surface-­‐associated	   biofilms	  and	  clearly	  show	  altered	  colony	  morphologies	  [117].	  It	  has	  been	  suggested	  that	  Pel	  polysaccharides	  can	  have	  a	  compensatory	  role	  in	  absence	  of	  other	  adhesins	  [118].	   A	   resent	   study	  has	   shown	   that	   Pel	   does	   not	   play	   a	   critical	   role	   in	   PAO1	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biofilm	   development,	   however	   describing	   the	   Psl	   as	   the	   predominating	  polysaccharide	   in	   the	   PAO1	   biofilm	   EPS	  matrix	   [119].	   Psl	   polysaccharides	   are	  encoded	  by	  a	  15	  gene	  spanning	  operon	  and	  has	  been	  shown	  to	  be	  essential	   for	  biofilm	   formation	   in	   P.	   aeruginosa	   strains,	   PAO1	   and	   ZK2870,	   however	   not	   in	  PA14	   strains	   that	   have	   3	   gene	   deletion	   in	   the	  psl	   operon	   [119,	   120].	  Ma	   et	   al.	  2006	  showed	  Psl	   to	  be	  required	   for	  adherence	   to	  mucin-­‐coated	  surfaces.	  Using	  an	   arabinose	   inducible	   psl	   construct,	   they	   showed	   the	   expression	   of	   the	   psl	  operon	   to	   be	   important	   in	   maintenance	   of	   the	   biofilm	   structure.	   Furthermore	  they	  showed	  the	  importance	  of	  Psl	  in	  cell-­‐to-­‐surface	  and	  cell-­‐to-­‐cell	  interactions	  as	  over-­‐expression	  of	  psl	  enhanced	  these	  events	  [121].	  
3.6.3 Extracellular	  DNA	  as	  a	  matrix	  component	  In	   addition	   to	   the	   previously	  mentioned	   components	   of	   the	  EPS	  matrix,	  extracellular	   DNA	   (eDNA)	   is	   an	   important	   matrix	   component	   and	   has	   been	  shown	   to	   have	   a	   stabilizing	   effect	   on	  P.	   aeruginosa	   biofilms	   [122,	   123].	   Larger	  quantities	  of	  eDNA	   is	  present	   in	   the	  CF	  airways,	  evidently	  originating	   from	  the	  necrosis	  of	  cellular	  components	  of	  the	  immune	  system,	  as	  the	  destruction	  of	  the	  abundant	   neutrophils,	   recruited	   by	   secreted	   cytokines	   and	   chemo-­‐attractants	  into	   the	   airways	   [124,	   125].	   The	   PQS	   system	   (section	   2.5)	   plays	   an	   important	  role	   in	  DNA	  release	  by	  P.	  aeruginosa.	  The	  PQS	   induced	  release	  of	  DNA	  could	   in	  that	  sense	  play	  an	  important	  role	   in	  the	  formation	  of	  biofilms	  in	  the	  airways	  of	  CF	   patients,	   however	   only	   in	   oxygenated	   regions	   [96].	   	   Extracellular	   bacterial	  DNA	  has	  furthermore	  been	  shown	  to	  contribute	  as	  a	  proinflamatory	  component	  of	  P.	  aeruginosa	  biofilms	  [126].	  In	  the	  flow	  cell	  systems	  (details	  in	  section	  9.3.3)	  it	   has	   been	   shown	   that	   the	   early	   steps	   of	   P.	   aeruginosa	   biofilm	   formation	   is	  disrupted	   by	   DNaseI	   in	   the	   biofilm	   media	   [127].	   The	   matrix	   contributes	   with	  several	   important	  aspects	  of	  P.	  aeruginosa	  persistency	  during	  airway	  infections	  and	   furthermore	  contributes	   to	  maintenance	  of	   the	  oxygen	  environment	   in	   the	  CF	  airways.	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4 The	  human	  airways	  The	  humane	  respiratory	  system	  is	  a	  complex	  network	  of	  branches	  and	  cavities.	  It	  can	   roughly	   be	   divided	   into	   the	   upper	   and	   lower	   parts,	   Figure	   5.	   	   The	   airway	  system	   can	   furthermore	   be	   subdivided	   into	   at	   least	   three	   different	  compartments;	  the	  conductive	  airways,	  the	  respiratory	  zone	  and	  the	  paranasal	  	  
	  sinuses.	   The	   conductive	   airways	   branch	   out	   from	   the	   trachea	   into	   the	   bronchi	  and	  bronchioles.	  The	  terminal	  bronchioles	  branch	  further	  out	  and	  establish	  the	  respiratory	  zone	  (insert	   in	  figure	  5.).	  The	  existence	  of	  an	  immense	  surface	  area	  
Figure	  5.	  Representation	  of	  the	  human	  respiratory	  system.	  Inset	  display	  the	  conductive	  and	  respiratory	  zones.	  Pictures	  modified	  from	  [1,	  2].	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within	  the	  respiratory	  zone	  allows	  the	  exchange	  of	  gasses	  within	  the	  respiratory	  bronchioles,	  alveolar	  ducts	  and	  alveolar	  sacs.	  The	  conductive	  and	  sinus	  segments	  of	   the	   airways	   are	   broadly	   considered	   to	   be	   anaerobic	   or	   micro-­‐anaerobic,	  compared	  to	  the	  highly	  aerated	  respiratory	  zone	  [128].	  	  	  The	   branching	   is	   the	   essential	   groundwork	   for	   the	   functionality	   of	   the	   lungs	  meaning	  that	  obstruction	  and	  trauma	  can	  lead	  to	  collapse	  and	  dysfunction	  in	  the	  essential	  gas	  exchange.	  These	  are	  essential	  problems	  for	  patients	  suffering	  from	  pneumonia	  and	  pulmonary	  obstructive	  diseases,	  as	  COPD	  and	  cystic	  fibrosis	  [8,	  129].	  	  
4.1 The	  CF	  airway	  environments	  It	   has	   become	   evident	   that	   the	   airways	   of	   CF	   patients	   contain	   different	  compartments	   with	   varying	   oxygen	   concentrations,	   ranging	   from	   the	   highly	  aerobic	  compartments	  to	  hypoxic	  and	  subsections	  of	  anaerobic	  environments.	  In	  the	  CF	  airways,	  the	  thickened	  mucus	  deposited	  in	  the	  airways	  allows	  bacteria	  to	  reach	  staggering	  concentrations,	  as	  seen	  with	  P.	  aeruginosa	  [130].	  
4.1.1 The	  sinus	  compartments	  	  The	   nasal	   cavities	   are	   extremely	   prone	   to	   getting	   in	   contact	  with	   bacteria	   and	  function	   as	   a	   first	   line	   of	   defense	   towards	   inhaled	   particles	   and	  microbes.	   The	  paranasal	  sinuses	  function	  as	  a	  humidifier	  and	  heat	  inhaled	  air	  and	  the	  cavities	  furthermore	   assist	   to	   exclude	   unwanted	   material	   from	   the	   lower	   respiratory	  tract	  [131].	  The	  CF	  sinus	  mucosa	  is	  an	  obvious	  abnormal	  site	   in	  virtually	  all	  CF	  patients	  that	  radiographically	  show	  opacified	  sinuses.	  As	  the	  sinus	  mucosa	  show	  the	   CF	   signature	   of	   reduced	  Cl-­‐	   permeability	   resulting	   in	   thickened	  mucus,	   the	  paranasal	   sinuses	  have	  an	   immensely	  reduced	  airflow	  [131,	  132].	  The	  mucosal	  linings	   of	   the	   sinuses	   are	   ciliated	   and	   would	   ideally	   transport	   mucus	   to	   the	  nasopharynx,	  but	  CF	  patients	  remain	  impaired	  in	  this	  clearing	  mechanism	  [132].	  As	   a	   direct	   consequence	   hereof	   the	   paranasal	   sinuses	   can	   act	   as	   a	  reservoir	  for	  potential	  reinoculations	  of	  the	  lower	  part	  of	  the	  airways	  [133].	  The	  sinus	  cavities	  have	  a	  significantly	  low	  O2	  content	  at	  the	  mucosa,	  as	  shown	  in	  the	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maxilliary	   sinuses5,	   where	   several	   CF	   patients	   were	   identified	   with	   anoxic	  conditions	   [134].	   Treatments	   for	   sinusitis	   remain	   weakened	   as	   antibiotic	  penetration	  and	  realization	  of	  sufficient	  therapeutic	  levels	  is	  less	  efficient	  in	  the	  sinus	   cavities	   than	   in	   the	   lungs,	   due	   to	   fundamental	   differences	   in	   the	   blood	  supply	   to	   the	   different	   compartments.	   Reduced	   effects	   of	   therapeutics	   lead	   to	  poor	  eradication	  of	  infecting	  bacteria	  causing	  recurrent	  periods	  of	  sinusitis	  and	  establishment	   of	   chronic	   infections	   [134,	   135].	   The	   sinuses	   hold	   high	   levels	   of	  IgA,	  compared	  to	  the	  pro-­‐inflammatory	  IgG,	  and	  thereby	  facilitate	  low	  infiltration	  of	  PMNs	  during	  P.	  aeruginosa	  infections,	  which	  in	  turn	  protect	  the	  bacteria	  from	  a	  pro-­‐inflammatory	  response	  [136].	  
4.1.2 Conductive	  zones	  	  The	  conductive	  zones	  of	  the	  respiratory	  system	  represent	  approximately	  5%	  of	  the	   total	   lung	   volume	   and	   include	   the	   trachea,	   the	   bronchi	   and	   the	   terminal	  bronchioles	   [100].	   Importantly,	   this	   section	   of	   the	   airways	   also	   sustains	   the	  capacity	   to	   produce	   mucus	   thereby	   being	   an	   important	   part	   in	   the	   defenses	  down	   towards	   the	   respiratory	   part	   of	   the	   airways.	   In	   healthy	   individuals	   the	  efficiency	   of	   this	   mucocilliary	   defense	   mechanism	   is	   practically	   capable	   of	  preventing	   particle	   accumulation	   and	   pathogenic	   adhesion	   and	   invasion	   [27,	  137].	   Respiratory	   submucosal	  mucous	   glands	   are	   present	   in	   the	   sinus,	   trachea	  and	   bronchi	   and	   produces	   the	   high	   molecular	   weight	   gel-­‐forming	   mucin	  macromolecules	   of	   the	   airway	   mucus	   layer	   [137].	   The	   beating	   motion	   of	   the	  epithelium-­‐expressed	   cilia	   transports	   mucus-­‐trapped	   components	   out	   the	  respiratory	   tract.	   As	   CF	   patients	   are	   impaired	   in	   the	   mucociliary	   clearance	  mechanism,	  due	  to	  the	  consequences	  of	  airway	  surface	  liquid	  dehydration	  (ASL),	  microbial	   colonizations	   occur	   frequently.	   In	   attempt	   to	   eradicate	   infections,	  patients	   are	   set	   to	   inhale	   nebulized	   antibiotics,	   which	   leads	   to	   high	  concentrations	  of	  the	  arranged	  antibiotics	  in	  the	  conductive	  zones	  [100].	  During	  
P.	  aeruginosa	   infections	  of	   the	  CF	  conductive	  zones	  of	   the	  airways,	   the	  bacteria	  are	   primarily	   located	   in	   biofilm	   clusters	   within	   the	  mucus	   layer	   [5,	   138].	   The	  consumption	   of	   oxygen	   by	   epithelial	   cells	   and	  P.	   aeruginosa	   aid	   differences	   in	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  Maxilliary	  sinuses;	  are	  the	  largest	  of	  the	  paranasal	  sinuses,	  drains	  into	  the	  nose.	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oxygen	   availability	   in	   the	  mucus,	   however	   immense	   respiratory	   bursts	   by	   the	  PMNs	  produce	  anaerobic	  niches	  [5,	  139].	  In	  contrast	  to	  the	  high	  IgA	  levels	  in	  the	  sinuses,	   the	  conductive	  airways	  are	   in	  comparison	  governed	  by	  high	  IgG	  levels.	  [136,	   140].	   	   Nebulized	   antibiotics	   used	   to	   treat	   CF	   lung	   infections	   reach	   high	  concentrations	  in	  the	  conductive	  zones	  but	  only	  low	  in	  respiratory	  zones[1].	  	  	  
4.1.3 Respiratory	  zones	  	  The	   respiratory	   sections	   of	   the	   lungs	   constitute	   the	   respiratory	  bronchioles,	  alveolar	  ducts	  and	  sacs.	   	  These	  specific	  sections	  are	  not	   lined	  with	  cilia	   expressing	   epithelial	   cells	   nor	   mucin	   producing	   glands	   [137,	   141].	   The	  regions	   epithelial	   surfaces	   are	   covered	   by	   an	   alveolar	   lining	   fluid	   (ALF)	   that	  consist	  of	  a	  plasma	  ultrafiltrate	  and	  secreted	  components	   from	  type	   II	  alveolar	  cells6.	  ALF	  contain	  a	  range	  of	  e.g.	  antimicrobial	  components,	  surfactants	  proteins	  and	   immunoglobulins	   [140].	   In	   contrast	   to	   the	   conductive	   zones	   and	   sinus	  compartments,	   the	   primary	   immunoglobulin	   is	   IgG	   rather	   than	   the	   IgA	   that	  predominate	   in	   ASL	   [140].	   Lacking	   the	   mucociliary	   defense	   mechanism,	   the	  respiratory	   zones	   rely	   on	   secreted	   defensin	   molecules,	   infiltrating	   alveolar	  macrophages	  and	  PMNs,	  which	  are	  recruited	  from	  the	  blood	  upon	  infection	  (see	  section	  6).   The	   respiratory	   zone	   is	   immensely	   oxygen	   rich	   as	   all	   the	   venous	   blood	  pass	   through	   the	  capillaries	  of	   the	  alveoles	   [100].	  However,	   if	  mucus	  plugs	  are	  formed	   within	   the	   respiratory	   zones	   of	   the	   CF	   airways,	   the	   environment	  becomes	   micro-­‐aerobic	   with	   highly	   reduced	   oxygen	   levels.	   Levels	   drop	   from	  approximately	   13%	   O2	   and	   5%	   CO2	   in	   unobstructed	   respiratory	   zones	   to	  approximately	   5%	   O2	   and	   6%	   CO2	   if	   mucus	   plug	   hampers	   the	   airflow.	   If	  abscesses	   are	   formed,	   areas	  within	   the	   respiratory	   zone	   turn	   anaerobic	   [100],	  figure	  6.	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  Type	  II	  alveolar	  cells:	  approximately	  5%	  of	  the	  alveolar	  cells	  that	  express	  microvilli,	  secrete	  alveolar	  fluid	  and	  stem	  cells	  for	  type	  I	  alveolar	  cells	  








Figure	   6.	   Schematic	   model	   of	   the	   hypothesized	   events	   that	   leads	   to	   chronic	  
infection	  in	  airways	  of	  CF	  patients.	  (a)	  Normal	  airway	  epithelia	  with	  a	  thin	  mucus	  layer	  (light	  green)	  on	  top	  of	  the	  cilia	  with	   normal	   PCL,	   (QO2)	   normal	   oxygen	   consumption,	   no	   oxygen	   gradients	   within	  mucus	  (denoted	  by	  red	  bar).	  Arrow	  representing	  normal	  mucocilliary	  movement.	  (b-­‐f)	  represent	  CF	  airway	  epithelia.	  (b)	  CF	  airway	  epithelial	  leading	  to	  a	  reduced	  PCL	  by	  excessive	   H20	   depletion,	   fallen	   cilia	  with	   consequential	   impaired	   net-­‐movement	   of	  dehydrated	   mucus	   (dark	   green),	   raised	   QO2.	   (c)	   Persistent	  mucus	   hyper-­‐secretion.	  Over	   time	   the	   height	   of	   the	   luminal	   mucus	  masses	   increase.	   Raised	   QO2	   in	   the	   CF	  epithelia	   generates	   steep	   hypoxic	   gradients	   within	   the	   thickened	   mucus	   (blue	  coloration	  in	  bar,	  right	  side)	  (d)	  P.	  aeruginosa	  deposited	  on	  the	  mucus	  will	  penetrate	  into	  the	  hypoxic	  zones	  of	  the	  mucus	  either	  actively	  or	  passively	  (see	  figure	  5)	  (e)	  P.	  aeruginosa	   adapt	   to	   the	   hypoxic	   environment.	   Within	   the	   stagnant	   mucus	   P.	  aeruginosa	  form	  macro-­‐colonies	  and	  produce	  increased	  formation	  of	  alginate.	  (f)	  The	  macro-­‐colonies	   that	   reside	   in	   the	   hypoxic	   zones	   of	   the	   mucus	   resist	   secondary	  defense	   mechanisms,	   including	   attracted	   neutrophils,	   setting	   the	   stage	   for	  progression	  of	  the	  infection	  into	  a	  chronic	  phase[5].	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5 P.	  aeruginosa	  and	  the	  CF	  airways	  as	  habitat	  As	   stated,	   most	   CF	   patients	   will	   eventually	   get	   colonized	   with	   P.	  
aeruginosa	   that	   will	   eventually	   establish	   long	   term	   infection	   if	   intermittent	  infections	   are	   not	   resolved.	   Colonization	   is	   facilitated	   by	   the	   rich	   supply	   of	  components	  in	  the	  mucus,	  with	  cell	  debris	  from	  both	  host	  and	  bacterial	  derived	  factors	  as	  mucins,	   lipids,	  nucleotides	  and	  proteins	  providing	  an	  array	  of	  amino	  acids,	  nitrates	  and	  carbon	  sources	  to	  sustain	  long	  term	  infections	  [142].	  Whereas	  several	   bacterial	   species	   only	   transiently	   colonizes	   the	   CF	   mucus,	   or	   are	   only	  present	   in	   low	  concentrations,	  P.	   aeruginosa	  commences	   to	   establish	  a	   chronic	  infection	   with	   high	   cell	   densities	   [130].	   Generating	   energy	   for	   demanding	  processes	   as	   alginate	   production	   and	   biofilm	   formation,	   the	   versatility	   of	   P.	  
aeruginosa	  to	  utilize	  various	  energy	  sources	  and	  nitrogenous	  oxides	  as	  electron	  acceptors,	  enables	  the	  organism	  to	  switch	  to	  anaerobic	  respiration	  thereby	  being	  able	  to	  cope	  with	  the	  micro-­‐aerobic	  and	  anaerobic	  environments	  [143-­‐145].	  	  In	  a	  study	  by	  Worlitzsch	  et	  al.	  2002,	  the	  properties	  of	  P.	  aeruginosa	  and	  its	  capabilities	   to	   penetrate	   into	   hypoxic	   zones	   of	   epithelial	   mucus	   layers	   was	  investigated.	   It	   showed	   that	   if	   deposited	   on	   a	   mucus	   layer,	   P.	   aeruginosa	  penetrates	  into	  the	  low	  oxygen	  zones,	  figure	  7.	  	  
Figure	  7.	  Localization	  of	  P.	  aeruginosa	  and	  flourescent	   beads	   in	   transported	   and	  stationary	   ASL	   (mucus)	   produced	   by	  planar	   CF	   cultures.	   Representative	  confocal	  images	  of	  ASL	  (red)	  fluorescent	  P.	  
aeruginosa	   (green)	   or	   green	   fluorescent	  beads.	  P.	  aeruginosa	  or	  beads	  were	  added	  to	  the	  air-­‐liquid	  interface.	  (a)	  X-­‐Z	  confocal	  image	   of	   P.	   aeruginosa	   or	   (b)	   beads,	   3	  minutes	   after	   addition	   to	   the	   surface	   of	  ASL	   (mucus)	   exhibiting	   rotational	   trans-­‐port.	   P.	   aeruginosa	   3	   minutes	   (c)	   and	   15	  minutes	   (d)	   after	   addition	   to	   stationary	  mucus.	   Beads	   at	   3	   minutes	   (e)	   and	   15	  minutes	   later	   (f)	   after	   addition	   to	  stationary	  mucus.	  Scale	  bars,	  100	  μm.[5]	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  In	  the	  absence	  of	  oxygen	  P.	  aeruginosa	  can	  utilize	  alternative	  electron	  acceptors.	  The	   ability	   of	   P.	   aeruginosa	   to	   utilize	   inorganic	   nitrogenous	   oxides;	   nitrate,	  nitrite	  and	  nitrous	  oxide	  as	  the	  terminal	  electron	  acceptors	  enables	  P.	  aeruginosa	  to	  sustain	  growth	  under	  anaerobic	  conditions	  [143].	  Under	  anaerobic	  conditions	  
P.	   aeruginosa	   is	   furthermore	   able	   to	   use	   arginine	   in	   a	   deiminase	   pathway	   for	  energy	  production	  although	  only	  able	   to	  sustain	   limited	  growth	  [146].	  Analysis	  of	   the	   CF	   sputum	   composition	   has	   revealed	   abundant	   amino	   acids	   as	   well	   as	  ample	  nitrate	  levels	  [145].	  Palmer	  et	  al.	  2007,	  have	  shown	  the	  dependency	  of	  P.	  
aeruginosa	   membrane-­‐bound	   nitrate	   reductase	   for	   growth	   in	   an	   in	   vitro	   CF	  medium	   [145].	  Antibodies	   raised	   against	   the	  nitrate	   reductase	  narG	  have	  been	  located	   in	   sera	   from	  P.	   aeruginosa	   infected	   CF	   patients,	   indicating	   that	   narG	   is	  expressed	  in	  vivo	  [147].	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6 Immunological	  responses	  to	  P.	  aeruginosa	  infections	  During	   infections	   of	   the	   respiratory	   system,	   microbes	   are	   challenged	   with	  several	   defense	  mechanisms	   as	   physical	   barriers	   and	   the	  mucociliary	   clearing	  mechanism	   [27,	   137].	   The	   mucus	   form	   the	   physical	   protective	   layers	   that	  furthermore	  contain	  a	  range	  of	  antimicrobial	  defense	  components	  [148].	  Several	  scenarios	  take	  place	  in	  the	  attempt	  to	  eradicate	  commencing	  colonizing	  bacteria	   from	   the	   airways	   of	   CF	   patients.	   Antimicrobial	   treatments	   are	  administered	  to	  the	  patients	   in	  the	  clinic	  and	  the	  body	  activates	  the	   innate	  and	  adaptive	  immune	  systems	  to	  fight	  of	  the	  bacteria	  [98,	  149].	  	  One	  of	  the	  hallmarks	  in	  the	  lung	  infections	  with	  P.	  aeruginosa	  is	  a	  strong	  PMN	  response.	  This	  division	  of	   the	   cellular	   innate	   immune	  weaponry	   relies	  on	  germ	   line	  encoded	  pattern	   recognition	   receptors	   (PRRs)	   that	   are	  expressed	  on	  cell	   as	   macrophages	   and	   neutrophils,	   in	   order	   to	   battle	   off	   the	   intruding	  microbes	   [150].	   As	   initial	   microbial	   recognitions	   take	   place,	   an	   inflammatory	  response	  that	  drives	  the	  recruitment	  of	  effector	  cells	  to	  the	  inflammation	  site	  is	  initiated.	   Neutrophils	   are	   recruited	   in	   large	   numbers	   to	   the	   site	   of	   infection	  [151].	   Of	   the	   PRRs	   are	   members	   of	   the	   Toll-­‐like	   receptor	   family	   (TLR)	   that	  recognizes	   conserved	  microbial	   structural	  moieties	   as	   lipopolysaccharides,	   pili	  and	  flagella.	  TLRs	  are	  expressed	  on	  the	  surface	  of	  inflammatory	  cells	  as	  well	  on	  the	  apical	  side	  of	  epithelial	  cells,	   figure	  8	   [152,	  153].	   	  Cells	  are	  recruited	  to	   the	  infectionsite,	  where	  they	  engulf	  bacteria	  or	  release	  their	  antimicrobial	  weaponry.	  Recruited	   dendritic	   cells	   transport	   foreign	   bacterial	   antigens	   to	   the	   lymphoid	  organs	  to	  activate	  an	  adaptive	  immune	  response,	  figure	  8	  [149].	  	  Activated	   neutrophils	   generate	   a	   range	   of	   microbicidal	   molecules	   as	  reactive	   oxygen	   species	   (ROS)	   and	   defensins	   [151,	   154].	   Epithelial	   TLRs	  recognize	  bacterial	  surface	  components	  as	  lipopolysaccharides	  and	  flagella.	  One	  epithelial	  TLR,	  TLR-­‐4	  bind	  through	  a	  recognition	  pathway	  of	  LPS	  bound	  by	  LSP-­‐binding	  protein	  (LBP),	  LPS:LBP	  complex	  bind	  to	  membrane	  protein	  CD14	  which	  then	   coordinate	   with	   TLR-­‐4.	   Successful	   TLR	   stimulation	   leads	   to	   induction	   of	  transcription	   factor	   NF-­‐κB,	   which	   drives	   IL-­‐8	   production	   and	   thereby	  recruitment	  of	  further	  neutrophils	  to	  the	  site	  of	  infection	  [153,	  155].	  Planktonic	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bacteria	  are	  efficiently	  phagocytized	  by	  the	  neutrophils,	  however	  if	  the	  infecting	  bacteria	  are	  not	  cleared,	  an	  ongoing	  vigorous	  inflammatory	  response	  will	  lead	  to	  
	  
Figure	   8.	   Respiratory	   defence	   against	   Pseudomonas	   aeruginosa.	   The	   respiratory	  defence	   against	  P.	   aeruginosa	   requires	  many	  mechanical,	   innate	   and	   adaptive	   defence	  mechanisms.	   First	   line	   of	   defence	   upon	   inhalation	   of	   P.	   aeruginosa	   is	   mechanical	  clearance	  via	  binding	  to	  mucins	  in	  the	  airway	  surface	  liquid	  (ASL)	  and	  clearance	  by	  the	  mucociliary	   transport	   mechanism.	   The	   ASL	   contains	   a	   myriad	   of	   anti-­‐pseudomonal	  molecules	  originating	  from	  e.g.	  the	  epithelium.	  The	  epithelium	  may	  also	  apoptose	  upon	  endocytosis	  to	  prevent	  further	  spreading.	  The	  epithelium	  also	  presents	  transmembrane	  PRRs	  that	  can	  signal	  immune	  cells	  through	  multiple	  cytokine	  networks.	  Several	  immune	  cells	  are	  implicated	  in	  the	  battle	  against	  P.	  aeruginosa	  with	  neutrophils	  as	  probably	  the	  most	  critical	  component	  in	  bacterial	  clearance	  and	  resolution	  of	  infection.	  Lymphocytes	  with	   helper	   T-­‐cells	   in	   three	  major	   subtypes	   have	   all	   been	   implicated	   in	   host	   defence	  [153].	  	  
	  	  substantial	   tissue	   damage	   [37].	   This	   scenario	   constantly	   takes	   place	   in	   the	   CF	  airways,	   where	   the	   viscous	   dehydrated	   mucus	   contributes	   to	   bacterial	  colonization	  due	   to	   the	   impaired	  mucus	  clearing	  mechanism.	  P.	  aeruginosa	   can	  reside	  within	   the	  mucus	   surrounded	  by	  an	   immense	  number	  of	  PMNs	   that	   are	  practically	   incapable	   of	   removing	   the	   bacteria,	   as	   seen	   in	   the	   lower	   airway	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compartments	   [138].	   The	   sinuses	   however,	   do	   not	   present	   a	   comparable	   PMN	  dominated	   inflammation	   [136].	   The	   short-­‐lived	   PMNs	   effectuate	   protection	  through	   phagocytosis	   and	   by	   release	   of	   inflammatory	  mediators,	   antimicrobial	  proteins	  and	  ROS	  [156].	  	  ROS	  exocytosed	  by	  the	  PMNs	  may	  induce	  mutations	  in	  the	  MucA	  gene	  of	  
P.	   aeruginosa,	   leading	   to	  overproduction	  of	   the	   exopolysaccharide	   alginate,	   see	  section	   3.6.1.	   This	   switch	   from	   a	   non-­‐mucoid	   to	   a	   mucoid	   phenotype	   is	  correlated	  with	  the	  formation	  of	  alginate	  encapsulated	  biofilms	  leading	  to	  a	  rise	  in	  serum	  circulating	  antibodies	  and	  PMNs	  that	  are	  totally	  incapable	  of	  destroying	  the	   bacteria	   [138].	   Mucoid	   bacteria	   are	   now	   capable	   of	   profoundly	   evading	  immune	  responses	  and	  can	  persist	  even	  under	  increasing	  antibiotic	  challenges[1,	  98,	  157].	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7 Antibiotic	  resistance	  The	   frequencies	   of	   the	   generally	   acquired	   resistance	   to	   antimicrobials	   vary	  according	   to	   continents	   and	   the	  wide	   uses	   of	   antimicrobials	   in	  medicine,	   crop	  production,	  production	  of	   food	  animals	  and	  as	  disinfectants	  [158-­‐161].	  An	  ever	  growing	   concern,	   is	   the	   trend	   of	   emerging	   multi-­‐drug	   resistant	   strains	   that	  emerge	   worldwide	   [162].	   This	   has	   critical	   implications	   for	   treatments	   in	   the	  future	   and	   on	   the	   efficiency	   of	   the	   current	   therapies	   available	   for	   combating	  bacterial	   infections.	   Emerging	   multi	   resistant	   bacteria	   have	   devastating	  outcomes	   for	   patients	   with	   infections	   spanning	   from	   severe	   urinary	   tract	  infections	  and	  pneumonia	   to	  surgical	  site	   infections,	  many	  of	  which	  are	  caused	  by	  Gram-­‐negative	  bacilli	  [44].	  	  
7.1 General	  resistance	  and	  tolerance	  mechanisms	  of	  P.	  aeruginosa	  
to	  antibiotics	  Treatment	  of	  P.	  aeruginosa	  infections	  with	  antimicrobial	  agents	  can	  be	  hindered	  by	  several,	  both	  inherent	  and	  acquired,	  resistance	  mechanisms.	  	  P.	  aeruginosa	  is	  resistant	   to	   a	  wide	   range	   of	   antibiotics	   that	   are	   normally	   used	   to	   treat	   Gram-­‐negative	   infections.	   Innately	   P.	   aeruginosa	   has	   the	   ability	   to	   produce	   several	  multi-­‐drug	   efflux	   pump	   systems,	   including	   the	   major	   MexAB-­‐OprM	   system,	  which	   removes	   a	   wide	   range	   of	   antimicrobial	   compounds	   as	   B-­‐lactams,	  chloramphenicol,	   flouroquiniolones,	   macrolides,	   novobicin,	   sulfonamides,	  tetracycline,	  gentamycin,	  ciprofloxacin	  and	  trimethoprim	  [163,	  164].	  The	  system	  is	   composed	   by	   the	  MexB	   broad-­‐spectrum	   pump	   that	   together	  with	   the	  MexA	  linker	   protein	   connect	   to	   the	   outer	  membrane	  porin	   forming	  OprM	   [164].	   The	  efficiency	  of	  these	  pump	  systems	  together	  with	  an	  overall	  membrane	  associated	  decreased	   influx,	   are	   the	   key	   parameters	   to	   the	  multi	   drug	   resistant	   bacterial	  phenotype	  [165-­‐167].	  In	  its	  natural	  environment	  it	  has	  been	  proposed	  that	  efflux	  pumps	   play	   a	   role	   in	   removing	   toxic	   components	   from	   the	   cytoplasm	   of	   the	  bacteria.	   It	   has	   been	   shown	   that	   the	   expression	   of	   several	  P.	   aeruginosa	  efflux	  pump	   systems	   are	   not	   significant	  when	   commencing	   to	   biofilm	   growth,	   as	   the	  expression	  of	  the	  systems	  decrease	  with	  maturation	  of	  the	  biofilm	  [168].	  It	  was	  also	  shown,	  that	  the	  expression	  was	  most	  profound	  at	  the	  bottom	  of	  the	  biofilm.	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Deletion	   mutant	   biofilms	   showed	   that	   none	   of	   the	   multidrug	   efflux	   pumps	  enhanced	  an	  overall	  increase	  in	  resistance	  to	  antibiotics	  [168].	  	  Bacterial	   biofilms	   are	   capable	   of	   being	   extensively	   more	   resistant	   to	  antibiotics	   and	   disinfectants	   than	   their	   isogenic	   planktonic	   equivalent	   with	  differences	   of	   approximately	   100-­‐1000	   fold	   [154].	  As	   stated,	  P.	   aeruginosa	   can	  reach	  high	   concentrations	   in	  CF	   sputum	   that	   entail	  mutations	   and	  exchange	  of	  genetic	  material,	  which	   in	   turn	   intensify	   the	  base	   for	  overall	  biofilm	  resistance	  [169,	  170].	  	  	  
P.	   aeruginosa	   carries	   resistance	   to	   β-­‐lactam	   antibiotics	   encoded	   on	   the	  chromosome,	   expressed	   through	   the	   AmpC	   β-­‐lactamases	   [171].	   The	   target	   for	  the	  β-­‐lactam	  antibiotics	  is	  the	  penicillin	  binding	  protein	  (PBP),	  which	  is	  localized	  in	   the	   cytoplasmic	   membrane	   and	   is	   essential	   for	   cell	   wall	   synthesis	   by	  peptidoglycan	   crosslinking.	   Several	   genes	   have	   been	   shown	   to	   influence	   the	  expression	   of	   AmpC	  with	   systematic	   effects	   on	  mutations	   in	   regulatory	   genes,	  leading	   to	   a	   hyper	   production	   of	   β-­‐lactamases	   [172-­‐174].	   Secretion	   of	   β-­‐lactamases	  into	  the	  extracellular	  matrix	  embedding	  the	  biofilm	  forming	  bacteria	  might	  hamper	  the	  penetration	  of	  the	  antibiotics	  due	  to	  β-­‐lactamase	  	  activity[175-­‐177],	  figure	  9.	  	  	  
P.	   aeruginosa	   employ	   a	   mechanistic	   change	   in	   the	   structure	   of	   the	  membrane	  in	  order	  to	  reduce	  the	  permeability,	  thereby	  increasing	  the	  resistance	  to	   antimicrobial	   compounds.	   P.	   aeruginosa	   incorporate	   an	   outer	   membrane	  protein	  OprD,	  a	  porin	  structure,	  that	  allows	  passive	  uptake	  of	  amino	  acids	  as	  well	  as	  allowing	  carpenems	  into	  the	  cell.	  Mutations	  leading	  to	  loss	  of	  OprD	  expression	  raise	  the	  resistance	  towards	  carpenems.	  	  Loss	  of	  OprD	  e.g.	  raises	  the	  MIC	  values	  for	   imipenem	   substantially	   to	   clinically	   relevant	   levels,	   however	   leaving	   no	  change	  in	  MICs	  of	  non-­‐carpenems	  [178].	  	  Resistance	   towards	   cationic	   antimicrobial	   peptides	   (CAMPs)	   are	   among	  the	  most	  widely	  distributed	  resistance	  mechanisms,	  as	  the	  production	  of	  CAMPs	  has	   been	   reported	   in	   essentially	   all	   groups	   of	   organisms	   [179].	   P.	   aeruginosa	  acquires	   resistance	   against	   CAMPs	   as	   colistin	   and	   polymyxin	   B,	   by	   outer	  membrane	  modifications	  of	  the	  LPS	  moieties.	  Polymyxins,	  like	  all	  CAMPs	  bind	  to	  negative	  charges	  on	  phosphates	  of	  the	  LPS	  component	  lipid	  A	  [179].	  Perpetrating	  the	  outer	  membrane	  organization,	  by	  CAMP	  binding	   to	   the	   lipid	  A,	   results	   in	   a	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destabilization	   and	   disruption	   of	   both	   the	   inner	   and	   outer	   membrane.	   LPS	  modifications	   are	   accomplished	   by	   aminoarabinose	   incorporation	   into	   lipid	   A,	  which	   changes	   the	   overall	   negative	   charge	   of	   the	   outer	   membrane,	   thereby	  lowering	  the	  affinity	  of	  the	  positively	  charged	  polymyxins	  [180,	  181].	  Colistin	  is	  one	   of	   the	   very	   important	   CAMPs	   used	   to	   treat	   P.	   aeruginosa	   infections	   in	   CF	  patients	   [40].	   Combinatory	   antibiotic	   therapy	   is	   efficient	   due	   to	   the	   fact	   that	  selected	   antibiotics	   can	   be	   directed	   towards	   metabolically	   diverse	  subpopulations	  of	  P.	  aeruginosa	  biofilms	  [182,	  183].	  




Figure	  9.	  Hypotheses	  for	  
mechanisms	  of	  antibiotic	  resistance	  
in	  biofilms	  	  Slow	  penetration	  Antibiotic	   (yellow)	   fail	   to	   penetrate	  into	   the	   deep	   layers	   of	   the	   biofilm	  thereby	   only	   affecting	   the	   outer	   layer	  of	  the	  biofilm.	  	  	  	  	  Resistant	  phenotype	  Some	  bacteria	  may	  differentiate	  into	  a	  phenotypic	   resistant	   state	   of	  dormancy	  (green).	  	  	  	  	  Microenvironment	  changes	  Micro	   scale	   gradients	   of	   waste	   -­‐	   e.g.	  changes	  in	  pH	  and	  available	  nutrients,	  changes	   in	   oxygen	   availability	   –	  anaerobic	  niches	  (red).	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microenvironment,	   such	   as	   oxygen	  depletion,	  waste	   product	   accumulation	   and	  changes	  in	  nutrient	  availability,	  causes	  changes	  in	  the	  individual	  cells,	  figure	  9.	  The	   hypothesis	   of	   the	   diffusion	   barrier	   formed	   by	   the	   biofilm	   EPS	  matrix	   has	  been	   proposed	   to	   hold	   ground	   for	   the	   fact	   that	   some	   positively	   charged	  antibiotics,	  e.g.	  aminoglycosides	  (tobramycin)	  can	  bind	  to	  the	  negatively	  charged	  EPS,	   preventing	   the	   antibiotics	   to	   reach	   the	   cells	   encased	   in	   the	   depth	   of	   the	  biofilm	  but	  this	  has	  also	  been	  contradicted	  by	  presentation	  of	  readily	  penetration	  without	  killing	  of	  the	  cells	  [7,	  184].	  However	  it	  is	  highly	  improbable	  that	  this	  will	  occur	   to	   comparatively	   uncharged	   antibiotics	   as	   β-­‐lactams	   [185].	   	   It	   has	   been	  suggested	  that	  cells	  residing	  in	  biofilms	  grow	  slower	  in	  response	  to	  nutrient	  and	  oxygen	   deprivation	   and	   that	   this	   could	   account	   for	   the	   specific	   tolerance	   of	  biofilms.	  Yet	  other	  studies	  have	  suggested	  that	   the	   full	  magnitude	  of	  resistance	  cannot	  be	  subscribed	  to	  such	  mechanisms	  [184,	  186].	  	  The	  described	  efflux	  pump	  systems	  have	  not	  been	  considered	  an	  essential	  part	  of	  the	  biofilm	  resistance	  regime,	  as	  four	  of	  the	  best	  studied	  efflux	  pump	  systems	  in	  
P.	  aeruginosa	  had	  no	  impact	  on	  the	  biofilm	  specific	  resistance	  in	  mature	  biofilms	  [168].	   But	   it	   has	   later	   been	   suggested	   that	   the	  MexAB-­‐OprM	   and	  MexCD-­‐OprJ	  efflux	  pump	  systems	  are	  involved	  in	  biofilm	  resistance	  to	  azithromycin,	  showing	  the	   MexCD-­‐OprJ	   essential	   for	   azithromycin	   resistance	   in	   developing	   biofilms	  [187].	   The	   cells	   located	   at	   the	   biofilm	   surfaces	   are	   readily	   supplied	   with	  adequate	   amounts	   of	   nutrients	   and	   are	   metabolically	   active,	   while	   deeply	  embedded	  cells	  are	  more	  prone	  to	  have	  a	  slower	  metabolization	  due	  to	  reduced	  levels	   of	   nutrients	   and	   oxygen.	   Local	   oxygen	   limitations	   have	   been	   shown	   to	  diminish	  the	  effect	  of	  antibiotic	  in	  vitro	  with	  additive	  effects	  due	  to	  the	  presence	  of	   nitrate,	   a	   rich	   component	   in	   CF	   sputum[142,	   188].	   The	   metabolic	   rate	   and	  growth	   are	   highly	   controlled	   by	   the	   environmental	   factors,	   leaving	   the	   biofilm	  subdivided	   according	   to	   various	   metabolic	   stages.	   Several	   antibiotics	   have	   a	  more	   profound	   effect	   on	   the	   most	   metabolically	   active	   cells	   e.g.	   ciprofloxacin,	  tobramycin	  and	  tetracycline	  and	  this	  can	  be	  exploited	  when	  choosing	  antibiotics	  at	  the	  clinic.	  
	  	   35	  
7.1.2 Persister	  phenotype	  Within	   the	   evolving	   biofilms	   a	   small	   fraction	   of	   cells	   is	   believed	   to	   display	   an	  exceptional	  form	  of	  multidrug	  tolerance.	  Cells	   in	  biofilms	  are	  slow	  growing	  and	  many	  are	  possibly	  in	  stationary	  state.	  A	  small	  fraction	  of	  these	  cells	  are	  thought	  to	  practically	  shut	  down	  cell	  division	  and	  go	  into	  a	  probable	  state	  of	  dormancy.	  This	   small	   subpopulation	   remain	   living	   irrespective	   of	   the	   antibiotic	  concentrations	   used	   [189].	   These	   so	   called	   persister	   cells	   are	   not	   considered	  mutants	   as	   they	   overtly	   revert	   to	   reproduce	   the	   original	  wild	   type	   population	  upon	   reinoculation	   in	   an	   antibiotic	   free	   environment	   [190].	   In	   that	   sense,	   this	  division	  of	  cells	  would	  be	  considered	  tolerant	  rather	  than	  resistant	  to	  antibiotic	  treatment	  [190,	  191].	   	  One	  hypothesis	  of	   the	  principal	  mechanism	  for	  persister	  formation	   is	   that	   they	   are	   phenotypic	   variants	   and	   are	   results	   of	   stochastic	  fluctuations	   of	   toxic	   proteins	   [192].	   	   However,	   several	   genes	   appear	   to	   be	  involved	   in	   the	   persistence	   of	   P.	   aeruginosa	   [193,	   194].	   Quorum	   sensing	   has	  formerly	   been	   excluded	   as	   having	   a	   role	   in	   this	   phenomena,	   however	   a	   recent	  study	  showed	  that	  cell-­‐free	  spent	  medium	   induces	  persistence	   in	  P.	  aeruginosa	  strains,	   but	   not	   in	   E.	   coli	   or	   S.	   aureus	   [190,	   192,	   195].	   Both	   the	   phenazine	  pyocyanin	   and	   the	   acyl-­‐homoserine	   lactone	   3-­‐OC12-­‐HSL,	   which	   are	   normally	  secreted	   in	   the	   later	   stages	   of	   growth,	   significantly	   increased	   the	   number	   of	  persisters	   as	   well	   as	   on	   overexpression	   of	   P.	   aeruginosa	   LasR,	   which	   leads	   to	  increased	   levels	   of	   3-­‐OC12-­‐HSL	   which	   resulted	   in	   increased	   tolerance	   to	   the	  fluoroquinolone	  ofloxacin	  [195,	  196].	  	  Mechanically,	   the	   in	   vivo	   situation	   of	   persister	   cells	   in	   CF	   would	   also	   be	  challenged	  by	   the	  deep	  embedment	  within	   the	  biofilm	  EPS.	  Phagocytes	   remain	  impaired	  in	  reaching	  the	  EPS	  embedded	  surviving	  persister	  cells	  after	  antibiotic	  therapy,	  setting	  the	  stage	  for	  recurrent	  P.	  aeruginosa	  infections.	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8 Central	  problems	  in	  P.	  aeruginosa	  infection	  routes	  Understanding	  disease	  transmission	  is	  fundamental	  for	  our	  possibility	  to	  predict	  and	   control	   epidemics	   as	   well	   as	   understanding	   virulence	   and	   routes	   of	  transmission	  between	  and	  within	  patients.	  In	  a	  regime	  of	  colonizing	  bacteria	  the	  race	   for	   nutrients	   and	   habitats	   is	   a	   constant	   battle	   for	   acclimatization	   to	   the	  surroundings.	  Infecting	  pathogens	  need	  to	  cope	  with	  changing	  environments	  and	  adapt	   to	   each	   specific	   niche	   and	   its	   specific	   challenges	   in	   order	   to	   persist.	   A	  central	  dogma	  in	  bacterial	  pathogenesis	  can	  be	  considered	  as	  micro-­‐evolutionary	  adaptations	  to	  the	  fluctuations	  in	  the	  growth	  environments	  [197,	  198].	  There	  are	  many	   aspects	   that	   need	   to	   be	   taken	   into	   account	  when	   trying	   to	   pinpoint	   the	  central	   mechanisms	   for	   manifestation	   of	   diversity	   and	   maintenance	   of	  phenotypic	  diversity	   in	   infectious	  bacterial	  populations.	  Adaptive	  genetic	   traits	  as	   a	   response	   to	   local	   environmental	   changes	   take	   place	   as	   a	   result	   of	   natural	  selection	   [199],	   building	   the	   foundation	   for	   the	   establishment	   of	   a	   dominant	  population	  adapted	  to	  a	  specific	  niche	  [200,	  201].	  The	   P.	   aeruginosa	   infections	   in	   CF	   patients	   is	   a	   paradigm	   of	   how	   an	  environmental	  bacterium	  can	  become	  a	  successful	  pathogen	  able	  to	  persist	  in	  an	  atypical	   hostile	   environment,	   under	   selective	   pressures	   from	   therapeutics	   and	  immune	  defense	  mechanisms	  [40,	  151,	  201].	  	  Importantly,	  P.	  aeruginosa	  has	  been	  shown	  as	  a	  successful	  biofilm	  former	  in	  the	  airways	  of	  CF	  patients	  adding	  structural	  complexity	  and	  nutrient	  patches	  to	  the	  environment	  [32,	  141,	  142].	  Genetic	  variation	  and	  adaptive	  diversification	  readily	   emerge	   from	   populations	   growing	   in	   highly	   structural	   environments.	  Spatial	  complexity,	  as	  the	  various	  multifaceted	  biofilm	  structures,	  can	  be	  seen	  as	  a	   cradle	   for	   genetic	   variations	   and	   adaptive	   diversifications,	   in	   which	   the	  maintenance	  of	   the	  diversifying	  population	  can	  be	   foreseen	  due	  to	  a	  balance	   in	  fitness	  effects	  [200,	  202].	  	  	  	  Bacteria	   living	   in	  biofilm	  communities	  are	  subjected	  to	  a	  stressful	  environment	  of	   changing	   nutrient	   and	   oxygen	   concentrations	   [5,	   7].	   Stressful	   environments	  lead	   to	   stress-­‐induced	   mutations	   by	   which	   the	   mutated	   bacteria	   prominently	  enhance	   the	   chance	   of	   adapting	   to	   challenges	   in	   the	   environment.	   Structured	  
	   38	  
environments	   give	   rise	   to	   different	   niches,	   which	   facilitate	   organization	   and	   a	  battle	  for	  survival	  of	  the	  fittest[203].	  	  Apart	  from	  adaptation	  through	  regulatory	  processes,	  phenotypic	  variants	  arise	  when	  different	  niches	  are	  present	  in	  a	  heterogeneous	  environment.	  Rainey	  et	  al.	  1998	  have	  shown	  that	  when	  P.	  fluorescens	  was	  introduced	  into	  a	  spatially	  structured	  microcosm,	  the	  founding	  genotype	  rapidly	  diversified	  and	  gave	  rise	  to	  a	  collection	  of	  morphological	  diverse	  niche	  specific	  strains	  [200].	  In	  an	  identical	  non-­‐structured	   environment,	   no	   diversification	   had	   arisen	   in	   the	   incubation	  period.	  The	  impact	  on	  diversification	  through	  the	  biofilm	  mode	  of	  growth	  in	  flow	  cells,	   where	   heterogeneous	   distribution	   of	   cells	   leads	   to	   local	   changes	   in	  nutrients,	   leads	   to	   a	   rapid	   production	   of	   morphological	   different	   variants,	   see	  figure	   10.	   Fast	   niche	   adaptation	   within	   the	   environment	   may	   generate	  populations	   of	   specialists	   that	   have	   adapted	   to	   and	   are	   populationwise	  maintained,	  however	  niche-­‐specialists	  often	  suffer	  loss	  in	  overall	  fitness	  [204].	  	  The	   acquisition	   of	   P.	   aeruginosa	   by	   CF	   patients	   is	   predominately	  accomplished	  from	  an	  environmental	  source	  [205].	  The	  switch	  to	  the	  CF	  airways	  challenges	   the	  environmental	  bacterium	  by	  a	   fundamental	  alteration	   in	  growth	  conditions	  and	  environment.	  The	  CF	  airways	  are	  a	  heterogeneous	  environment	  and	  present	  several	  niches	  with	  different	  oxygen	  concentrations	  and	  a	  variety	  of	  endogenous	   stress	   factors	   as	   well	   as	   administered	   chemotherapeutics	   [141,	  152].	   Comparable	   to	   the	  microevolution	   studies	   in	   test	   tubes,	   the	   airways	   give	  rise	  to	  profound	  adaptation	  to	  the	  various	  niches	  with	  fluctuating	  environmental	  changes	  putting	  pressure	  on	  metabolic	  and	  physiological	  adaptation.	  	  Moreover,	  the	  impact	  of	  the	  immune	  defenses	  in	  the	  airways,	  through	  the	  production	  of	  e.g.	  oxygen	   radicals,	   have	   been	   associated	   with	   DNA	   damage	   in	   CF	   P.	   aeruginosa	  isolates	  and	  mutations	  in	  the	  genes	  responsible	  for	  DNA	  repair	  systems	  lead	  to	  the	  mutator	   phenotype	   [169].	   Mutations	   arising	   during	   an	   infection	   of	   the	   CF	  airways	   create	   a	   foundation	   for	   arising	   variants	   that	   are	   fit	   to	   cope	   with	   the	  changing	  and	  hostile	  environment.	  	  	  	  








Figure	  10.	  Morphotypic	  diversification	  in	  PAO1	  flow	  cell	  biofilms.	  4	  day	  old	  PAO1	  biofilms	  grown	   in	   flow	  cells	   (center	  coloni,	   from	  PAO1	  original	   inoculum	  culture).	  The	  flow	  cell	  systems	  were	  set	  up	  as	  shown	  in[206]	  with	  a	  10%	  LB	  media	  supply.	  At	  day	  4,	  each	  channel	  was	  harvested	  with	  glass	  beads	  in	  0.9%	  NaCl.	  The	  harvested	  biofilms	  were	  plated	   on	   LB	   agar	   plates	   and	   left	   overnight	   at	   37°C	   before	   colony	  morphologies	  were	  screened	  with	  a	  Zeiss	  axioplan	  microscope	  with	  a	  x2.5	  plan	  objective.	  Here	  showing	  4	  day	   old	   harvested	   biofilm	   however	   morphotypes	   were	   already	   found	   at	   day	   2	   (not	  shown),	  unpublished	  data	  Martin	  W.	  Nielsen	  and	  Fatima	  Y.	  Coronado,	  2011.	  	  	  Importantly,	  P.	  aeruginosa	  has	  proven	  itself	  highly	  capable	  of	  coping	  with	  the	  CF	  environments	  underlined	  by	  the	  fact	  that	  virtually	  all	  CF	  patients	  end	  up	  with	  a	  chronic	  P.	  aeruginosa	  infection,	  often	  with	  the	  same	  lineage	  persisting	  for	  decades	  [207].	  Furthermore	   it	  has	  been	  shown,	   that	  CF	  patients,	  who	  receive	  a	  lung	   transplant	   are	   very	   often	   recolonized	   by	   the	   identical	   strain	   [208].	   This	  gives	   strong	   indications	   on	   a	   scenario	   of	   the	   upper	   airways	   as	   a	   reservoir	   for	  reinoculations	  of	  the	  lower	  airways	  [133].	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8.1 Bacterial	  epidemiology	  in	  the	  CF	  patient	  The	   Copenhagen	   CF	   Center	   has	   since	   1973	   been	   storing	   P.	   aeruginosa	   isolate	  samples	  from	  CF	  patients	  [209].	  This	  impressive	  collection	  of	  isolates	  has	  opened	  an	  opportunity	  for	  exploring	  the	  evolutionary	  path	  that	  has	  taken	  place	  since	  the	  start	  of	   the	  collection	  [4,	  210].	  Furthermore,	  a	  sinus	  surgery	  program	  has	  been	  initiated	   at	   the	   Copenhagen	  CF	   Center	   opening	   up	   a	   possibility	   to	   gain	   further	  insight	   into	   the	   foundation	   of	   the	   inescapable	   switch	   from	   intermittent	   to	  chronic	   infections.	   During	   intermittent	   colonization,	   and	   at	   the	   early	   stages	   of	  chronic	   infection,	   the	   genotypic	   diversity	   is	   high	   [207].	   Early	   aggressive	  antibiotic	   treatments	   have	   been	   successful	   in	   temporarily	   eradicating	   the	  bacteria	  from	  intermittently	  colonized	  CF	  patients,	  however	  showing	  a	  pattern	  of	  recolonization	   by	   identical	   clones	   or	   environmental	   strains	   [211].	   Intermittent	  colonization	   can	   range	   from	   several	   months	   to	   years	   with	   repeated	   cycles	   of	  treatment	   and	   recolonization	   [133].	   The	   antibiotic	   penetration	   in	   the	   sinus	  compartments	  is	  less	  efficient	  and	  might	  allow	  for	  adaptive	  mutations	  that	  prime	  the	  bacteria	  to	  cope	  with	  the	  far	  more	  harsh	  environment	  of	  the	  lower	  airways	  [98,	  210].	  	  	   Interestingly,	   long-­‐term	   chronic	   infections	   show	   a	   very	   low	   genotypic	  diversity	   and	  within	   the	   group	   of	   CF	   patients	   at	   the	   CF	   center,	   two	   dominant	  clones	  DK1	  and	  DK2	  (earlier	  denoted	  r	  and	  b)	  have	  been	   identified	  [207].	   	  The	  two	   dominant	   clones	   have	   spread	   among	   the	   patients	   probably	   through	  exchange	  by	  patient-­‐to-­‐patient	  contact	  in	  the	  Copenhagen	  CF	  clinic.	  However,	  as	  case	  studies	  they	  are	  highly	  interesting.	  The	  strains	  must	  be	  considered	  as	  highly	  adapted	   to	   the	   CF	   airways	   as	   they	   are	   shown	   to	   be	   capable	   of	   outcompeting	  other	  strains	  or	  as	  co-­‐infecting	  the	  patient	  as	  seen	   for	  patient	  11,[207].	  A	   large	  fraction	   of	   the	   chronically	   infected	   patients	   have	   furthermore	   been	   identified	  with	   the	  DK1	  and/or	  DK2	   lineages,	  with	  43	  patients	  out	  of	  162	   identified	  with	  the	  DK2	  linage	  since	  1973.	  	  The	  DK2	  is	  a	  highly	  successful	  and	  transmissible	  P.	  aeruginosa	  linage	  that	  has	  persisted	   for	  more	   than	  200.000	  generations	   in	  CF	  patients	   from	  the	  same	  cohort	   [4].	   Over	   the	   many	   years	   the	   DK2	   lineage	   has	   persisted	   in	   the	   CF	  community,	   it	  must	  initially	  have	  had	  to	  adapt	  to	  the	  stressful	  conditions	  of	  the	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CF	  airways,	  having	  a	  high	   impact	  on	   the	  evolutionary	  progress	  of	   the	  bacterial	  population.	   In	  many	  ways	  one	   can	  parallelize	   the	  evolutionary	  events	  with	   the	  long-­‐term	   study	   conducted	   by	   Richard	   Lenski	   and	   colleagues,	   although	   their	  experimental	   setup	   lack	   the	   environmental	   complexity	   of	   the	   host	   [212].	   The	  DK2	   linage	   has	   undergone	   an	   array	   of	   adaptive	   events	   to	   become	   a	   successful	  colonizer	  of	  the	  CF	  airways.	  Data	  analysis	  of	  genotypic	  and	  metabolic	  traits	  show	  that	  the	  early	  isolates	  genotypically	  show	  more	  similarity	  to	  the	  wild	  type	  PAO1	  strain,	  see	  figure	  11.	  The	  data	  indicate	  that	  an	  evolutionary	  path	  leading	  to	  major	  adaptive	  events	  in	  the	  DK2	  lineage	  occur	  before	  1979.	  The	  following	  period	  of	  29	  years	  were	  only	  characterized	  by	  few	  phenotypic	  changes,	  with	  early	  regulatory	  mutations	   seen	   in	   the	   mucA,	   lasR	   and	   rpoN	   affecting;	   expression	   of	   alginate	  production,	   quorum	   sensing	   and	   nitrogen	  metabolism	   and	  motility	   [4,	   41,	   85],	  respectively.	   The	   DK2	   linage	  was	   shown	   to	   undergo	   an	   initial	   period	   of	   rapid	  adaptation.	  Interestingly,	  it	  was	  found	  that	  the	  adaptive	  processes	  leading	  to	  the	  
chronic	  stage	  and	  persistence	  in	  the	  DK2	  linage	  did	  not	  lead	  to	  high	  diversity	  in	  the	   individual	   patients,	   judged	   from	   phenotypic/genotypic	   comparisons	   in	  
Figure	   11.	   Phenotypic	   relationships	   and	   dynamics	   among	   DK2	   isolates.	  Principal	   component	   analyses	   of	   the	   microarray	   expression	   data.	   Show	   a	   similar	  pattern	   for	   phenotypic	   biolog	   data	   (not	   shown).	   Data	   suggest	   that	   major	   changes	  occurred	  before	  1979.	  First	  principal	  component	  (PC1)	  loadings	  for	  each	  isolate	  are	  graphed	  as	   a	   function	  of	   time	  (and	  estimated	  generations).	   PC1	   represents	  42%	  of	  the	   total	   variation	   among	   isolates.	   Error	   bars	   indicate	   standard	   deviations	   of	  biological	  triplicates	  of	  the	  same	  isolate,	  Yang	  et	  al,	  2011[4].	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sputum	   samples	   or	   from	   comparisons	   between	  patients	   infected	  with	   the	  DK2	  clone	   [4].	  Evolutionary	   trails	   furthermore	   leads	   to	   the	   foundation	  of	   specialists	  that	  are	  more	  fit	  to	  a	  discriminating	  environment	  but	  have	  a	  reduced	  fitness	  to	  other	  environments.	  	  	   The	   CF	   lung	   environment	   is	   a	   heterogeneous	   habitat	   with	   several	  niches	   where	   microorganisms	   can	   grow	   in	   structured	   communities	   [138].	  Several	  events	  as	  coughing,	  the	  use	  of	  the	  “airway	  clearing	  vest7”,	  flushing	  of	  the	  airways	   etc.,	   leads	   to	   geographic	   fluctuations	   of	   the	   bacterial	   distributions,	  accelerating	  interactions	  and	  competition.	  Adaptive	  mutations	  have	  the	  potential	  to	  endow	  evolving	  strains	  with	  the	  capacity	  to	  replace	  strains	  with	  lower	  fitness	  in	   a	   specific	   environment.	   However,	   if	   the	   genetic	  makeup	   leads	   to	   a	   reduced	  fitness	   relative	   to	   the	   ancestral	   or	   opposing	   strain,	   it	   will	   not	   be	   capable	   to	  outcompete	   the	   opposing	   strains	   though	   still	   being	   a	   specialist	   to	   the	  environment	  as	  it	  originally	  adapted	  to.	  	  	   	  	   Traditionally	  competition	  experiments	  have	  been	  conducted	   in	  simple	  selective	   setups	   with	   growth	   rate	   as	   the	   measured	   parameter,	   however	   the	  complexity	  of	  the	  CF	  airways	  with	  the	  wide	  range	  of	  selective	  forces	  as	  nutrient	  levels,	   oxygen	   concentrations,	   antibiotics	   and	   ROS	   needs	   to	   be	   taken	   into	  consideration,	   described	   in	   the	   previous	   sections.	   This	   scenario	   is	   shown	   in	  Figure	   12	  with	   a	   fairly	   simple	   setup,	   that	   show	   the	   importance	   of	   one	   of	   such	  factors	   to	  evaluate	  how	   fit	   the	  adapted	  strain	   is	   relative	   to	   the	  ancestor.	   If	   two	  isolates	   are	  mixed	   in	   a	   1:1	   ratio	  without	   an	   environmental	   challenge,	   then	   the	  fastest	   growing	   isolate	   takes	   over,	   see	   table	   1.	   At	   the	   0µg/ml	   of	   colistin,	   the	  ancestral	  CF333-­‐1991	  strain	  with	  a	  doubling	   time	  of	  56	  min	  will	   take	  over	   the	  population	   by	   outcompeting	   the	   slower	   growing	   adapted	   strain	   CF333-­‐2007	  with	   a	   doubling	   time	   of	   78	  min.	   Between	   24-­‐48h	   CF333-­‐1991	   takes	   over	   (not	  shown	   data).	   However	   sub-­‐MIC	   concentrations	   lead	   to	   a	   shift	   in	   fitness	   and	  hence	   dominating	   strain,	   Figure	   12	   C	   and	   D.	   CF333-­‐2007	   is	   more	   fit	   to	   the	  conditions	  that	  correlate	  with	  long	  adaptation	  in	  the	  CF	  environment.	  






Figure 12 Competition experiment. Two DK2 P. aeruginosa isolates form CF patient 
CF333 competition in test tubes under different colistin concentrations. Competitions 
are set up in a 1:1 inoculum of each isolate, and allowed to grow together in a LB media 
with individual concentrations of colistin sulfate (Sigma Aldrich, Glostrup, Denmark) in 
5 ml shaken test tubes for 24 hours before the samples were fixated in 2% 
paraformaldehyde and analyzed by Flow Cytometry (BD FACSCantoII, BD Biosciences, 
San Jose, CA, USA). Histograms represent GFP- or non-expressing populations. Patient 
CF333 isolates CF333-1991 and CF333-2007. 
A and B represent the individual isolates grown for 24h in LB media under the specific 
colistin concentrations, A) CF333-1991-GFP and B) CF333-2007-GFP. 
C and D represent identical isolates as in A and B +/- GFP expression of the strains, 
inoculated 1:1. C) CF333-1991-GFP vs. CF333-2007 and D) CF333-1991 vs. CF333-
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  Table	  1	  
Strain	   in	  vitro	  doubling	  time	  (min)	   	  	  	  MIC	  	  Colistin	   mucA	   algU	   rpoN	   lasR	  CF333-­‐1991	   56	   	  	  	  	  	  7µg/ml	   ∆G430	   A55G	   T1256C	   deletion	  CF333-­‐1997	   59	   >256µg/ml	   ∆G430	   A55G	   T1256C	   deletion	  CF333-­‐2003	   74	   >256µg/ml	   ∆G430	   A55G	   T1256C	   deletion	  CF333-­‐2007	   78	   >256µg/ml	   ∆G430	   A55G	   T1256C	   deletion	  	  	  	  	  	  	  	  	  	  	  Table	  adapted	  from	  Yang	  et	  al.	  2011,	  supplementary	  data	  table	  S1[4].	  Inserted	  MIC	  	  	  	  	  	  	  	  	  	  	  	  values	  from	  Lei	  Yang	  unpublished	  data,	  [213]	  	  Conducting	   experiments	   to	   measure	   the	   adaptive	   traits	   and	   changes	   in	   the	  relative	   fitness	   in	   order	   to	   gain	   insight	   into	   the	   evolutionary	   trajectory	   in	  microbial	   populations,	   sets	   the	   requirement	   for	   integration	   of	   selective	   and	  community	  shaping	  forces.	  The	  impact	  of	  the	  information	  will	  provide	  significant	  contribution	  to	  understanding	  aspects	  of	  evolutionary	  biology.	  Recognizing	  these	  aspects,	  will	  contribute	  to	  sculpting	  directed	  treatment	  strategies	  suited	  for	  both	  generalists	  and	  niche	  specialists	  that	  might	  be	  dominating	  the	  different	  stages	  of	  infection.	  For	  obvious	  reasons	   is	  not	  possible	   to	  conduct	   infection	  studies	  with	  CF	  patients.	  Therefore,	  an	  immense	  amount	  of	  work	  has	  gone	  into	  developing	  both	  
in	  vitro	  and	  in	  vivo	  model	  systems	  to	  investigate	  P.	  aeruginosa	  infections	  and	  the	  individual	   aspects	   thereof.	   Conducting	   long-­‐term	   experiments	   to	   study	   the	  evolutionary	   traits	   of	   P.	   aeruginosa	   in	   the	   CF	   airway	   environments,	   is	   highly	  problematic	   though	   as	   the	   available	  models	   do	   not	   embrace	   the	   complexity	   of	  airways	  as	   in	  vitro	  systems	  or	  animal	  models	  are	  either	  practically	   inaccessible	  or	  do	  not	  recapitulate	  the	  human	  disease,	  see	  section	  9.	  This	  is	  the	  foundation	  for	  the	   Ph.D.	   project;	   to	   construct	   in	   vitro	  models	   for	   future	   investigations	   of	   e.g.	  fitness	   measures,	   inter-­‐airway	   transmissions,	   adaptability	   to	   applied	   stresses	  and	  competition	  with	  oxygen	  as	  the	  key	  component.	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9 Model	  systems	  for	  CF	  investigations	  	  
9.1 Experimental	  systems	  –	  patients	  	  Culturing	   bacterial	   specimens	   from	   CF	   patients	   remains	   important	   both	  diagnostically	  and	  for	  in	  vitro	  studies	  and	  as	  a	  resource	  for	  subsequent	  genotypic	  analyses.	  P.	  aeruginosa	  samples	  from	  CF	  patients	  have	  made	  the	  foundation	  for	  the	   unique	   collection	   for	   the	   long	   term	   evolution	   study	   conducted	   on	   isolates	  from	   the	  Copenhagen	  CF	   center	   [4,	   207].	   Samples	   from	  patients	   are	   accessible	  through	   different	   sampling	   processes.	   Bronchoalveolar	   lavage	   fluid	   (BALF)	   is	  considered	  a	  gold	  standard	  for	  detection	  of	  pathogens	  in	  the	  lower	  airways	  of	  CF	  patients	   and	  might	   be	   the	   solution	   in	   young	   children,	   who	   have	   difficulties	   in	  producing	   coughed	   up	   sputum	   samples	   [214].	   However,	   as	   BALF	   samples	  require	   the	  use	  of	  a	  bronchoscope	  and	   is	   time	  consuming,	   sputum	  samples	  are	  far	  more	  accessible.	  Lungs	  from	  transplanted	  or	  succumbed	  patients,	  give	  direct	  access	  to	  the	  most	  distal	  generations	  in	  the	  lungs	  [5,	  138].	  Such	  direct	  access	  to	  aggregates	   from	   both	   the	   conductive	   and	   respiratory	   zones	   of	   the	   lungs,	   have	  given	  profound	  insight	  to	  the	  vast	  biofilm	  formation	  with	  heavy	  PMN	  infiltration	  [138].	  Performing	  infection	  studies	  on	  CF	  patients	  are	  obviously	  not	  possible,	  therefore	  the	  use	  of	  in	  vitro	  and	  in	  vivo	  model	  systems	  is	  essential	  for	  accomplishing	  such	  studies.	  	  However	  such	  systems	  might	  not	  perform	  to	  a	  sense	  that	  allows	  direct	  extrapolation	  to	  the	  human	  CF	  pathology.	  	  
9.2 	  In	  vivo	  models	  for	  cystic	  fibrosis	  For	   many	   years	   the	   use	   of	   animal	   models	   as	   substitutions	   for	   the	   human	  organism	   has	   been	   a	   central	   tool	   for	   scientists	   in	   order	   to	   investigate	   human	  diseases.	   The	   production	   of	   transgenic	   animals	   has	   been	   the	   central	   turning	  point	   for	   investigations	  of	  specific	  cellular	   functions.	  Knocking	  out	  or	  replacing	  genes	  for	  resulting	  nonfunctional	  or	  altered	  phenotypes,	  has	  accomplished	  this.	  Several	   animal	   models	   have	   been	   produced	   to	   investigate	   traits	   in	   chronic	   P.	  
aeruginosa	  infection	  studies.	  Animal	  studies	  enable	  repeated	  experiments,	  which	  is	   a	   valuable	   advantage	   when	   performing	   infection	   studies.	   Model	   species	  include	  several	  rodent	  models	  as	  rat	  [161],	  mice	  [215-­‐217]	  and	  guinea	  pigs	  [218,	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219]	  as	  well	  as	  other	  species	   like	   ferrets[220],	  monkeys	  [221]	  and	  the	  recently	  produced	   CF	   pig	   [222,	   223].	   The	   ongoing	   effort	   to	   produce	   alternative	   animal	  models	  has	  had	  the	  purpose	  of	  generating	  models	  capable	  to	  recapitulating	  the	  development	   in	   CF	   pathology.	   CF	   airway	   and	   pancreatic	   disease	   progression	  show	  scarce	  resemblance	  between	  mice	  and	  humans	  [224].	  For	  many	  years	  mice	  have	  been	  the	  primary	   in	  vivo	  models	   for	  CF	  research.	  This	   is	  primarily	  due	  to	  the	  obvious	  reasons	  as	   low	  costs,	  ease	  of	  production	  and	  handling.	   It	  only	  took	  three	  years	  after	  the	  identification	  and	  cloning	  of	  the	  CFTR	  gene	  until	  the	  first	  CF	  mouse	  model	   was	   reported	   [215].	   However	  mice	   do	   not	   acquire	   spontaneous	  and	  chronic	  infections	  as	  seen	  with	  human	  CF	  patients	  [225].	  Cftr-­‐/-­‐	  mice	  do	  not	  show	  the	  same	  upregulation	  of	  ENaC	  as	  seen	  in	  the	  lower	  airways	  of	  CF	  patients	  [226,	   227].	   Attempts	   to	   reproduce	   the	   effect	   of	   mucus	   accumulation	   in	   the	  airways	  of	  mice	  have	  been	  accomplished	  by	  overexpression	  of	  ENaC	  as	  well	  as	  induction	  of	  mucus	  overproduction	   [228,	   229].	   Several	   groups	  have	   attempted	  different	   methods	   to	   inoculate	   the	   lungs	   of	   CF	  mice	   with	   bacteria	   in	   order	   to	  reproduce	  more	  chronic	  traits	  as	  evident	  in	  the	  human	  infections.	  	  Methods	  have	  generally	  been	  focused	  on	  mechanical	  confinement	  of	  the	  bacteria	  in	  the	  lungs	  of	  the	  mice	  by	  embedment	  of	   the	   inoculating	  bacteria	   in	  agar,	  agarose	  or	  alginate	  beads,	   resulting	   in	   a	   more	   successful	   defect	   of	   bacterial	   clearance	   [216,	   230-­‐232].	  Successful	  studies	  with	  non-­‐embedded	  bacteria	  have	  been	  conducted	  with	  mucoid	  P.	  aeruginosa	  strains	  [233,	  234].	  	  CFTR	   knockout	   pigs	   have	   been	   shown	   to	   develop	   cystic	   fibrosis	   disease	   in	  multiple	  organs	  comparable	  to	  human	  CF	  patients.	  The	  piglets	  did	  not	  show	  any	  signs	  of	  lung	  disease	  or	  signs	  of	  infection	  or	  inflammation	  in	  the	  first	  days	  of	  life	  and	   both	   CFTR-­‐/-­‐	   and	   CFTRF508del/F508del	   developed	   lung	   disease	  within	   the	   first	  months	  of	  their	  life	  [235].	  Stoltz	  et	  al.	  2010,	  showed	  that	  the	  CF	  pigs	  are	  impaired	  in	   clearing	   bacteria	   just	   after	   birth	   in	   the	   absence	   of	   inflammation.	   They	  furthermore	  state	  that	  over	  time,	  the	  CF	  pigs	  show	  several	  CF	  hallmark	  features	  of	   inflammation,	   mucus	   accumulation	   and	   infection	   as	   seen	   in	   the	   human	   CF	  patients[235,	  236].	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However	   complications	   with	   the	   models	   are	   severe	   as	   CRTR-­‐deficient	   piglets	  develop	   meconium	   ileus8	   and	   surgery	   is	   required	   in	   order	   for	   the	   piglets	   to	  survive	   [235].	   Production	  of	   the	  CF	  pigs	   is	   indisputably	   an	   important	   research	  tool	   for	   CF	   research,	   that	   will	   answer	   many	   questions,	   but	   it	   is	   also	   a	   model	  accompanied	  with	  high	  financial	  costs.	  For	  this	  reason	  it	  is	  restricted	  to	  a	  small	  fraction	  of	  the	  CF	  research	  community.	  	   In	  conclusion,	  differences	  in	  disease	  traits	  in	  various	  organs	  do	  not	  make	  the	  majority	  of	  CF	  animal	  models	  ideal	  for	  especially	  long-­‐term	  infectious	  studies	  as	  anatomic,	  physiologic	  and	  differences	   in	   intrinsic	  defense	  mechanisms	  gives	  rise	  to	  limitations	  of	  the	  models	  [230].	  	  
9.3 In	  vitro	  models	  for	  cystic	  fibrosis	  investigations	  
9.3.1 Universal	  Test	  tubes	  Test	  tubes	  have	  been	  used	  for	  hundreds	  of	  years	  to	  grow	  microbial	  cultures	  and	  still	   remain	   an	   essential	   tool	   in	   research.	   Immense	   amounts	   of	   research	   have	  been	   conducted	   with	   planktonic	   cultures	   as	   they	   are	   easily	   manipulated	   in	  laboratory	   settings	   and	   grow	   in	   e.g.	  microplates,	   flasks,	   test	   tubes,	   chemostats	  and	   membrane	   diffusion	   chambers.	   Such	   experimental	   setups	   are	   substantial	  tools	   for	   a	   wide	   range	   studies	   of	   e.g.	   culture	   developments,	   growth	   rates,	  antibiotic	   susceptibility	   tests	   and	   long	   term	   evolutionary	   experiments	   [237].	  Easy	   system	   manipulations	   provide	   suitable	   environmental	   conditions	   for	  investigating	  desired	  microorganisms	  and	  culture	  combinations.	  The	  simple	  test	  tubes	   are	   the	   obvious	   choice	   for	   initial	   tests,	   fast	   visualizations	   of	   e.g.	  aggregations,	   biofilm	   capabilities,	   antibiotic	   tests	   etc.	   However	   test	   tubes	   are	  highly	  limited	  in	  the	  slightest	  comparison	  to	  the	  natural	  habitat	  of	  microbes.	  	  One	  such	   limitation,	   is	   how	   to	   extrapolate	   data	   to	   the	   microorganism’s	   natural	  habitat,	  as	  the	  culture	  systems	  might	  be	  even	  too	  artificial,	  with	  e.g.	  less	  than	  1%	  of	  the	  109	  bacterial	  cells/gram	  soil	  are	  estimated	  to	  be	  culturable	   in	   laboratory	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  condition	  that	  leads	  to	  obstruction	  of	  the	  intestine	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media	  [238].	  	  Furthermore,	   as	   biofilms	   are	   considered	   the	  major	   general	   natural	   lifestyle	   of	  bacteria,	   (see	   section	   3)	   and	   as	   transitioning	   from	   planktonic	   cultures	   to	   the	  biofilm	   mode	   of	   growth	   highly	   differ	   in	   gene	   expression	   and	   regulation,	   the	  comparison	   to	   a	   natural	   habitat	   becomes	   even	   less	   distinct	   [239].	   However,	  screenings	   in	   microplates	   for	   phenotypic	   profiles	   (Biolog),	   biofilm	   formation,	  competition	   experiments	   among	   others	   are	   highly	   beneficial	   in	   fast	   screenings	  for	  selection	  of	  interesting	  candidates	  from	  e.g.	  recovered	  P.	  aeruginosa	  isolates	  from	  CF	  sputum	  samples.	   
9.3.2 Cell	  lines	  In	   addition	   to	   available	   animal	   models,	   the	   development	   of	   immortalized	   cell	  lines	   has	   had	   a	   substantial	   positive	   impact	   on	   biochemical,	   cytotoxic,	   genetic,	  physiological	  studies	  for	  many	  years.	  In	  CF	  research	  immortalized	  cell	  lines	  have	  contributed	  to	  the	  understanding	  of	  the	  underlying	  mechanisms	  of	  CF	  due	  to	  the	  scarcity	  of	   tissue	  and	  primary	  cell	  material	   for	  such	  studies.	  Airway	  epithelium	  has	  been	  the	  main	  focus	  of	  immortalized	  cell	  lines,	  leading	  to	  the	  availability	  of	  a	  variety	   of	   WT	   and	   CFTR-­‐/-­‐	   cell	   lines	   [240].	   In	   vitro	   cultures	   of	   immortalized	  epithelial	  cells	   from	  the	  airways	  of	  both	  CF	  and	  non-­‐CF	   individuals,	  have	  made	  important	   contributions	   to	   characterization	   between	   the	   CFTR	   genotype	   and	  disease	  phenotype	  [241].	  Such	  cell	  lines	  have	  furthermore	  been	  indispensable	  in	  high	   through	   put	   screening	   for	   the	   development	   of	   new	   therapeutics	   for	   CF	  treatment	  [240].	  	  The	  airway	  epithelium	  is	  an	  essential	  environmental	  interface	  and	  epithelial	  cells	  have	   been	   cultured	   from	   both	   animal	   and	   human	   airways.	   	   Both	   primary	   and	  immortalized	   cell	   cultures	   can	   present	   the	   specific	   cellular	   properties	   but	   lack	  the	   structural	   complexity	   of	   the	   organs.	   Most	   immortalized	   cell	   lines	   do	   not	  maintain	   proper	   cellular	   differentiation	   and	   the	   specific	   cell	   properties	   [240].	  Ongoing	   work	   is	   carried	   out	   to	   establish	   new	   and	   improved	   cell	   lines	   for	   CF	  research	  [242].	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9.3.3 Biofilm	  investigations	  –	  methodology	  Due	   to	   the	   notion	   that	   microbes	   primarily	   live	   in	   biofilm	   communities,	   an	  immense	   amount	   of	   work	   has	   gone	   into	   refining	   ways	   to	   obtain	   detailed	  information	  on	  bacterial	  biofilms.	  	  One	  crude	  high	  throughput	  biofilm	  screening	  method	  is	   firstly	  based	  on	  the	   adhesive	   properties	   of	   microorganisms	   to	   microtiter	   plates	   followed	   by	  biomass	   detection	   by	   a	   staining	   with	   crystal	   violet.	   	   This	   method	   is	   a	   highly	  useful	   tool	   for	   screening	   purposes	   in	   the	   identification	   process	   of	   genetic	  evaluations	   for	   important	   biofilm	  promoting	   genes,	   however	   it	   is	   a	   very	   crude	  and	  error	  prone	  method	  [243,	  244].	  	  	  Aspects	  of	  biofilm	  formation	  at	   the	  air-­‐liquid	   interface	  can	  be	  addressed	  by	  angling	  the	  culture	  chamber,	  allowing	  the	  biofilm	  to	  establish	  and	  inspect	  by	  phase-­‐contrast	  microscopy	  [245].	  This	   type	  of	  static	  assay	  utilizes	  visualization	  aspects	   compared	   to	   the	   pellicle	   formation	   assay	   that	   relies	   on	   properties	   as	  intercellular	   adhesion	   of	   surface	   proteins	   in	   order	   to	   sustain	   a	   floating	  phenotype	  [117,	  246].	  Two	  tremendously	  high	  resolution	  visualization	  methods	  are:	   Atomic	   Force	   Microscopy	   [247],	   a	   member	   of	   the	   scanning	   probe	  microscopy	   family;	   and	   electron	  microscopy	   [248].	   These	  methods	   rely	   on	   an	  altering	   of	   the	   specimens	   for	   visualizing	   measures,	   making	   each	   sample	   time	  point	  measurements	  with	  no	  possibility	  for	  continuous	  biofilm	  investigations.	  A	  big	   leap	   forward	   arose	   with	   the	   Confocal	   Laser	   Scanning	   Microscope	   (CLSM)	  which	  was	  developed	   towards	   the	   1980s.	   This	   specific	   type	   of	  microscope	  has	  the	   possibility	   of	   obtaining	   high-­‐resolution	   optical	   images	   at	   selective	   depths.	  The	  advances	   in	  different	  staining	  techniques	  have	  allowed	  researchers	  to	  gain	  insight	   into	   in	   vitro	   biofilms	   from	  patient	   samples	   by	   the	  utilization	   of	   various	  fluorescent	   staining	   techniques	   or	   the	   by	   expression	   of	   various	   reporter	  proteins.	  	  The	  flow	  cell	  system	  is	  one	  of	  the	  most	  important	  contributors	  to	  studies	  on	  microbial	  biofilms,	  figure	  13.	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In	   combination	   with	   the	   confocal	   microscope	   and	   various	   staining	  techniques,	   the	   flow	   cell	   system	  becomes	   an	   impressive	   tool	   for	   niche	   specific	  investigations	  of	  microbial	  biofilms,	  figure	  13.	  Furthermore	  it	  is	  an	  efficient	  tool	  for	   analyzing	   the	   distributive	   effects	   of	   antimicrobial	   agents	   and	   other	  environmental	   factors	   [98,	   184,	   188,	   191].	   Confocal	   images	   are	   acquired	   at	  section	   by	   section	   and	   collectively	   assembled	   in	   computer	   programs	   as	   the	  Imaris	   software	   (Bitplane	   AG)	   to	   generate	   3D	   representative	   images	   [249].	  Additionally	  the	  biofilm	  data	  can	  be	  quantified	  with	  computer	  programs	  such	  as	  COMSTAT	  [250,	  251].	  However,	  biofilm	  formed	  in	  these	  systems	  is	  an	  “artificial	  biofilm”	   with	   biofilm	   propagation	   on	   a	   glass	   substratum	   compared	   to	   the	   P.	  
aeruginosa	   biofilms	   in	   the	   airways	  of	   CF	  patients	   [138].	   Furthermore,	   the	   flow	  cell	  systems	  are	  mono-­‐compartmental	  and	  lack	  the	  dynamics	  of	  the	  CF	  airways.	  	  	  	   	  
Figure	  13.	  	  Graphic	  representation	  of	  the	  assembled	  flow	  cell	  system[6]	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10 Microfluidic	  systems	  –	  organ	  on	  a	  chip	  To	   imagine	   possible	   microfluidic	   applications	   one	   could	   look	   at	   how	   nature	  through	   millions	   of	   years	   of	   evolution	   has	   sculptured	   many	   parts	   of	   the	  mammalian	  physiology	  into	  an	  amazing	  network	  of	  microfluidic	  systems.	  These	  systems	  are	  essential	  for	  us	  to	  function	  as	  humans.	  Examples	  of	  such	  structurally	  specialized	  systems	  are	  the	  lymphatic-­‐	  and	  cardiovascular	  systems	  as	  well	  as	  the	  fundamental	  nephrons	  in	  the	  kidneys.	  Essential	  to	  these	  systems	  is	  the	  fact	  that	  minimizing	   distances	   between	   compartments	   allow	   specific	   laws	   of	   physics	   to	  dominate.	   Diffusive	   properties	   are	   the	   ruling	   forces	   that	   drive	   gas	   exchange	  between	  the	  blood	  capillaries	  and	  the	  respiratory	  segments	  of	  the	  lungs	  (alveolar	  sacs,	  duct,	  bronchioles),	  principles	  and	  ideas	  that	  I	  have	  taken	  into	  consideration	  in	  my	  works.	  The	   uses	   of	   microfluidic	   systems	   have	   expansively	   progressed	   in	   the	  world	  of	  biology	  during	  the	  last	  decades.	  Many	  beneficial	  aspects	  to	  microfluidic	  systems	  have	  proven	  their	  worth	  in	  several	  aspects	  due	  to	  the	  small	  volumes	  and	  benefits	  of	  the	  large	  surface	  area	  to	  volume	  ratios	  [252].	  Only	  small	  volumes	  are	  needed	   in	  such	  systems	   thereby	  reducing	  cost	   for	   reagents,	  expensive	  drugs	   in	  approval	  trials	  and	  reducing	  amounts	  of	  chemical	  waste	  produced.	  	  The	  most	  pronounced	  effort	  has	  primarily	  gone	   into	  the	  development	  of	  systems	  for	  evaluation	  of	  cellular	  behavior	  to	  soluble	  components.	  The	  world	  of	  microfluidics	   has	   many	   application	   possibilities	   that	   will	   gain	   further	   ground	  within	   the	   next	   decades,	   as	   the	   advances	   in	   micro-­‐	   and	   nano-­‐fabrications	   are	  constantly	  progressing.	  	  Researches	   are	   equipped	   with	   several	   options	   for	   studying	   isolated	  proteins	   and	   cultured	   cells,	   however	   whole	   animals	   or	   newly	   dissected	   body	  parts	  are	  needed	   for	   tissue	  experiments	  and	  do	   raise	  a	   series	  of	   ethical	   issues.	  The	   concept	   of	   “organ	   on	   a	   chip”	   is	   still	   a	   work	   in	   progress,	   however	   single	  compartments	   and	   functionalities	   of	   organs	   have	   already	   been	   constructed	   in	  microfluidic	   systems.	   Conducting	   animal	   studies	   are	   very	   costly	   and	   in	   some	  instances	  not	  even	  good	  enough	  models	   for	  representing	   the	  human	  disease	   in	  question,	  as	  discussed	  in	  section	  9.2.	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Several	  projects	  have	  gone	  into	  the	  fabrication	  of	  micro-­‐devices	  that	  can	  generate	   identical	   physiological	   patterns	   of	   the	   organs	   in	   question.	   One	   of	   the	  important	   applications	   for	   microfluidic	   systems	   is	   the	   refinement	   for	   drug	  testing.	   In	   vitro	   cultures	   of	   liver	   cells	   have	   been	   extensively	   studied	   as	   many	  drugs	   fail	   in	  clinical	  studies	  because	  they	  have	  damaging	  effects	  on	  the	   liver	  or	  because	  of	  the	  toxicity	  of	  the	  liver	  metabolites	  [253,	  254].	  	  Preclinical	  drug	  trials	  on	  animals	  have	  proven	  to	  be	  insufficient	  for	  toxicity	  evaluations	  due	  to	  species-­‐specific	  differences	  between	  humans	  and	  animal	  hepatocytes	  [254,	  255].	  Several	  groups	   have	   looked	   into	   fabrication	   of	   microfluidic	   systems	   for	   specific	   organ	  representative	  devices.	  Among	   these	  devices	  are	  microfluidic	   systems	   for	  bone	  [256],	  muscle	   [257],	  gut	   [258],	  kidney	   [259]	  and	   the	  gastrointestinal	   tract[260,	  261].	  Sung	  et	  al.	  2010	  used	  a	  microfluidic	  system	  to	  investigate	  the	  toxicity	  of	  an	  anticancer	   drug	   on	   cultures	   of	   liver,	   lung	   and	   bone	   marrow	   cells.	   This	   was	  achieved	   in	   a	   device	   with	   interconnections	   between	   the	   cell	   chambers,	  mimicking	   organ-­‐organ	   interactions	   [262].	   Günther	   et	   al.	   2010	   combined	  microfluidics	  with	  surgically	  removed	  arteries	  to	  study	  the	  small	  vessels	  ability	  to	  prevent	  the	  blood	  from	  flushing	  into	  and	  damaging	  the	  capillaries	  [263].	  Such	  combinations	  can	  bring	  down	  the	  number	  of	  animals	  used	  over	  time	  as	  it	  allows	  more	   accurate	   setups	   and	   have	   even	   improved	   reproducibility	   and	   imaging	  [263].	   Studies	   on	   imitating	   lung	   functionalities	   and	   gas	   exchange	   have	   been	  attempted	   by	   microfluidic	   approaches.	   Potkay	   et	   al.	   2011,	   recently	   published	  their	  work	  on	  a	  device	  that	  will	  efficiently	  ventilate	  the	  blood	  without	  pumps	  or	  pure	  oxygen	  supplies,	  unfortunately	  the	  system	  remain	  far	  from	  being	  clinically	  relevant	   [264].	   Huh	   et	   al.	   2007	   have	   performed	   experiments	   to	   investigate	  induced	   cellular	   injury	   upon	   small	   airway	   epithelial	   cells	   inside	   a	  microfluidic	  device	  [265].	  A	   functional	  study	  of	  an	   in	  vitro	   lung	  model	  was	  produced	  by	  the	  same	   group	   years	   later,	   where	   they	   constructed	   a	   multi-­‐compartment	  microfluidic	   device	   that	   enabled	   vacuum-­‐induced	   stretching	   of	   a	   PDMS	  membrane	   seeded	   with	   endo-­‐	   and	   epithelial	   cells	   [266].	   Several	   aspects	   of	   a	  normal	   functional	   lung	   were	   investigated	   and	   suggested	   synergetic	   effects	   of	  physiological	   mechanical	   stresses	   due	   to	   breathing	   could	   act	   in	   synergy	   with	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nanoparticles	  accelerating	   toxic	  effects	   in	   the	   lung.	  They	  also	  conducted	  TNF-­‐α	  stimulation	   for	   ICAM-­‐19	  expression	  on	   the	  endothelium	   facilitating	  adhesion	   to	  the	  activated	  endothelium	  of	  neutrophils.	  Adherent	  neutrophils	  were	  shown	  to	  squeeze	   through	   the	   cell	   layers	   and	   pores	   in	   the	   chamber	   separating	   PDMS	  membrane.	   The	   system	   was	   used	   to	   mimic	   the	   innate	   immune	   response	   to	   a	  bacterial	  pulmonary	  infection	  by	  migrating	  neutrophils’	  engulfment	  of	  live	  E.	  coli	  deposited	  on	  the	  epithelial	  side	  in	  the	  device	  [266].	  	  	  	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9	  ICAM-­‐1:	  Intercellular	  adhesion	  molecule-­‐1	  is	  a	  surface	  expressed	  adhesion	  molecule	  that	  is	  important	  attachment	  anchors	  for	  e.g.	  circulating	  immune	  cells.	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11 Fabrication	  and	  oxygen	  sensing	  
11.1 Materials	  for	  fabrication	  Many	   work	   aspects	   with	   microfluidic	   systems	   are	   defined	   by	   the	   way	   of	  fabrication	  and	  choice	  of	  materials.	  Several	   fabrication	  methods	  can	  be	  used	   in	  order	  to	  make	  the	  microstructures	  needed	  for	  the	  desired	  designs.	  	  Silicon	  is	  one	  of	  the	  best	  known	  and	  purest	  materials	  known	  with	  a	  high	  demand	  in	   fabrication	   of	   electronics	   as	   microprocessors,	   memory	   circuits,	  microstructures	  and	  was	  initially	  also	  used	  for	  fabrication	  of	  microfluidic	  devices	  [252].	   However,	   due	   to	   inflexibility,	   cost	   of	   production,	   need	   for	   special	  fabrication	  facilities	  and	  lack	  of	  optical	  transparency,	  thermoplastics	  and	  silicone	  rubber	   materials	   have	   become	   the	   primary	   materials	   for	   microfluidic	  fabrications.	   The	   poly(dimethylsiloxane)	   (PDMS)	   elastomer	   have	   become	   a	  preferred	   material	   due	   to	   ease	   of	   rapid	   prototype	   fabrication	   and	   ease	   of	  bonding	  to	  other	  materials.	  Besides	  being	  a	  very	  biocompatible	  material	  PDMS	  is	  furthermore	   impermeable	   to	  water	   but	   very	  permeable	   to	   gasses	   [267].	   These	  properties	   have	   been	   used	   in	   the	   studies	   of	   constructing	   the	   human	   airway	  model	  biochips	  (paper	  II-­‐VI).	  	  	  
11.2 Methods	  for	  fabrication	  of	  microstructures	  Soft	   lithography	   techniques	   allow	   replication	   of	   PDMS	  microfluidic	   devices	   by	  the	  use	  of	   fabricated	  mold	  systems.	  Several	  techniques	  as	  e.g.	  photolithography	  or	  micro-­‐milling	   can	   be	   used	   for	   fabrication	   of	   the	  mold	   [268-­‐270].	   The	  mold	  holds	  a	  template	  of	  the	  designed	  structures	  to	  be	  formed	  where	  to	  a	  PDMS	  two-­‐component	  pre-­‐polymer	  mixed	  with	  a	  cross-­‐linking	  agent	  is	  poured	  and	  allowed	  to	   cure	   at	   moderately	   elevated	   temperature[269]	   (paper	   II-­‐V).	   To	   obtain	   a	  functional	  micro-­‐channel	  device,	  the	  PDMS	  model	  must	  furthermore	  be	  bonded	  to	  enclose	  the	  fabricated	  micro-­‐structures.	  The	  highly	  gas	  permeable	  properties	  of	  the	  cured	  PDMS	  polymer	  can	  be	  abolished	  by	  conformally	  shielding	  it	  with	  low	  permeable	  materials	  (paper	  IV).	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Microstructure	   fabrication	   can	   furthermore	   be	   accomplished	   by	   laser	  ablation.	  This	  method	  requires	  a	  high-­‐powered	  pulsed	  laser	  to	  remove	  material	  from	   a	   surface.	   The	   lasers	   used	   for	   ablation	   rely	   on	   light	   absorption	   in	   the	  material	  as	  well	  as	  the	  pulse	  rate	  produced	  by	  the	  laser.	  The	  pulsed	  excimer	  UV	  laser	   is	  one	  of	   the	  highly	  used	   lasers	  as	  most	  plastics	  absorb	  UV	   light	   (193nm,	  ArF),	  (248	  nm,	  KrF)	  and	  is	  for	  this	  reason	  used	  for	  ablation	  in	  materials	  as	  PS,	  PC,	  PVC	   and	   PMMA	   [271,	   272]	  whereas	   CO2	   lasers	   function	   in	   the	   infrared	   region	  (10.6	  µm)	  and	  are	  typically	  used	  for	  micro-­‐fabrication	  in	  PMMA.	  An	  advantage	  of	  the	   laser	   ablation	  method	   is	   its	   use	   for	   precision	   cutting	   in	   different	  materials	  such	  as	  membranes	  and	  foils	  [273-­‐275].	  Milling	  is	  a	  very	  flexible	  method	  for	  structure	  fabrication	  in	  a	  wide	  range	  of	   different	  materials.	   Even	   though	   the	   tools	   for	   precession	  milling	   are	   scaled	  down	  to	  the	  range	  of	  5µm	  it	  is	  a	  method	  that	  produces	  a	  high	  roughness	  in	  the	  materials.	  The	  milling	  method	  is	  not	  capable	  of	  achieving	  very	  small	  features	  in	  the	   polymers	   but	   will	   be	   able	   to	   produce	   reproducible	   structures	   down	   to	  100µm	   [252].	   Several	   parameters	   need	   to	   be	   taken	   into	   consideration	   for	  successful	   fabrication	   such	   as	   the	   right	   size	   tool,	   coolant	   and	   setups	   that	  eliminate	   vibrations	   in	   the	   polymer.	   The	  method	   has	   limitations	   regarding	   the	  choice	   of	   material	   as	   soft	   polymers	   are	   problematic	   due	   to	   their	   elastic	  properties,	  however	   it	  has	  been	  accomplished	  by	  applying	  croygenic	  cooling	   to	  the	  polymer	  during	  the	  milling	  process[276].	  	  
11.3 Assembly	  of	  microfluidic	  devices	  Many	   fabrication	  methods	  are	  possible	   for	  producing	  microfluidic	   systems	   in	  a	  wide	   range	   of	   different	   polymeric	   materials,	   however	   no	   matter	   which	  fabrication	   method	   is	   employed,	   sealing	   of	   the	   open	   channels	   is	   necessary	   in	  order	   to	   finalize	   the	   fabricated	   fluidic	  paths.	  There	  are	  different	  considerations	  to	   take	   into	   account	   when	   selecting	   the	   method	   of	   bonding,	   especially	   if	  integration	   of	   materials	   of	   other	   chemical	   and	   functional	   properties	   into	   the	  device	   is	   desired.	   The	   strength	   of	   the	   bonding	   is	   a	   critical	   consideration	   for	  generating	   a	   functional	   seal	   between	   the	   two	   substrates.	   Important	  considerations	   for	   the	   interface	   between	   the	   substrates	   are	   surface	   chemistry,	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optical	  considerations	  and	  material	  compatibility.	  Thermoplastics	  are	  comprised	  of	  a	  wide	  range	  of	  polymers	  that,	  as	  elastomers,	  change	  their	  physical	  properties	  near	   the	   glass	   transition	   temperature	   (Tg).	   The	   Tg	   temperature	   is	   specific	   for	  each	   polymer	   and	   is	   the	   specific	   temperature	   at	  which	   the	   polymer	   reversibly	  changes	   in	  viscosity	  [277].	  The	  transition	  point	   in	  the	  material	  viscosity	  can	  be	  utilized	   to	   bond	   different	   kinds	   of	   thermoplastics	   with	   compatible	   Tg	   to	   each	  other.	   The	   process	   of	   thermal	   fusion	   bonding	   requires	   that	   the	   materials	   are	  heated	   to	   temperatures	  near	  Tg.	  When	  the	  materials	  are	  assembled	  pressure	   is	  applied	  to	  increase	  the	  mating	  contact	  forces	  [277].	  Exposures	  to	  either	  plasma	  or	  UV	  light	  are	  successful	  ways	  to	  lower	  the	  Tg	  of	  different	  materials,	  which	  can	  improve	  the	  bonding	  strength	  [277-­‐279].	  	  Enclosing	   the	   microfluidic	   channels	   between	   two	   polymers,	   can	  furthermore	   be	   accomplished	   by	   solvent	   bonding	   [280].	   The	   solvent	   bonding	  method	   utilizes	   the	   thermoplastic	   solubility	   in	   specific	   solvents	   to	   attain	  entanglement	   of	   the	   polymer	   chains	   at	   the	   interface	   between	   the	   substrates	  [277](papers	  IV-­‐VI).	  Rapid	  prototyping	  as	  well	  as	  bonding	  materials	  of	  different	  polymer	  groups	  can	  be	  accomplished	  by	  the	  use	  of	  pressure	  sensitive	  adhesive	  tapes	   (PSA)	   [281].	   The	   ease	   of	   pattern	   cutting	   in	   PSA	   enables	   fast	   and	   easy	  variations	  in	  shapes	  and	  sizes.	  This	  method	  has	  been	  used	  in	  papers	  (II-­‐IV).	  
11.4 Oxygen	  sensing	  and	  control	  of	  oxygen	  concentrations	  In	   cell-­‐based	   applications,	   the	   potential	   to	   generate	   micro-­‐environments	   with	  controllable	   oxygen	   concentrations	   will	   enable	   investigations	   in	   environments	  that	  have	  substantial	  influence	  on	  cell	  development	  and	  function.	  With	  the	  talks	  of	  monitoring	  and	  controlling	  the	  oxygen	  concentrations,	  the	  permeability	  of	  the	  selected	   materials	   is	   of	   crucial	   importance.	   The	   choice	   of	   material	   needs	   to	  satisfy	  criteria	  as	  biocompatibility	  and	  low	  oxygen	  permeability.	  Table	  2	  shows	  the	   oxygen	   permeability	   of	   different	   polymers,	   which	   are	   highly	   used	   in	  fabrication	  of	  microfluidic	  devices.	  Furthermore	  each	  polymer	  realizes	  a	  range	  of	  different	   properties	   with	   respect	   to	   e.g.	   stiffness,	   transparency,	   Tg,	  hydrophobicity	  as	  well	  as	  the	  gas	  permeability.	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Polymer	  	  	  
Oxygen	  permeability	  Barrer	   cm3·mil·100inch-­‐2	  ·24h-­‐1·atm-­‐1	   cm3·mm·m-­‐2·	  24h-­‐1·atm-­‐1	   m3·m·m-­‐2·s-­‐1·Pa-­‐1	  PDMS	   800.0	   133	  333	   2	  067	  183	   6.00·10-­‐15	  VITON®	   14.0	   2	  333	   36	  176	   1.05·10-­‐16	  FEP	   4.5	   748	   11	  600	   3.37·10-­‐17	  COC	   2.6	   428	   6	  641	   1.93·10-­‐17	  PC	   1.8	   302	   4	  677	   1.36·10-­‐17	  PMMA	   1.4	   225	   3	  488	   1.01·10-­‐17	  ETFE	   0.6	   100	   1	  550	   4.50·10-­‐18	  PEEK	   0.1	   20	   309	   8.97·10-­‐19	  
	  
Table	  2.	  Oxygen	  permeability	  of	  different	  polymers:	  PDMS-­‐	  polydimethylsiloxane,	  
FEP	   -­‐	   fluorinated	   ethylene	   propylene,	   COC	   -­‐	   cyclic	   olefin	   copolymer,	   PC	   –	  
polycarbonate,	   PMMA	   -­‐	   poly(methyl	   methacrylate),	   ETFE	   -­‐	   poly(ethylene-­‐co-­‐
tetrafluoroethylene),	   PEEK	   -­‐	   poly(ether	   ether	   ketone)	   (table	   from	   Skolimowski,	  
M.[282])	  	  	   Several	  different	   functional	  microfluidic	  devices	  produced	  in	  PDMS	  have	  been	   applied	   to	   biological	   applications	   [283].	   PDMS	   is	   a	   chemically	   inert,	  thermally	   stable,	   permeable	   to	   gasses	   and	   biocompatible	   material,	   properties	  that	   are	   all	   favorable	   in	   cell	   culture	   applications	   [267].	   The	   material’s	  permeability	   to	   vapor	   and	   gasses	   makes	   it	   ideal	   for	   separation	   of	   liquids	   of	  different	   composition	  with	   possibilities	   of	   desired	   uniform	   gas	   concentrations.	  Fabrication	  of	  microfluidic	  devices,	  where	  PDMS	  is	  implemented	  as	  a	  separation	  between	   liquid	   media	   channels	   and	   gas	   channels,	   will	   allow	   control	   of	   e.g.	  dissolved	  oxygen	  by	   the	  composition	  of	   the	  gas	  mixture	   [284,	  285].	  The	  desire	  for	  conducting	  experiments	  with	  oxygen	  concentrations	  of	  above	  air	  saturation	  will	   require	   pure	   oxygen	   supply.	   When	   desired	   the	   use	   of	   oxygen	   scavenging	  liquids,	   to	  control	  oxygen	  levels	   in	  microfluidic	  devices,	  reduces	  the	  complexity	  of	  the	  setup.	  	  	  Incorporating	  PDMS	  into	  microfluidic	  devices	  enables	  the	  vast	  diffusion	  of	  gasses	   across	   the	   PDMS	   polymer.	   As	   seen	   in	   Table	   2,	   several	   of	   the	   polymeric	  materials	  have	  a	  considerably	  lower	  gas	  permeability	  compared	  to	  PDMS.	  PEEK	  has	  the	  lowest	  permeability	  of	  the	  polymers	  listed.	  The	  PEEK	  polymer	  is	  a	  non-­‐
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transparent	  polymer	  that	  is	  a	  very	  resilient	  and	  biocompatible	  material	  however	  is	  has	  difficulty	  in	  bonding	  [286-­‐289].	  However	  constructing	  devices	  in	  low	  gas	  permeable	  materials	   is	   desirable	   in	   transparent	   and	   cheaper	  polymers	   such	  as	  polymethyl	  methacrylate	  (PMMA)	  or	  polycarbonate	  (PC)	  [290,	  291].	  PC	  is	  a	  very	  low	  cost	  material	  with	  high	   robustness	   and	  a	  high	  Tg	   temperature,	  however	   it	  has	  very	  poor	  resilience	   to	  certain	  organic	  solvents	  and	  high	  absorbance	   in	  UV	  [290],	   (paper	   IV-­‐VI).	   The	   slightly	   less	   gas	   permeable	   PMMA	   is	   often	   used	   for	  injection	  molding	  purposes	  of	  mass	  productions,	  however	  most	   thermoplastics	  can	   be	   used	   for	   injection	   molding.	   It	   is	   a	   chemical	   and	   biological	   compatible	  material	   with	   good	   bonding	   capabilities	   and	   with	   its	   low	   cost	   one	   the	   most	  preferred	  thermoplastics	  for	  microfluidic	  fabrications	  [291](paper	  II-­‐III).	  
11.4.1 Oxygen	  scavengers	  Implementing	   oxygen	   into	   experimental	   setups	   often	   rely	   on	   the	   use	   of	  connected	   gas	   containers.	   Besides	   being	   a	   safety	   precaution,	   gas	   tanks	   set	  restrictions	   to	   flexibility	   and	   maneuverability.	   	   The	   use	   of	   scavenging	   liquids	  have	   successfully	   been	   used	   to	   prevent	   oxygen	   corrosion	   of	  metal	   surfaces	   as	  well	   as	   preservatives	   in	   food	   [292].	   The	   direct	   use	   of	   oxygen	   scavenging	  chemicals	  in	  the	  media	  of	  biological	  systems	  will	  alter	  the	  chemical	  environment	  for	  the	  cells	  and	  could	  furthermore	  have	  toxic	  effects	  [292,	  293].	  But	  the	  use	  of	  scavenging	   solutions	   can	   though	   eliminate	   the	   use	   of	   gasses	   to	   control	   oxygen	  environments,	   however	   separation	   between	   the	   cell	   culture	   environments	   and	  scavenger	   is	   required.	   Materials	   with	   high	   oxygen	   permeability	   as	   silicone	  rubbers	  (PDMS)	  can	  be	  utilized	  as	  separating	  membrane	  material	   [294]	  (paper	  II,	  III	  and	  IV)	  	  
11.4.2 Oxygen	  sensing	  	  Integration	  of	  oxygen	   sensors	  within	  microfluidic	  devices	  allows	  quantification	  of	   oxygen	   concentrations	   in	   integrated	   cell	   culture	   environments,	   being	   a	  powerful	   tool	   for	  evaluating	   the	  oxygenic	  effects	  on	  cell	   viability,	  behavior	  and	  consequences	  for	  drug	  efficiency.	  	  Early	  work	  with	   oxygen	   sensors	   has	   been	   focused	   on	   the	   Clark-­‐type	   electrode	  sensors	   that	   record	   a	   current	   flow	   that	   is	   caused	   by	   the	   reduction	   of	   oxygen	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[295].	  The	  integration	  of	  such	  electrodes	  does	  however	  require	  miniaturization	  of	   the	   sensors	   to	   microscale.	   Miniaturized	   sensors	   have	   been	   developed	   and	  integrated	   into	   microfluidic	   devices	   where	   they	   have	   been	   used	   in	   measuring	  oxygen	  consumption	  by	  E.	  coli	  [296].	  	  For	  long-­‐term	  measurements	  however	  the	  electrode	  will	  easily	  be	  contaminated	  besides	  adding	  complexity	  to	  the	  setup	  by	  requiring	   electrical	   connections	   and	   furthermore	   it	   consumes	   oxygen	   in	   itself.	  	  To	   circumvent	   such	   disadvantages	   for	   measurements	   in	   microfluidic	   devices	  there	  is	  a	  lot	  of	  interest	  in	  integration	  of	  optical	  detection	  methods.	  Many	   of	   the	   optical	   oxygen	   sensors	   function	   by	   the	   principle	   of	   reversible	  luminescence	  quenching	  by	  the	  presence	  of	  oxygen.	  Oxygen	  absorbs	  the	  energy	  that	  would	  have	  been	  emitted	  as	  a	   luminescence	  photon	  [297].	  Various	  oxygen	  sensitive	   indicators	   are	   available	   and	  mainly	   fall	   into	   two	  main	   categories,	   the	  ruthenium	   complexes	   and	   metalloporphyrin	   type	   molecules.	   The	   most	  commonly	   used	   oxygen	   sensing	   compounds	   include	   the	   ruthenium-­‐based	  Ruthenium-­‐tris-­‐4,7-­‐diphenyl-­‐l,l0-­‐phenanthroline	   and	   Ruthenium(II)-­‐tris(l,l0-­‐phenanthroline)[298,	  299].	  Ruthenium	  complexes	  have	  a	  very	   short	   lifetime	   in	  the	  state	  of	  excitation	  (100ns	  -­‐	  1µs),	  which	  means	  a	  lower	  sensitivity	  to	  oxygen.	  In	   low-­‐oxygen	   environments,	   as	   anaerobic	   bacterial	   cultures,	   it	   is	   necessary	   to	  use	  highly	  sensitive	  oxygen	  sensors	  as	  metalloporphyrin	  based	  types	  that	  have	  a	  longer	   excited	   lifetime	   state	   (10µs	   -­‐	   1ms)	   and	   thereby	   a	   higher	   sensitivity	   to	  oxygen	   [300,	  301].	  The	  metalloporphyrin	  based	  probes	  are	  primarily	  based	  on	  the	  platinium(II)-­‐	   and	  palladium(II)	   complexes	   of	   actaethyl-­‐porphyrin	   (Pt-­‐	   and	  Pd-­‐OEP)	  (paper	  III)	  [302,	  303].	  They	  exhibit	  long	  luminescence	  lifetime	  but	  have	  somewhat	   modest	   photostabilities	   which	   is	   why	   other	   complex	   Pt-­‐	   and	   Pd-­‐	  derivatives	   of	   octaethyl-­‐porphyrin	   ketone	   (Pt-­‐	   and	   Pd-­‐OEPK)	   have	   been	  developed	  with	  higher	  photostability	  [304].	  Intracellular	  sensing	  complexes	  have	  furthermore	  been	  proposed	  for	  the	  probe	  that	  comprise	  the	  Pt(II)-­‐meso-­‐tetrakis-­‐(pentafluorophenyl)porphyrin	   with	   a	   nanoparticle	   of	   a	   cationic	   polymer	   [305,	  306]	   (paper	   IV).	   The	   metalloporphyrin	   compounds	   are	   predominantly	  embedded	  in	  a	  polymer	  or	  sol-­‐gel	  matrix,	  as	  certain	  kinds	  of	  metalloporphyrins	  are	  not	  soluble	  in	  water	  [300,	  307].	  	  Embedment	  of	  the	  probe	  in	  a	  polymer	  or	  sol-­‐gel	  matrix	  is	  very	  often	  carried	  out	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in	  order	  to	  immobilize	  the	  sensor	  to	  a	  substrate	  and	  shield	  off	  the	  oxygen	  sensor	  to	   the	   cell	   culture	   media	   for	   longer	   durability	   of	   the	   sensor	   and	   shielding	   of	  unwanted	   side	   effects	   in	   the	   cultured	   organism	   [300,	   307,	   308].	   	   The	   polymer	  matrix	  must	  be	  biocompatible	  to	  be	  used	  with	  cell	  culture	  systems	  as	  the	  organic	  modified	   silica	   (ormosil)	   and	   sol-­‐gels	   that	   have	   been	   optimized	   for	   optical	  properties	  as	  well	  as	  good	  oxygen	  permeability	  [309].	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12 The	  microfluidic	  systems	  of	  the	  thesis	  The	  extent	  of	  the	  work	  presented	  in	  this	  thesis	  has	  primarily	  been	  focused	  on	  the	  development	   of	   new	   systems	   for	   investigating	   bacterial	   biofilms.	   Ideas	   for	   the	  systems	  were	   inspired	   by	   the	   knowledge	   of	   the	   physiological	   events	   in	   the	   CF	  airways.	   An	   extensive	   amount	   of	  work	   has	   gone	   into	   optimizing	   the	   emerging	  systems	  in	  order	  to	  adapt	  and	  improve	  the	  developed	  prototypes.	  	  	  The	  first	  task	  pursued	  was	  to	  translate	  essential	  parts	  of	  the	  established	  flow	  cell	  system	  (section	  9.3.3)	  into	  a	  microfluidic	  setup,	  which	  quickly	  generated	  a	  range	  of	  challenges.	  Leaking	  systems	  were	  the	  most	  profound	  and	  problematic	  part	  of	  the	  optimizing	  steps	  as	  small	  leakages	  can	  terminate	  entire	  systems.	  Gas	  bubbles	  generate	   massive	   inconsistencies	   in	   flow	   systems,	   especially	   in	   microfluidic	  channels,	  where	   they	  obstruct	   channels	   and	   lead	   to	   change	  or	   bring	   the	   liquid	  flow	   stream	   to	   a	   halt.	   Many	   tests	   have	   been	   terminated	   due	   to	   gas	   bubble	  formations	   and	   have	   lead	   to	   the	   development	   of	   systems	   to	   avoid	   bubble	  formations	  in	  the	  microfluidic	  devices.	   	  A	  vast	  numbers	  of	  biological	  trials	  have	  been	   conducted	   in	   order	   to	   optimize	   the	   systems	   to	   the	   versions	   presented	   in	  this	   thesis.	  Many	   prototype	   versions	   are	   not	   presented	   in	   the	   thesis,	   but	   have	  been	  an	  extensive	  part	  of	  the	  work	  of	  this	  thesis	  and	  furthermore	  the	  foundation	  for	  the	  final	  presented	  versions.	  The	  systems	  have	  been	  revised	  and	  redesigned	  in	   order	   to	   cope	   with	   material	   inconsistencies,	   requirements	   of	   sterility,	  detection	  methods	  and	  formation	  of	  bubbles	  in	  the	  systems.	  	  The	   presented	   systems	   are	   finalized	   designs	   and	   functionalized	   microfluidic	  systems	   to	  mimic	   physiological	   important	   scenarios	   of	   the	   bacterial	   infections	  taking	   place	   in	   micro-­‐environments	   of	   CF	   airways.	   The	   systems	   have	   the	  capability	   of	   controlling	   and	   monitoring	   the	   oxygen	   environment	   within	   the	  culture	   chambers.	  Moreover,	   bacterial	  migration	   between	   the	   different	   oxygen	  environments	   is	   established	   in	   one	   system.	   	   A	   compartmental	  modeling	   of	   the	  human	   airways	   and	   CF	   bronchi	   in	   a	  microfluidic	   approach	   that	   has	   previously	  not	  been	   reported	   is	  presented	  here.	   Ideas	   from	   the	  microfluidic	   systems	  have	  furthermore	   been	   transferred	   to	   the	   established	   flow	   cell	   system	   in	   order	   to	  circumvent	  bubble	  formation	  in	  the	  flow	  chambers	  (not	  presented	  in	  the	  thesis).	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  On	   of	   the	   most	   important	   achievements	   with	   the	   microfluidic	   devices	   is	   the	  incorporation	   of	   a	   gas	   permeable	  membrane,	  which	   is	   an	   essential	   component	  that	  allows	  control	  of	  dissolved	  oxygen	  concentrations	   in	  the	  growth	  chambers	  (paper	   II-­‐III).	   Within	   the	   growth	   chambers	   oxygen	   gradients	   are	   steered	  throughout	  the	  length	  of	  the	  channel,	  facilitated	  by	  an	  oxygen	  scavenging	  liquid.	  A	  successful	   “easy	  to	   fabricate”	  and	  “easy	  to	  handle”	  system	  was	  produced	  and	  allows	   easy	   oxygen	   control	   of	   the	   oxygen	   environment,	   within	   the	   culture	  chamber.	  P.	  aeruginosa	  PAO1	  was	  tested	  for	  its	  capability	  of	  initial	  attachment	  to	  the	   substratum,	   and	   for	   several	   days	   of	   cultivation,	   in	   a	   system	  with	   lowered	  oxygen	  concentrations.	  	  A	  development	  was	  made	   to	   advance	   the	  oxygen	   controlling	   systems	   to	  produce	  a	  more	  physiological	  relevant	  approach	  in	  order	  to	  mimic	  the	  previously	  subdivisions	  of	  the	  airways,	  the	  micro-­‐aerobic/anaerobic	  niche	  of	  the	  conductive	  airways,	  the	  oxygen	  rich	  respiratory	  areas	  and	  the	  essentially	  anaerobic	  sinuses.	  	  These	   different	   compartments	   gave	   the	   inspiration	   for	   the	   initiative	   toward	  making	  a	  microfluidic	   system	  of	   the	  airways,	   the	  Microfluidic	  Airways	  Model	  –	  MAM.	  The	  micro-­‐chambers	   in	   the	  presented	  model	   allow	  cultivation	   in	  oxygen	  environments	   set	   to	   mimic	   the	   three	   airway	   compartments.	   The	   assembled	  modular	   system	   is	  highly	   versatile,	  with	  modules	   that	   can	  easily	  be	   exchanged	  for	   a	   wide	   range	   of	   alternative	   setups.	   	   The	   extraordinary	   complexity	   of	   the	  system	  increased	  the	  amount	  of	  trials	  that	  has	  gone	  into	  validating	  the	  material’s	  capabilities	   for	   sterilization,	   pressure	   endurance	   and	   cultivation	   of	   bacteria	  became	  one	  of	  the	  most	  time	  consuming	  missions	  before	  finalizing	  the	  presented	  system	  (paper	  IV).	  The	  module	   for	  mimicking	  the	  three	  compartments	  was	   finally	  achieved	  by	   interconnecting	   media	   of	   different	   oxygen	   saturation	   levels,	   figure	   14.	   The	  system	   allows	   connections	   to	   be	   made	   between	   the	   chambers,	   created	   in	   a	  manner	  that	  allows	  opening	  and	  closing	  between	  the	  chambers.	  	  For	   bacterial	   cultivation,	   this	   allows	   free	   movement	   between	   the	  connected	   compartments	   mimic-­‐king	   the	   rather	   free	   movement	   in	   the	   human	  airways.	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  One	   of	   the	   most	   fundamental	  occurrences	   in	   the	   CF	   airways	   is	  the	   impaired	   mucociliary	   clearing	  system	  and	  accumulation	  of	  mucus	  in	   the	   airways.	   To	   mimic	   this,	   a	  system	  was	   developed	   that	  would	  be	  able	  to	  imitate	  the	  accumulated	  mucus	   in	   the	   airways,	   as	   a	   CF	  bronchi	  (paper	  V	  and	  VI).	  The	  idea	  of	   the	   chip	   was	   to	   induce	   a	   solid	  support,	   which	   was	   realized	   by	  the	   introduction	   of	   an	   alginate	  hydrogel.	  The	  separate	  channels	  are	  mimicking	  the	  air	  lumen	  and	  the	  arteries	  of	  the	   bronchi.	   The	   membrane	   furthermore	   supports	   epithelial	   cells	   that	   are	  cultured	   on	   the	   bottom	   side	   of	   the	   membrane.	   The	   cells	   are	   supplied	   with	  nutrients	   from	   the	   channel	   that	   can	   diffuse	   across	   the	   membrane-­‐associated	  barriers	  and	  diffuse	  into	  the	  hydrogel,	  figure	  15.	  	  	  	  
	  
Figure	  15	  Presentation	  of	   the	   founding	   idea	   for	   the	  microfluidic	  device	  to	  mimic	  
the	   CF	   bronchi.	   a)	   Representation	   of	   the	   mucus	   accumulation	   in	   the	   CF	   bronchi,	   b)	  schematic	   visualization	   of	   the	   circled	   section	   in	   a.,	   c)	   illustration	   of	   the	  model	   for	   the	  microfluidic	  interpretation	  of	  the	  mucus	  covered	  CF	  epithelia.	  	  It	  present	  a	  ready	  system	  set	   for	  bacterial	   inoculation	  and	  subsequent	  confocal	  microscopy	  visualization	  of	  the	  forming	  bacterial	  micro-­‐colonies.	  	  	   The	   introduced	   systems	   are	   presented	   in	   the	   following	   publication	  section,	  which	  include	  a	  DVD	  (backcover)	  with	  the	  video	  file	  from	  the	  paper	  I.	  	  
Figure	  14	  Media	  interconnections	  MAM	  model	  (paper	  IV)	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Abstract
Many microbial cells have the ability to form sessile microbial communities defined as biofilms that have altered physiological and pathological
properties compared to free living microorganisms. Biofilms in nature are often difficult to investigate and reside under poorly defined conditions1.
Using a transparent substratum it is possible to device a system where simple biofilms can be examined in a non-destructive way in real-time:
here we demonstrate the assembly and operation of a flow cell model system, for in vitro 3D studies of microbial biofilms generating high
reproducibility under well-defined conditions2,3.
The system consists of a flow cell that serves as growth chamber for the biofilm. The flow cell is supplied with nutrients and oxygen from a
medium flask via a peristaltic pump and spent medium is collected in a waste container. This construction of the flow system allows a continuous
supply of nutrients and administration of e.g. antibiotics with minimal disturbance of the cells grown in the flow chamber. Moreover, the flow
conditions within the flow cell allow studies of biofilm exposed to shear stress. A bubble trapping device confines air bubbles from the tubing
which otherwise could disrupt the biofilm structure in the flow cell.
The flow cell system is compatible with Confocal Laser Scanning Microscopy (CLSM) and can thereby provide highly detailed 3D information
about developing microbial biofilms. Cells in the biofilm can be labeled with fluorescent probes or proteins compatible with CLSM analysis. This
enables online visualization and allows investigation of niches in the developing biofilm. Microbial interrelationship, investigation of antimicrobial
agents or the expression of specific genes, are of the many experimental setups that can be investigated in the flow cell system.
Video Link
The video component of this article can be found at http://www.jove.com/video/2383/
Protocol
1Department of Systems Biology, Danish Technical University
2Department of Biology, University of Copenhagen
1. Assembly of the Flow Cell System with All Components
The assembled flow system includes: autoclavable tubing, bubble traps, medium/waste bottle and flow cells as shown in Figure 1. All these parts
can be reused between experiments.
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Figure 1. The flow cell system setup (essential components of the setup). The flow cell system consists of several components: a medium bottle,
a peristaltic pump, bubble traps, the flow cell, a waste bottle, and diverse sections of tubing interconnected by various connectors. Figure kindly
provided by Rune Lyngklip.
2. Assembly of the Flow Cell
 
Figure 2. Schematic drawing of flow cell and bubble trap2. Detailed description of the dimensions used for the production of a) flow cell b) bubble
trap, DTU Systems Biology. Reprinted with permission of John Wiley & Sons, Inc. (DTU Systems Biology was formerly entitled Biocentrum, as
depicted in the figure)
 
Figure 3. Illustration of the silicone glue application lines for attachment of the glass substratum. The indicated cover glass is placed over the
silicone glue to attach it to the flow cell.
3. Medium Bottle
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1. The flow cell (Figure 2a) is treated with thin lanes of silicone glue, using a syringe (Figure 3).
2. Place a cover slip on top of the silicone lines (Figure 3). Glass cover slips are used as substratum for P. aeruginosa while PVC cover slips are
applied for S. cerevisiae biofilm.
3. Turn the flow cell over and place it on a flat surface with the cover slip side down. Press gently on the back of the flow cell to push the cover
slip onto the base of the flow cell. Turn the flow cell over and inspect for areas that are not sealed by the silicone. The handle (piston) part of a
syringe can be used as a tool to gently press the glass and flow cell together.
1. Place a feeding silicone tube (2 mm inner diameter) in a medium bottle and insert a straight connector at the other end.
2. Add medium to the bottle (for medium content see "media" paragraph)
 
4. Connecting the Bubble Trap, Flow Cell and Pump
Assemble all tubing according to the outline in Figure 1. Use silicone tubing except for the part that goes through the peristaltic pump where
Marprene tubing is applied.
5. STERILIZING AND WASHING THE FLOW SYSTEM
6. INOCULATION OF THE FLOW CELL
7. STAINING OF BIOFILM FOR MICROSCOPY
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Cover connector and bottle with metal foil and autoclave the medium. Make sure that the end of the supply tube is fixed above the liquid level
in the medium bottle or a siphon effect may empty the medium bottle when autoclaving.
1. In order to connect the tube from the medium bottle to all individual flow chambers, split a tube into the required number of inlets applied in
the experiment. Use T-connectors to make the desirable number of connection tubes from the feed tube to the Marprene tubes in the pump
(see Figure 1, T-connector). It is generally a good idea to keep the same sequence order of tubes and flow cells throughout the system, to
facilitate identification of components in case of faults in the system.
2. Connect each individual feeding tube (2 mm in diameter) to Marprene tubes in the pump using straight connectors. Connect the Marprene
tubing to a bubble trap (Figure 2b) via intermediate silicone tubing (1 mm in diameter). Make sure that the pump is connected to the inlet at
the tallest part of the bubble trap.
3. Connect the resulting outlet tube of the bubble traps to the flow cell inlet (1 mm in diameter), make sure that the length of these tubings allows
the flow cell to be moved to the stage of the confocal microscope (typically 1 m).
4. Place 5 mL syringes on top of the bubble traps. Close the tops with suitable caps.
5. On the flow cell outlet connect a short, approximately 40 mm piece of (1 mm in diameter), tubing and use a "reducing" straight connector to
attach a waste tube (2 mm in diameter) of needed length. Place waste tubes in the waste container.
6. Importantly, the waste container must always be placed at the same level as the flow cells, never below flow-cell level. Also, make sure that
the end of the waste tubing is fixed above the expected level of waste liquid to avoid flush-back due to a siphon effect when handling the flow
cells.
1. Remove bubble trap caps and place them in 70% ethanol to keep them sterile.
2. Run at highest pump speed to fill the system with 0.5% (v/v) sodium hypochlorite in water.
3. Place the bubble trap caps back on when the bubble traps are completely filled.
4. Tap the flow cells to remove bubbles in the flow chamber. Take care not to damage the fragile cover glass.
5. Allow the system to sterilize for 3-4 h at a flow rate of 3 mL/h/channel (0.2 mm/s linear flow rate).
6. Wash the system 2-3 times to wash out all the hypochlorite. Fill and empty the system with sterile water. Bubble traps must be emptied
completely between each wash. This can be done by pumping in air until bubble traps have been emptied. After emptying, remove caps from
the bubble traps before refilling the system. Replace caps after the bubble traps have been completely filled with liquid. Repeat as required.
7. Run sterile water through the system at a low flow rate (1-3 mL/h/channel) over night or proceed to the next step.
8. Connect the medium bottle to the inlet and flush the system with medium over night at low flow rate (3 mL/h/channel) at the temperature
where the experiment will be performed. Note: bubble traps must be emptied for water before the system is filled with medium.
1. From an overnight culture make a dilution to a desired optical density (for P. aeruginosa e.g. 0.001 OD600nm and 0.1 OD600nm for S. cerevisiae
).
2. Use a 0.5 mL syringe with a 27G needle to load enough inoculum to fill the chamber. 250 μL is sufficient for the flow chambers having the
dimensions specified in this work (Figure 2., 40 mm x 4 mm x 1 mm).
3. Stop the peristaltic pump.
4. Clamp off the silicone tubing leading to the flow cell to prevent back flow into the system.
5. Sterilize the inoculation site on the silicone tubing by wiping it with 70% ethanol.
6. Insert the needle into the silicone tube and introduce the tip into the inlet of the flow cell. Slowly inject the inoculum into the chamber (be
careful not to inject air bubbles).
7. Remove the needle and wipe the injection site with 70% ethanol followed by immediate sealing of the hole using silicone glue over the
injection site.
8. Turn over the flow cell and let the micro-organisms adhere to the substratum for 1 hour without flow through the flow cell.
9. Turn the flow cell, start the medium pump (3 mL/h/channel) and take the clamp off the silicone tube.
10. The system is placed for incubation, at 37°C in the case of P. aeruginosa and 30°C in the case of S. cerevisiae.
11. Biofilm in the flow chambers can now be visualized by CLSM.
1. Make a dilution of the appropriate staining (e.g. 1:1000 Syto 9 live stain for S. cerevisiae)
2. Stop the peristaltic pump.
3. Clamp of the silicone tubing leading to the flow cell.
4. Sterilize inoculation site on the silicone tubing by wiping it with 70% ethanol.
5. Use a 0.5 mL syringe with a 27G needle to load enough staining solution to fill the chamber. 250 μL is sufficient for the flow chambers used
here.
6. Insert the needle into the silicone tube and introduce the tip into the inlet of the flow cell. Slowly inject the staining solution into the chamber
(be careful not to inject bubbles).
7. Remove the needle and wipe the injection site with 70% ethanol followed by immediate sealing of the injection site.
8. Leave the flow cell without flow for 15 minutes.
9. Take off the clamp and start the flow (3 mL/h/channel)




We have demonstrated a flow cell system that represents a powerful tool in biofilm investigations. Combined with 3D imaging by confocal
microscopy, the system has a range of advantages in comparison to other methods of analyzing microbial biofilms by means of more traditional
microscopic techniques. This system allows 3D visualization of living microbial biofilm communities without disturbance of the community. Light
microscopy will not provide detailed information about niches of the biofilm and while electron microscopy provides nanoscale resolution of the
biofilm, it does not allow live cell imaging.
Using the described flow channel system we have previously elucidated the spatial distribution of bacterial cells sensitive to several antibiotics5-8
(Figure 4a), distribution of extracellular compounds, e.g. DNA9-11 and, the distribution of motile and non-motile cells of the same species within a
bacterial community4,6,9 (Figure 4c). We envision that the flow cell system can be used to study aspects of yeast biofilms. This may be the spatio
temporal distribution of yeast biofilm in response to environmental factors such as fungicides as well as identification of genes involved in yeast
biofilm development. Though yeast is not known to differentiate into motile and non-motile cells, other aspects of biofilm diversification may be
studies such as the morphological shift from yeast to pseudohyphal cells and the shift from haploid to diploid cells.
We have shown a system that comply with several microbial species and will work with several staining techniques. A variety of different staining
probes and fluorescent proteins, such as GFP, enable specific niche investigations in the developing biofilm and is an efficient tool in analyzing
the effect of antimicrobial agents or other environmental factors. The information that can be gained is very detailed (Figure 4) and features in the
biofilm can be quantified with computer programs such as COMSTAT12,13.
Overall, the most critical aspect of the protocol is the fact that it is a time-consuming process. It is also a limitation that the cells need to be able to
grow on a non-fluorescent, transparent surface. Since the biofilm formed is analyzed using a confocal microscope, the depth that can be
investigated is limited to a few hundred micrometres14.There are further technical limitations inherent in the design: the system is not suited for
high throughput screening, as an experienced researcher can handle at most about 15 channels per experiment, which in turn can take several
days to prepare. However, antibiotics or mutants that are considered relevant for biofilm studies can initially be mass screened with other
methods such as crystal violet staining before the most interesting candidates are transferred to the flow cell system. The cover glass sheets are
very thin and break easily, and care should be taken when handling the systems. In addition the tubing should be examined daily during the run of
an experiment; as considerable "back-growth" in the inlet tubes just upstream of the flow cells can occur. Such contamination can be solved by
removing several centimeters of silicone tube from the inlet side of the flow cells, using sterile technique.
 
Figure 4. a) 4 day old PAO1 - GFP biofilm treated for 24h with Colistin and Propidium iodide for dead staining (red stain) b) 3D presentation of a
three day old P. aeruginosa PAO1 (P. aeruginosa wild type) - GFP biofilm6 c) 3D picture presentation of a PAO1 - CFP pilA mutant (blue) with an
PAO1 wild type YFP (yellow) d) 5 day old PAO1 - GFP biofilm presented as a 3D picture e) 26 h S. cerevisiae (PTR3 mutant in CEN.PK
background) biofilm stained with Syto-915.
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ABSTRACT
Here we report work towards development of a microfluidic system that can 
simulate the aerobic and anaerobic conditions in the human airways. The main pur-
pose of this device is to mimic habitats of bacteria that usually attack airways of cys-
tic fibrosis (CF) patients. The presented system enables the study of formation, 
growth, and dissolution of the bacterial biofilms, which is the main cause of the 
massive pulmonary deficiency and eventually death of CF patients. The ultimate 
goal for the microdevice is to replace the existing animal models (mice) in the de-
velopment of new drugs and new treatment strategies in CF. 
KEYWORDS: biochip, cystic fibrosis, biofilm, airways, microsystem 
INTRODUCTION
The airways consist of at least three independent compartments, the conductive 
airways (the trachea, bronchii and bronchioles), the oxygen exchange compartment 
(alveoles) and a third, less recognized compartment, the paranasal sinuses (maxillary 
sinuses, frontal sinuses and ethmoid sinuses). In the first and the last compartment 
the environment is essentially anaerobic while in the alveoles the environment is 
highly aerated. 
THEORY
To simulate the environ-
mental conditions, especially 
the oxygen level which is 
major parameters affecting 
biofilm growth in CF pa-
tients, we propose the micro-
fluidic airways model (Fig-
ure 1). The model consists 
of microchambers for bacte-
rial biofilm growth and mi-
crofluidic channels for pro-
viding oxygen-scavenging 
liquid or oxygen-rich liquid. 
To avoid any impact on the 
Figure 1.  Human airways system, (B) top view 
sketch of Microfluidic Airways Model (MAM) and 
(C) cross-section view of MAM 
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growth of microorganisms from these liquids, the compartments are separated by an 
oxygen permeable membrane. All media and liquid flow is controlled by external 
pumps. The oxygen level in the chambers can be controlled by varying the flow 
rates (Figure 3). A sensing layer for oxygen concentration measurements was incor-
porated at the bottom of the chambers. To provide the possibility of tracking bacte-
rial re-infections, the bacteria growth chambers exposed to different oxygen levels 
were interconnected with channels (Figure 1 B).  
EXPERIMENTAL 
The biochip (Figure 2) was fabricated by micromilling of inlets and outlets and 
laser ablation of the channels in poly(methyl methacrylate). Poly(dimethylsiloxane) 
(PDMS) was used as the oxygen permeable membrane. The oxygen permeability of 
PDMS is a well known property, and its use for supplying oxygen in microdevices 
has been reported [1,2]. However, to our knowledge, no applications comprising ac-
tive removal of oxygen by means of utilizing concentration gradients below oxygen 
saturation has been reported. This mechanism mimics the physiological oxygen ex-
change in the airways compartments. The lid comprising the oxygen sensing layer 
was fabricated by doping uncured PDMS with platinum(II) octaethylporphyrin 
(PtOEP), diluted with THF and spincoated to a thickness of approx. 15 μm on a 100 
μm thick glass lid followed by thermal curing. Substitution of the usually used sen-
sor matrix (ORMOSIL) [3] with PDMS allows to perform biological experiments in 
a 100 μm deep microchamber that is constructed from uniform material. All layers 
were sealed by silicone adhesive tape. 
Figure 2: Designed (A) and fabricated (B) microdevice
To form the dissolved oxygen gradient in one of the culture chambers, oxygen 
scavenger (5% sodium sulphite water solution) was pumped through the correspond-
ing microchannel situated beneath the membrane. The second channel was con-
stantly flushed with oxygen saturated water.  
RESULTS AND DISCUSSION 
Formation of the oxygen concentration gradient inside the culture chamber was 
modelled, using  numerical simulation with COMSOL 3.4 software (Figure 3), and 
experimentally confirmed by photoluminescence lifetime recordings on a multilabel 
reader Victor2 (Perkin-Elmer Life Sciences) with the PtOEP sensing layer. 
A Glass with sensor for 
oxygen level imaging 
Culture chambers with 
media flow 
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The microsystem was used for bacterial biofilm culture. A Pseudomonas aerugi-
nosa strain, isolated from a CF patient (B54-1 WT-blue), was tagged with four dif-
ferent fluorescent proteins and inoculated. The experiment was carried out for 7 
days. The biofilm was formed in 2 days and was not dissolving during the entire ex-
periment. Confocal scanning laser microscopy was used for monitoring the biofilm 
formation (Figure 4).
0.1 ml·h-1 0.5 ml·h-1
2.0 ml·h-1
Figure 3: Left and 
above: oxygen gra-
dient in the designed 
microdevice at vari-
ous flow of the fluid in the chamber. Right: com-
parison between simulated and measured oxygen 
concentration
Figure 4: Confocal images 
of the bacterial biofilm for-
mation in the microdevice. 
Cells express different fluo-
rescent proteins (FP) (top: 
YFP, bottom from left to 
right: RFP, GFP, CFP).
CONCLUSIONS
The presented microfluidic chip was successfully used for generation of the oxy-
gen gradient, which was easily regulated by altering the media flow rate and moni-
tored by time-resolved photoluminescence measurements with integrated microsen-
sor. Separation of the oxygen scavenger allows utilising the chip for cell culture. 
The system was used for culturing of Pseudomonas aeruginosa biofilm. Future 
research will be focused on studies of the different antibiotic treatment strategies of 
bacterial biofilms. 
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A microfluidic chip for generation of gradients of dissolved oxygen was designed, fabricated and tested.
The novel way of active oxygen depletion through a gas permeable membrane was applied. Numerical
simulations for generation of O2 gradients were correlated with measured oxygen concentrations. The
developed microsystem was used to study growth patterns of the bacterium Pseudomonas aeruginosa in
medium with different oxygen concentrations. The results showed that attachment of Pseudomonas
aeruginosa to the substrate changed with oxygen concentration. This demonstrates that the device can
be used for studies requiring controlled oxygen levels and for future studies of microaerobic and
anaerobic conditions.
Introduction
The generation of concentration gradients of different chemicals
in microfluidic biochips is a problem often addressed in the
literature. Typically, for the water soluble components, these are
generated by diffusive mixing in microchannels by splitting and
merging streams with different concentrations of the molecules
of interest.1–6
In this work we address the creation of controlled oxygen
gradients in perfusion based cell culture chips. A few reports exist
that involve e.g., the direct oxygen generation by electrolysis of
water molecules,7 a technique that requires microelectrode
fabrication and that potentially can lead to small concentrations
of hydrogen peroxide, generated in the same process. A different
approach is to exploit the very high diffusivity and solubility
of oxygen in poly(dimethylsiloxane) (PDMS).8–10 PDMS is
a chemically inert, biocompatible and optically transparent
polymer11 that is very commonly used for fast construction of
microdevices.12,13 Its properties make it a popular material for
construction of cell culture based microdevices. Furthermore it
can be utilised as a component in an active scheme of oxygen
removal due to its gas permeability.
Active removal of dissolved oxygen from a liquid at the
macroscale can be achieved in many ways. These include
bubbling liquid with nitrogen gas, electrochemical reduction of
dissolved oxygen, biological consumption or chemical reaction
with an oxygen scavenger.7,14–16 At the microscale the first
method would lead to extensive drying of the liquid, while the
other two complicate the fabrication of such a system.
There are a few very recently published examples of the use of
PDMS based microfluidic chips in which the authors are using
nitrogen or nitrogen–oxygen gas mixtures to develop dissolved
oxygen gradients.17–19 The main advantage of such a solution
would be the possibility of reaching dissolved oxygen concent-
rations above air saturation point (9.2 ppm at 293 K and
1013.25 hPa).10 The main disadvantages are the complexity of the
setup and the possibility of slowly drying out the chamber when
a low liquid media flow is used.
The use of oxygen or other gas containers is difficult in cell
culture labs, due to safety reasons and usually very confined
space. Therefore, the application of a liquid oxygen scavenger is
highly preferable over systems that rely on such gas containers
in order to control the specific levels of oxygen gradients. Direct
addition of an oxygen scavenging agent such as sulfite or
pyrogallol to the cell culture media will alternate its chemical
composition which will have a heavy impact on the cultured
organisms.20 Therefore, in this paper we propose the use of a gas
permeable PDMS membrane to separate an oxygen scavenging
liquid from the cell culture media. To control the oxygen
gradient across the cell culture microchamber we rely on the
combination of the diffusive and advective oxygen transport
within the microchip. To the authors best knowledge, there is so
far no scientific report on such a system applied in biological
studies.
It is crucial to be able to monitor the oxygen concentration at
the microscale and here the classical amperometric method is not
feasible because of the bulkiness of sensors and restriction to only
point measurements. The most recent progress in miniaturization
of the Clark electrode21 allows one to build an electrode micro-
array22,23 which would allow monitoring gradients within
microfluidic devices in the future. However, most widely used
techniques for measurements of oxygen concentrations in
microfluidic devices are based on optical methods, which involve
photoluminescent dyes or polymer matrices doped with these
probes.24,25 The basic phenomena responsible for oxygen sensing
is dynamic quenching of luminescence by molecular oxygen.26
Most of the probes with very high quenching constants are based
on either ruthenium complexes, such as tris(bipyridyl)ruth-
enium(II)27 and Ru(II)-tris(4,7-diphenyl-1,10-phenanthroline)28–30
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or metalloporphyrins, mainly platinum(II) and palladium(II)
octaethylporphyrin (accordingly PtOEP and PdOEP)31–35 and
platinum(II) meso-tetra (pentafluorophenyl) porphyrin
(PtTFPP).32,36,37 Other probes, like Erythrosin B38 or pyrene,39
are also reported as suitable for oxygen sensing purposes.
The main advantage of the metalloporphyrin based sensors
over complexes of ruthenium based sensors is the much higher
sensitivity. This is especially important for sensing not pure
oxygen, but atmospheric air saturated cell culture media, where
the air saturation scale remains biologically relevant. Metal-
loporphyrins are non-soluble in water which is the main reason
why metalloporphyrins are usually embedded in polymers
or silicone sol–gel matrices.32,40 Consequently, ruthenium
complexes as water-soluble compounds can be added directly to
the culture media,19 which definitely would simplify the task of
sensing the dissolved oxygen concentration of the media. Such an
addition would however lead to unspecified alterations in the
metabolism of the cultured cells.10
Here we show the development of a microfluidic device that
combines chambers for cell culturing, an oxygen gradient
generator and an integrated optical sensor. This device was
designed for high compatibility with hardware available in most
laboratories. The system allows one to perform cell culturing
without directly adding an oxygen scavenger or oxygen sensing
compound to the culture media. This microfluidic system is
applied as a useful tool for biological studies where oxygen niches
are required and measurable.
Many bacteria experience fluctuating environmental changes
in their living habitats. This is caused by changes in available
nutritional factors and variation in oxygen concentrations which
the bacteria will have to adapt to in order to become a successful
colonizer.41
One such bacteria is the opportunistic pathogen Pseudo-
monas aeruginosa (P. aeruginosa) which is a recurrent and
persistent cause of lung infections in patients with the genetic
disease cystic fibrosis (CF).42 Here we use P. aeruginosa as the
model organism due to its history as a pathogen in highly
diverting oxygenated milieus. In order for this pathogen to
successfully colonize the human airways it needs to cope with
varying nutritional and oxygen levels.43 Differences in oxygen
levels are generated within the viscous mucus layer of the CF
airways and stress the bacteria to make a respiratory switch to
cope with microaerobic or especially anaerobic conditions.
Anaerobic growth of P. aeruginosa requires the presence of
alternative electron acceptors as NO3
, NO2
 or arginine in
which the bacteria renders to generate profound biofilm.44,45
Conditions of varying oxygen availability within the mucus
layers of the CF respiratory system is a metabolic challenge for
the bacteria and here we show a device that will be highly




The fabricated device is comprised of five layers (Fig. 1). The
first two bottom layers (coloured red in Fig. 1A) are made of
a very low oxygen permeable material (PMMA, R€ohm GmbH
& Co. KG, Germany, oxygen permeability: 1.35 barrers46).
They contain inlets and outlets in order to connect the micro-
channel (300 mm width, 200 mm depth, 184 mm total length)
and culture chamber. The microchannel and culture chamber
were fabricated by laser ablation (48-5S Duo Lase carbon
dioxide laser, SYNRAD Inc., USA). The third layer, the
membrane, is made of 60 mm thick oxygen permeable material
(PDMS, Dow Corning Corp., USA), obtained by spincoating
(60 s, 800 rpm) uncured PDMS on an ETFE substrate
(Tefzel Fluoropolymer Film, 200LZ, DuPont de Nemours
(Luxembourg) S.A., Luxembourg) followed by curing in 70 C
for 1 h. The ETFE substrate was used here as a temporary
solid support for the membrane and was subsequently removed
after integration of the membrane into the microchip. The
fourth layer, a 150 mm thick cell culture chamber, was
fabricated by laser ablation in the low oxygen permeable ETFE
foil. The culture chamber was sealed with a glass slide covered
with the oxygen sensing dye. The sensing layer was fabricated
by doping uncured PDMS with PtOEP (Sigma-Aldrich
Denmark A S1) diluted in THF. The solution was spincoated
(60 s, 3000 rpm) to a thin film (thickness approx. 8 mm) on the
120 mm thick glass slide and cured at 70 C for 20 min. All
layers were sealed by silicone adhesive tape (ARcare 91005,
Adhesive Research, Inc., Ireland) and integrated with the base
module which contains the milled (Mini-Mill/3PRO, Minitech
Machinery Corp., USA) fluidic connectors (Fig. 1B). The
microchip was designed to fit with outer dimensions to the
microscope slide standard (76  26 mm).
Fig. 1 Schematic presentation of the different layers of the device (A)
and the fabricated microdevice (B). Here dyes are injected to visualize the
microstructures of the assembled system (blue for channel and yellow for
chamber).
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Numerical simulations
The oxygen concentration gradients were numerically simulated
in COMSOL Multiphysics 3.5a in accordance to the chamber
geometry of the designed device. For the numerical simulation,
the following conditions were assumed: the density and viscosity
of the liquid are similar to water (1000 kg m3 and 0.001 Pa s,
respectively), a maximum concentration of oxygen in water
(saturation point at standard conditions) of 0.281 mol m3,
a diffusion coefficient of oxygen in water of 1.9  109 m2 s1,
a diffusion coefficient of oxygen in PDMS of 4.1  109 m2 s1,
oxygen solubility in PDMS 0.18 cm3(STP) cm3 atm.8 The equi-
librium between oxygen in water and in PDMS can be described
by eqn (1). The rate constant of oxygen transport from water to
PDMS (k1 in eqn (1).) was set as 1.0  102 m s1 47 and the rate





The ratio of these two rate constants, under steady state
condition, is equal to the ratio of oxygen concentrations in water
and in PDMS (2). This can otherwise be expressed as a partition
coefficient (Kp) between the oxygen in PDMS and in the water
phase. This implicates the linear correlation between oxygen












The oxygen flux at the PDMS–water boundaries was modelled
according to eqn (4). The signs at rate constants depend on the
direction of oxygen diffusion.
fluxO2 ¼ k2$CPDMSO2  k1$CwaterO2 (4)
To simplify the simulation we additionally assumed a rapid
reaction of the oxygen at the interface between the membrane
and the oxygen scavenging liquid (0% oxygen concentration at
this interface as a boundary condition) (Fig. 2). This condition
can be achieved with an adequate flow of the scavenging liquid
and the addition of a catalyst.15 The liquid flow in the chamber
varied from 1 ml min1 to 500 ml min1, which corresponds to
a Peclet number for dissolved oxygen from 0.6 (diffusive trans-
port) to 290.4 (advective transport).
Photoluminescence lifetime measurements of the oxygen gradient
To form the gradient of dissolved oxygen in the growth chamber,
an oxygen scavenger (10% sodium sulfite solution with 0.1 mM
CoSO4 as catalyst, both from Sigma-Aldrich Denmark A S
1)
was pumped by a syringe pump (model 540060, TSE Systems
GmbH, Germany) through the microchannel situated beneath
the membrane with a constant flow rate of 20 ml min1, while the
growth chamber above the membrane was flushed with atmo-
spheric air saturated water with varying flow rates according to
the values used in the numerical simulations.
Photoluminescence lifetime measurements of the PtOEP based
sensor were carried out on a multi-titre plate reader (Wallac
Victor2, Perkin-Elmer Life Sciences, USA). The entire microchip
was mapped to the sectors of a 384 well plate (Fig. 3). The
excitation wavelength was 340 nm and the emission wavelength
was 640 nm.
In order to correlate the photoluminescence lifetime
measurements with the oxygen concentration, a two point cali-
bration was made. The phosphorescence decay curves for the
Fig. 2 Schematic model of the oxygen gradient generation in the microdevice.
Fig. 3 The chamber mapped to the sector of a 384-wells microplate (the
green area is the biochip, blue circles are the 384 microplate wells while
the red circles are the oxygen gradient measurement points).
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sensing layer flushed with oxygen free and air saturated water
were recorded.
For calculation of the oxygen gradient, in total 12 location
points were used. For each measurement location, the decay of
the phosphorescence curve was determined by reading the
intensities after excitation pulses at 5, 10 15, and 20 ms and then
with 10 ms intervals to 170 ms. In total, 20 points were used for the
determination of each phosphorescence decay curve. The
monoexponential model of the phosphorescence decay was
assumed according to eqn (5), where I(t) is the phosphorescence






The data were fit to the model using MATLAB 2008a software
and phosphorescence lifetime was determined for every location
point. In order to convert the phosphorescence lifetime to the
dissolved oxygen concentration, a two-point calibration was
done by measuring phosphorescence lifetimes of oxygen free and
atmospheric air saturated water.
Cultivation of Pseudomonas aeruginosa, PAO1 within the
microfluidic chip
Pseudomonas aeruginosa strain PAO148 tagged with a green
fluorescent protein (GFP)49 was grown in the flow chambers of the
device. The individual chambers were either set up with water in
the channels as a control or with oxygen scavenging liquid. PAO1
biofilms were cultivated in chambers irrigated with FAB medium.
For the initial attachment experiment the media was supple-
mented with 0.3 mM glucose and for the long term cultivation
experiments with 10.0 mM sodium citrate. Several studies have
demonstrated that FAB media supplemented with sodium citrate
as the sole carbon source promote a carpet-like biofilm instead of
microcolonies and mushroom-like structures. This generates
a better possibility of quantitative comparison of the bacterial
biomass developed under different oxygen environments.50
The flow chambers were inoculated by injecting 500 ml over-
night culture diluted to an OD600 of 0.005 into each flow
chamber. This inoculum ensured that the entire culture chamber
was filled. To drive the growth of bacterial biofilm on the glass
side the chip was turned upside down without flow for 1 h after
inoculation. The media flow was subsequently started at the
flowrate of 10 ml min1 using a peristaltic pump (Watson Marlow
205S, Watson-Marlow Inc, USA), directly followed by detection
of attached bacteria by confocal laser scanning microscopy
(CLSM).
In order to illustrate biofilm development in different oxygen
environments the long term cultivation of PAO1 was performed
for 4 days using sodium citrate supplemented FAB media. All
steps were carried out at 37 C.
Microscopy and image analysis
Microscopic observations and image acquisitions were per-
formed on a Zeiss LSM 510 CLSM (Carl Zeiss, Jena, Germany).
Detectors and filter settings were set for monitoring GFP.
Confocal images of the 1 h initial attachment was taken using the
63/1.4. For each indicated time point 7 pictures were taken in
random locations of the specific oxygen saturation point. For the
long term experiments, pictures were taken at day 4 using
the 40/1.4 Plan-Neofluar oil objective. The first location for the
long term biomass measurements was chosen at an oxygen
concentration of 97%. Each consecutive measurement was per-
formed in intervals of 1 mm down the oxygen gradient (see Fig. 8
and Fig. 9 later). All images were processed using the IMARIS
software package (Bitplane AG, Z€urich, Switzerland).
For quantification of biomass the COMSTAT software was
used. COMSTAT defines biomass as a biomass volume divided
by the substratum area (mm3 mm2).50
Results
Description of the system
We have fabricated a multilayer system where we incorporated:
a PDMS immobilised oxygen sensing probe, a culture chamber,
a gas permeable membrane and a microfluidic channel for
oxygen scavenging.
The purpose of the microfluidic channel is to constantly flush
the PDMS membrane with an oxygen scavenging liquid. This
allows oxygen transport across the membrane by diffusion from
the growth chamber to the microchannel. Here the oxygen is
irreversibly consumed in a rapid chemical reaction. The oxygen
gradients generated within the chamber can be monitored by the
oxygen sensing probe.
The culture chamber was used for P. aeruginosa cultivation in
different dissolved oxygen environments.
Numerical simulations of the oxygen gradients
In order to verify the generation of dissolved oxygen gradients
within the microdevice, numerical simulations were performed.
The gradient can be observed in a horizontal as well as a vertical
plane. Since PAO1 strain forms biofilm on the glass side of the
chamber only the oxygen gradient from the top horizontal plane
was taken into consideration (Fig. 4).
The oxygen gradients vary with the media flow rate (Fig. 4)
due to changes in the ratio of advective and diffusive transport.
This ratio can be described by the Peclet number (Pe) (see eqn (6)
and Fig. 2 where L is the characteristic length, V is the velocity
the media and D is the diffusion coefficient of oxygen in water).
In the first case where the flow rate of the media is low
Fig. 4 Simulations of the oxygen saturation gradients in the growth
chamber according to the various flow rates of culture media.
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(1 ml min1, Pe ¼ 0.6), only a very short horizontal distance
within the chamber is needed to remove almost all the oxygen.
When the flow rate within the chamber is increased, the oxygen
saturation at the end of the chamber increases accordingly (2%
at 10 ml min1 (Pe ¼ 6), 43% at 50 ml min1 (Pe ¼ 29), 63% at
100 ml min1 (Pe ¼ 58) and 88% at 500 ml min1 (Pe ¼ 290) (last




Photoluminescence lifetime measurements of the oxygen
gradients
A two point calibration of the PDMS immobilised oxygen probe
was made to be able to calculate oxygen gradients generated
within the microfluidic device. The determined phosphorescence
lifetimes for oxygen free and atmospheric air saturated water
were: 69.7  0.4 ms and 8.2  0.1 ms, respectively. These
measurements allowed us to make a correlation between the
photoluminescence lifetime and oxygen concentration (Fig. 5).
The comparison between the numerically simulated and
measured oxygen concentration gradients were made in order to
validate both the theoretical model and the experimental data
(Fig. 6). The simulation curves were plotted as oxygen saturation
in water from the middle chamber cross-section versus the length
of the channel. For each curve, twelve measurement points were
used according to the spots marked in Fig. 3.
The measured oxygen gradients follow the data obtained by
the numerical simulations (Fig. 6). The variance coefficients
between simulated and measured oxygen concentrations were
2.2%, 5.9% and 13.5% for, accordingly, 100, 50 and 10 ml min1
media flow rates. The measured oxygen concentrations were
slightly higher than the simulated ones at high flow rates and
slightly lower at low flow rates. These differences can be
explained by the flexibility of the PDMS membrane, which was
not taken into consideration in the numerical simulations, for the
sake of model simplicity, The membrane is slightly deflecting due
to hydraulic pressure differences between the chamber and the
channel with oxygen scavenger. This affects the chamber depth
(L, Fig. 2), oxygen diffusion length and consequently the oxygen
gradient.
According to both the numerical simulations and experimental
measurements of the oxygen concentrations, we have shown that
it is possible to control the oxygen gradient by merely alternating
the media flow.
Reduced initial attachment and biofilm growth in the microdevice
To investigate the effect of the oxygen concentration on the
growth of the P. aeruginosa PAO1, we cultivated this strain in the
chip with a defined media known to support aerobic growth. We
hypothesised that the lack of an alternative electron acceptor
would affect the growth pattern of PAO1 under low oxygen
concentrations. As a reference point for comparison purposes,
we arbitrarily chose the culture chamber section with 20% of
atmospheric air saturation (microaerobic conditions).
Following one hour of attachment under this low oxygen
concentration, the attachment capacity of PAO1 to the PDMS
surface was highly reduced. As shown in Fig. 7, PAO1 prefers to
attach to the PDMS surface (shown 146.6mm  146.6mm area)
during conditions of higher air saturation. The attachment
characteristics of PAO1 was furthermore investigated by time-
lapse confocal microscopy. In a setup where the cells were
allowed 1 h of initial attachment under atmospheric air saturated
media, it was shown that the cells readily leave their attachment
site after the media is reduced in oxygen concentration (data not
shown).
Fig. 5 Phosphorescence decay curve for oxygen free and atmospheric air
saturated water (see equation 5).
Fig. 6 Comparison between simulated (dashed lines) and measured
(solid lines) oxygen concentration gradients in the culture chamber at
different media flow rates.
Fig. 7 Initial attachment of P. aeruginosa strain PAO1 at the end of
microchambers recorded after 1 h of attachment: (A) media saturated
with atmospheric air, (B) 20% of dissolved oxygen saturation.
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In order to quantitatively compare the effect of different
oxygen environments on PAO1 growth we used a FAB media
supplemented with sodium citrate as the sole carbon source.
We measured bacterial biomass formed after 4 days of culti-
vation in the microchambers. Under aerobic conditions
(Fig. 8A) an even distribution of carpet-like biofilm is spread
over the substratum. The drop in oxygen availability has a high
impact on the cells ability to form a stable and evenly
distributed biofilm (Fig. 8B). Fig. 9 shows clear correlation
between PAO1 biomass and the oxygen gradient generated
within the culture chamber.
Discussion
One of the main goals of our work was to design a device that
was fairly easy to fabricate and handle. In order for a device to be
a successful asset to a wide range of functional purposes in
a laboratory, the need for complicated setups and supplies
should be reduced as much as possible. In this paper we
presented a developed system which easily produces controllable
oxygen gradients within a culture chamber.
We exploit the advantages of an oxygen scavenging liquid over
methods which involve flushing the channel with oxygen–
nitrogen gaseous mixtures.19 This significantly reduces the
complexity of the setup and need of additional equipment.
Since PDMS is highly permeable, not only to O2 and N2 but
also to water vapour, the use of pressurised gases would cause
extensive drying of the culture media during long term experi-
ments. In the case of low media flow rates, this could lead to
severe changes in media osmolarity51 and introduce bubbles
within the culture chamber.52
The use of an oxygen tank in the laboratory is furthermore
a serious safety threat to the personnel, therefore any solution
which would eliminate it from the setup is highly desirable.
Furthermore we have produced a system which is cheap in
expenses for oxygen scavenging due to very small amounts of
chemicals needed.
The designed microfluidic system was integrated with a thin
film sensor which was used for the detection of dissolved oxygen
concentration gradients within the cultivation chamber. The
oxygen concentrations were monitored by photoluminescence
lifetime measurements. This specific way of monitoring oxygen
concentration is compatible with several different detection
methods as micro plate readers and fluorescence lifetime imaging
microscopes.
Since bleaching of the oxygen probe by short excitation pulses,
as used in time-resolved spectroscopy, is much lower than in the
case of excitation with continuous light, the proposed thin film
sensor can be used for long term experiments.
Prolonged exposition of the culture chamber to a strong light,
used for oxygen probe excitation, would be harmful for the
cultivated cells.53 Therefore, the short excitation pulses used in
Fig. 8 Four day old biofilm of P. aeruginosa PAO1 cultivated in FAB media supplemented with 10 mM sodium citrate under: (A) atmospheric air
saturation, (B) oxygen saturation (from left to right): 97%, 79%, 60% and 41%.
Fig. 9 Comparison of bacterial biomass developed in different oxygen
environments. The red bars represent the PAO1 biomass within the
culture microchamber under the oxygen gradient (red line). The blue bars
represent PAO1 biomass produced in the atmospheric air saturated
media.
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time-resolved spectroscopy techniques are preferable over
continuous light excitation.
Furthermore, the choice of not using dissolved oxygen probes
generate a system in which the influence of the probes on the
cells10 is completely eradicated. A significant advance over
previous approaches,19 where the authors created a system in
which oxygen probes were present within their setup, is that we
generated a highly biocompatible chip where the toxicity of the
probes is eliminated.
For the making of the thin film sensor, we chose a PDMS
matrix over the organically modified silica (ORMOSIL), which
was widely used as a sensor matrix in previous works.32 This
substitution allows one to perform biological experiments
without exposing the cultivated organism to two different envi-
ronments (a hydrophilic glass-like surface in the case of
ORMOSIL and a hydrophobic silicone rubber surface in the case
of PDMS). Having these two surfaces with radically different
properties could bias biological experimental data. This is
especially important in studies of bacterial biofilm formation,
where adherence will vary according to hydrophilicity of
a specific surface.54 However in other applications, especially for
mammalian cell cultures, the use of ORMOSIL could be
advantageous due to its chemical inertness55 and the possibility
of relatively easy surface modifications.56
Moreover, the cracking problem, reported for low molecular
mass ORMOSIL precursors40 is not present in PDMS films.
Another advantage of the PDMS based matrix is the rapid
fabrication time. The curing time for thin PDMS films is only
20 min while gelation and drying time of ORMOSIL based
matrices, reported in the literature, can be as long as 2 weeks.34
The results from photoluminescence lifetime measurements of
the dissolved oxygen gradients, which was generated within the
culture chamber, correlated well with the results obtained from
the numerical simulation. This does not only confirm the
correctness of the mathematical model of the oxygen transport in
the microfluidic system but also the reliability of time-resolved
luminescence measurements done using the proposed PtOEP film
sensor.
We consider that the discrepancies between simulated and
measured oxygen concentrations observed at some media flow
rates are due to deflection of the PDMS membrane. In order to
include this effect in the numerical simulations one would need to
incorporate one of the stress–strain models for a hyperelastic
material. In the literature one can encounter a limited number of
examples with numerical simulations of PDMS deflection.57,58
However, to our best knowledge, there is no literature data
describing how the gas permeability of PDMS is changing
according to the strain.
When the only changes in dissolved oxygen levels are due to
the chemical reaction with scavenger and diffusion–advection
transport, the numerical simulations can predict the approximate
shape of oxygen gradients within the chamber of the microchip.
However, when this is not the case, e.g. when the chamber is used
for cell culturing or when the material properties are not well
characterised, a simple mathematical model cannot precisely
predict the oxygen consumption. In such a case it will be
necessary to use an integrated sensor.
The designed system was successfully applied to support
growth of P. aeruginosa PAO1 biofilm. PAO1 responded to the
low oxygen concentration environment by a reduced number of
attached cells to the surface of the microchamber after the one
hour adherence period. This indicates that the oxygen concent-
ration within the microenvironment of the attachment site is
highly important for PAO1 to effectively bind to this surface.
The specific response to the low oxygen availability shows
that PAO1 under flow conditions seems to lack the ability to
effectively form an irreversible attachment.
In the CF lungs environment, the bacteria are living in a mucus
matrix with the presence of DNA, proteins and other factors59
which are highly diverting over the course of infection. This
is currently not possible to fully grasp in the experimental
conditions. However the most important factor in the chronically
infected CF patients is the oxygen tension.45 The presented device
makes it possible to generate such differences in oxygen levels
and is here proven to make an excellent platform for this kind of
experimental setup.
Concluding remarks
In this paper we presented a novel approach for oxygen gradient
generation within a microfluidic biochip. The system was
successfully fabricated by micromilling, laser ablation and spin-
coating techniques.
The simple layer-by-layer design allows the incorporation of
several desirable elements as the integrated gas permeable
membrane which we exploited by an oxygen scavenging liquid to
produce the desired oxygen environments. The experimental
data correlated as expected to the numerical simulations per-
formed.
Stability and biocompatibility experiments were successfully
performed over a long term biofilm culture, which proves the
system as an excellent foundation for oxygen dependent studies.
We successfully made a system that does not rely on toxic dyes
or difficult setups, but was built to be easy and safe to operate as
well as highly mobile and compatible with common used bio-
logical laboratory equipment such as microscopes and multi-titre
well plate readers.
In future CF biofilm studies, desired to be investigated in
different oxygen environments, this platform could furthermore
be used with the incorporation of other biologically important
factors, like DNA and proteins. This would be a great advance
towards mimicking the CF airways.
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A modular microfluidic airways model system that can simulate the changes in 
oxygen tension in different compartments of the cystic fibrosis airways was 
designed, developed and tested. The fully reconfigurable system composed of 
modules with different functionalities: multichannel peristaltic pumps, bubble traps, 
gas exchange chip and cell culture chambers. We have successfully applied this 
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system for studying the antibiotic therapy of P. aeruginosa, the bacteria mainly 
responsible for morbidity and mortality in cystic fibrosis, in different oxygen 
environments. Furthermore, we have mimic the bacterial reinoculation of the aerobic 
compartments (lower respiratory tract) from the anaerobic compartments (CF 
sinuses) following an antibiotic treatment. This effect is hypothesised as the one on 
the main reasons for recurrent lung infections in CF patients. 
I. INTRODUCTION 
The human airways are complex multi-compartmental habitats for infectious bacteria. 
In healthy humans, the majority of the airways are essentially kept sterile as a result of highly 
efficient clearing mechanisms
1
. In cystic fibrosis (CF) patients, this clearing mechanism is 
severely impaired and bacterial infections inflict deteriorating health and becomes the major 
cause of mortality in these patients
2, 3
. 
 The human airways consist of at least three independent compartments, the 
conductive airways (the trachea, bronchi and bronchioles), the oxygen exchange 
compartment (alveoli), and a third, less investigated compartment, the paranasal sinuses 
(maxillary sinuses, frontal sinuses and ethmoid sinuses). In the first and the last compartment, 
the environment is essentially anaerobic
4
, while the alveoli are highly aerated. 
 In healthy individuals, the conductive airways are constantly cleared by mucociliary 
transport of entrapped microorganisms
5
. As a result, very few bacteria will ever reach the 
alveoli. Bacteria that do evade this clearing mechanism will rapidly be cleared by the actions 
of the immune system. The sinuses also have a mucociliary clearance mechanism although 









 Cystic fibrosis patients suffer from a defect in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene. The affected gene codes for the CFTR protein, which is 
a chloride channel that is present in the epithelial cell membrane. Reduced or absent function 
of the CFTR will lead to highly reduced secretion of chloride and accordingly water over the 
cell membrane
7
. A direct consequence of this defect is that the mucus layer in the conductive 
airways becomes very viscous and the mucociliary clearance mechanisms are highly 
impaired
3, 8
. This results in frequent and recurrent infections of the CF airways, with the risk 
of pneumonia. As the bacteria infect the lungs in large numbers, the immune system tries to 
eradicate the infection but with a reduced effect since the bacteria are embedded in mucus 
and more or less recalcitrant to the cellular defence
9
. Instead the lung tissue is gradually 
damaged by the on-going immunological exposure, eventually leading to massive pulmonary 
deficiency and death
10
. In the clinic, the infections can be treated with cocktails of antibiotics, 
which can reduce or sometimes eradicate the infectious agents
11
 
 Bacterial airway infections in patients with a normal mucosa are relatively easy to 
treat with antibiotics. This is unfortunately not the case for CF patients and the myriad of 
infections they acquire during their lifetime leave each patient with a high need for recurrent 
antibiotic treatments. This is a multifactorial phenomenon and there are a lot of theories that 
try to explain this
12-14
. The most obvious reason for a treatment failure is the hindered 
diffusion of the antimicrobial agent through the thick and viscous mucus layer
15, 16
. However, 
according to recent findings, the main reason may reside in limited oxygen availability in 
some parts of the airways
17, 18





human physiology of the airways and furthermore upheld by the consumption from epithelial 
and immune cells in the local surroundings. 
 As Pseudomonas aeruginosa (P. aeruginosa) infections are almost inescapable in CF 
patients, especially in older patients, this makes P. aeruginosa an important organism for 
studies of “oxygen” phenomena19. P. aeruginosa is a facultative anaerobic bacteria20 with 
reduced growth
21
 and metabolic activity
18
 at low oxygen levels. Antibiotics such as 
tobramycin, ciprofloxacin, and tetracycline preferentially kill the physiologically active 
bacteria living at high oxygen levels (aerobic environment), while colistin is more effective 
on the physiologically inactive bacteria growing in an anaerobic environment
10, 22
. 
 An antibiotic treatment has the potential to clear a lung infection, yet after a few 
months the same bacteria are very likely to reappear, possibly as a result of reinoculation 
from the anaerobic environment of the sinuses
23
. In this context the sinuses could very well 
serve as a reservoir for “sinus” bacteria, which are difficult to treat with antibiotics and can 
cause the reinfection of otherwise cleared patients. 
 The now classical ways of studying CF related bacterial infections, primarily P. 
aeruginosa, are either to use animal models or to grow the bacteria in flow-cell systems.  
 A number of different animals have been tried as models of chronic infections in CF 
patients
24






 and rhesus monkeys
30, 31
. However the 
most important animal model is a mouse
32-35
. The use of an animal model is expensive and 
rise ethical concerns
36, 37
. Furthermore, animal models for CF related infections are still not 
ideal, mainly due to immunological differences between man and e.g. mouse. Mice do not 











 In flow-cell based systems, the bacteria are allowed to form a biofilm on a surface, as 
in the airways, and can then be monitored using a confocal microscope
11, 41
. However, this is 
not a suitable model for the human airways as they are subdivided into aerobic and anaerobic 
compartments. 
 The advancement in micro- and nanofabrication and assembly, as well as better 
understanding of microfluidics, has made possible the development of devices for modelling 
different tissue organs. Thanks to these devices, the control over the environment, relations 
and interactions between the cells and tissues at microscale with high spatial and temporal 
resolution can be achieved
42, 43
. The yet small but fast growing number of microdevices that 





















 In the field of mimicking the human airways, Huh at al.
57, 58
 proposed a microfluidic 
device that can simulate injuries to the airways epithelia done by liquid plug flow. Recently, 
Huh at al. proposed a model of the vacuoles in the lung
59
. In this work the phagocytosis of 
planktonic Escherichia coli cells by neutrophils on the epithelial surface was shown. 
 In our previous work
21
 we have shown the possibility of using a 
poly(dimethylsiloxane) (PDMS) membrane and an oxygen scavenging liquid to control the 
oxygen gradient within cell culture microchambers. However, according to the authors’ best 





would allow to observe the influence of the microenvironment of these compartments on the 
recurrence of CF related infections has not been reported previously. 
 Therefore, the aim of this work was to make a model system, which simulates the 
three compartments of the airways to better understand the interplay between them. Using 
this artificial airways model, we can look into the bacterial details in the three compartments, 
their transmitting interaction, and the states of the bacterial inhabitants before, during and 
after antibiotic treatment. 
II. MICROFLUIDIC AIRWAYS MODEL 
The three sections of human airways: the conductive airways (trachea, bronchi and 
bronchioles), which are considered micro-aerobic, the highly aerobic gaseous exchange 
compartments (the alveoli) and the compartments of the paranasal sinuses, which are 
basically anaerobic (FIG. 1 a), are reproduced in this Microfluidic Airways Model (MAM). 
This is realized by constructing cell culture microchambers with different oxygen levels 
(FIG. 1 b). A microchamber with atmospheric air oxygenated media (aerobic environment) is 
connected by a channel to a microchamber with culture media saturated below the 
atmospheric air saturation level (micro-aerobic environment). This chamber is consecutively 
connected to a chamber with deoxygenated media (anaerobic environment). The connections 
between the chambers as well as outlets can be closed and opened and the actual oxygen level 








FIG. 1. (a) The human airways system60 and (b) the Microfluidic Airways Model (MAM)  
III. DESIGN 
The above model was implemented, as a modular system comprised of the following 
distinct modules: a modified previously described multichannel microfluidic peristaltic 
pump
61, 62
, a bubble trap, gas exchange and cell culture chambers (FIG. 2). The system allows 
to simultaneously cultivate cells in 8 chambers (3 of them facilitate aerobic environment, 2 
micro-aerobic environment and 3 anaerobic environment). 
 These modules can be attached to form a microfluidic platform. The detailed design of 
each of these modules and the platform is available in the supplementary materials at [URL 







FIG. 2. Modular implementation of MAM 
IV. MATERIALS AND METHODS 
A. Microfabrication 
The material of choice for most of the parts was polycarbonate (PC) (Nordisk Plast 
A/S, Denmark). This material exhibits low oxygen permeability (1.8 barrer
63
), very good 
mechanical and optical properties
64
 as well as being resistant to alcohols and oils, which is 
important for sterilization and microscopy. The structures in PC were obtained by 
micromilling (Mini-Mill/3PRO, Minitech Machinery Corp., USA) followed by 
tetrahydrofuran vapour assisted bonding (50°C, 1.5 MPa). 
 PDMS inlays were fabricated by casting the silicone mixture (Sylgard 184, Dow 
Corning Corp., USA) against the milled mould. The PDMS parts were bonded to PC using 
silicone adhesive tape (ARcare® 91005, Adhesive Research, Inc., Ireland). The tape was cut 






 The gaskets used for sealing the modules to the platform, as well as check valves, 
were fabricated by milling in fluoroelastomer VITON A (J-Flex Rubber Products, UK). 
B. Cultivation of P. aeruginosa strains 
The P. aeruginosa laboratory strain PAO1 was used for all biofilm experiments. The 
PAO1 strain was originally isolated from a burn wound
65
. PAO1 was fluorescently tagged at 
a neutral chromosomal locus with GFP or mRFP1 with miniTn7 constructs as previously 
described
66
. A P. aeruginosa medium (FAB)
41, 67
 supplemented with 0.3 mM glucose and 65 
mM KNO3 (FAB-GN) was used for biofilm cultivation. All biofilms and batch cultures were 
grown at 37°C. PAO1 was pre-cultured overnight in Luria Bertani (LB) media and prepared 
for inoculation in FAB-GN media. The overnight culture was diluted to an OD600 of 0.01 and 
subsequently 100 l was inoculated with a Gilson P200 pipette through the designed inlets. In 
order to visualise the bacteria migration, the anaerobic culture chambers were inoculated with 
the GFP tagged strain and microaerobic and aerobic chambers were inoculated with the 
mRFP1 tagged strain. The device was left upside down for an hour without media flow. 
Following the one hour incubation period, the media flow was started at 500 l·h-1 per 
channel. After 48 hours of cultivation in the growth chambers the media was exchanged to 
media supplemented with 50 g·ml-1 of the antibiotic, Ciprofloxacin (Sigma-Aldrich, 
Denmark A/S). 24 hours antibiotic treatment was followed by staining with 1 M SYTOX 
Blue dead cell stain (Molecular Probes, Invitrogen, Denmark). The chambers were left for 48 
hours running on media without Ciprofloxacin. This was done in order to subsequently 





between the chambers and cells were allowed to migrate for 24 hours before analysed with 
confocal laser scanning microscopy.  
 The interconnections between chambers were made with PVC tubing attached to 
PEEK connector plugs that were inserted into the specific chambers with different oxygen 
levels. 
C. Dissolved oxygen level control 
In order to control the dissolved oxygen levels in the cell culture media, one of the 
PDMS gas exchange module inlays was supplied with an oxygen scavenger (10% sodium 
sulphite solution with 0.1 mM CoSO4 as catalyst, both from Sigma-Aldrich Denmark A/S). 
The second inlay was left open to atmospheric air. 
 Determination of the oxygen levels in the cell culture chambers was achieved using  
the phosphorescent oxygen-sensitive nanoprobe based on Platinum(II)- tetrakis-
(pentafluorophenyl) porphine (PtTFPP) dye
68
 (Luxcel Biosciences, Ireland). The oxygen 
levels were determined by: (i) phosphorescence intensity and lifetime measurements on an 
Axiovert 200 wide-field microscope (Carl Zeiss, Germany)  upgraded for phosphorescence 
lifetime imaging (LaVision Biotec, Germany), and (ii) phosphorescence lifetime 
measurements on a multi-label plate reader (Victor2, Perkin-Elmer Life Sciences, USA). The 
imaging experiments were performed as described in
69
 using pulsed excitation with a 390 nm 
LED and emission collection at 655±50 nm. Plate reader measurements were performed as 
described in
68
, using excitation at 340 nm and emission at 642 nm. For such measurements 
the device was inoculated with non-fluorescent P. aeruginosa laboratory strain PAO1, then 
maintained under a flow of medium, containing 0.01 mg.ml
-1
 of probe, for 12h and then 





in the device, which can be used to monitor oxygenation and conduct biological experiments 
for several days. 
 The correlation between the phosphorescence intensity or photoluminescence lifetime 
and dissolved oxygen concentration was determined by two-point calibration: at 0% and 
100% of atmospheric air oxygen saturation in the culture media. The 0% atmospheric air 
oxygen saturation was obtained by supplementing the glucose containing culture media with 
glucose oxidase (Sigma-Aldrich Denmark A/S) as previously described in
70
. Each cell culture 
chamber was calibrated separately. 
D. Confocal microscopy and image analysis 
Confocal fluorescence images were taken with a Leica TCS SP5 microscope using a 
50x/0.75W objective. 4 random pictures were taken from each chamber. Settings for 
visualization of the probes were: 514 nm excitation and 613-688 nm emission for mRFP1; 
488 nm excitation and 517-535 nm emission for GFP; 458 nm excitation and 475-490 nm 
emission for SYTOX Blue dead stain. All images were processed by the Imaris 7 software 
package (BITPLANE AG, Zürich, Switzerland). 
V. RESULTS 
A. Integration of the modular microfluidic system 
The microfluidic modules described in supplementary material at [URL will be 
inserted by AIP] were successfully fabricated and assembled on a microfluidic platform (FIG. 





actuated by two motors obtained from commercially available LEGO® Mindstorms® NXT 
2.0 robotic kit
71




FIG. 3. (a) Microfluidic platform with modules and the peristaltic micropump (b). 
 
B. Determination of the dissolved oxygen level 
The differences between the phosphorescence intensity of the P. aerugionsa biofilm, 
stained with the PtTFPP nanoprobe, in the aerobic and anaerobic environments was 
investigated in order to determine the oxygen removal efficiency from the culture media 
using the gas exchange module (FIG. 4). The phosphorescence intensity increased 
approximately two-fold in anaerobic conditions as compared with aerobic conditions. 
 A two-step calibration curve was established by measuring The photoluminescence 
lifetime of the nanoprobe in oxygen free and atmospheric air-saturated media. The 
photoluminescence lifetime was determined to be 54.5±1.3 µs (oxygen free media) and 
29.7±0.6 µs (and atmospheric air-saturated media). Oxygen concentration in atmospheric air-
saturated media was determined to be 0.281 mM 
72
. The measurements were performed at 
(a) (b) Culture chamber module 
Microfluidic modular platform 
Gas exchange module 
Bubble trap module 







room temperature. Assuming a reversible collisional quenching model
73
, the Stern-Volmer 
constant was determined to be  2.97 mM
-1
.  
 The photoluminescence lifetimes of the nanoprobe in the chambers, resembling 
aerobic, micro-aerobic and anaerobic environments, were: 30.5 µs, 35.8 µs and 51.1 µs, 
respectively, which corresponds to 94.2%, 62.7% and 7.9% of atmospheric air-saturation of 




FIG. 4. Phosphorescence intensity (top panel) and lifetime (bottom panel) images of the P. aeruginosa biofilm 






C. Cultivation of P. aeruginosa strains in different oxygen 
environments 
PAO1 biofilm formation was analysed 24 hours after inoculation. In order to follow 
the trail of each specific population following each inoculation, we used different fluorescent 
tagged versions of PAO1. The initial 24 hour cultures, under different oxygen environments 
in presence of nitrate as an alternative electron acceptor, gives rise to highly equivalent 
biofilm formations within the oxygen compartments (FIG. 5 a-c).  
 The green confocal image (FIG. 5 a) originates from GFP tagged bacteria and was 
cultivated under the lowest oxygen saturation. The red biofilm derives from mRFP1 tagged 
bacteria and was cultivated in microaerobic (FIG. 5 b) and aerobic conditions (FIG. 5 c). 
However, under the tested conditions in a minimal media, the biomass within first 24 hours 
of growth reached highly equivalent magnitudes of biomass regardless of oxygen tension. 
Under anaerobic conditions, supplemented with nitrate as electron acceptor, PAO1 has in LB 
media shown to develop 3 fold more biomass
74
.  
 In order to evaluate the efficiency of the antibiotic ciprofloxacin on PAO1 biofilms 
under conditions on differentially lowered oxygen availability in a FAB-GN media, each 
chamber was challenged with the same ciprofloxacin concentration. After 24 hours of 
incubation each chamber received media supplemented with 50 g·ml-1 of the antibiotic 
ciprofloxacin for a period of 24 hours. The treatment would present the differences in the 
effectiveness of the antibiotic in a developing PAO1 biofilm. Dead cells in the biofilms were 
visualized by staining each chamber with Sytox blue dead cell stain (FIG. 5 d-f). The effect 





PAO1-GFP biofilm was much more susceptible to the antibiotic treatment than biofilm 
formed under higher oxygen concentrations. The antibiotic concentration was chosen to 
eradicate the majority of cells in the establishing biofilms, though low enough to allow 
surviving cells. PAO1 had in that sense been established enough to produce a healthy biofilm 
and represent a community associated environment.    
 Following the 24 h treatment with ciprofloxacin, the chambers were taken off the 
antibiotic containing media for 48 hours and connections between the different oxygen 
environments were made (FIG. 5 g-i) (see connection details in the supplementary materials 
at [URL will be inserted by AIP]). This enabled tracking of the bacteria in a novel way that 
has previously not been possible. We setup the system in a way to follow in which direction, 
if any, the surviving bacteria would move. As the ciprofloxacin treatment had been stopped 
the only difference between the chambers were the differences in oxygen concentrations. The 
small green clusters on FIG. 5 a) and i) come from the GFP tagged bacteria. This proves that 
PAO1 moves from chambers with low oxygen tension (FIG. 5 g) to microaerobic (FIG. 5 h) 






7.9% oxygen saturation 62.7% oxygen saturation 94.2% oxygen saturation 
   
(a) (b) (c) 
   
 (d) (e) (f) 
   
(g) (h) (i) 
   
FIG. 5. 3D representation of the PAO1 biofilms at different oxygen saturation in FAB-GN media (minimal media 
supplemented with nitrate). PAO1 expresses either the fluorescent protein GFP or mRFP1. a-c): 24 hours old biofilms in 
FAB-CN media. d-f): 48 h after inoculation the cells were challenged with 50 µg·ml-1 Ciprofloxacin for 24 hours and then 
stained with dead stain SYTOX Blue. g-i): Interconnected chambers of the different oxygen saturation environments. 
VI. DISCUSSION AND CONCLUSIONS 
In this paper we describe design, fabrication, working principle and application of a 
highly complex modular microfluidic system. Integration of different modules, bringing in 





exchange and bacterial culturing on a microfluidic lab-on-a-chip system, has been shown to 
be successfully achieved. The modularity allows addition and removal of the different 
functionalities. The design permits easy reconfiguration and tailoring of the system to match 
particular needs. In case of malfunctions in a single module, the system benefits from its 
modular construction and allows uncomplicated exchange of the broken module without the 
need for fabrication of other essential parts of the system. This is particularly important in the 
field of life science microfluidic systems, in which not yet all of these components are 
suitable for mass production. Furthermore it allows quick prototype testing of different 
system configurations. 
 The microfluidic system in its present configuration enables comparison of changes 
between anatomically driven oxygen tensions in different compartments of the CF airways 
model, as well as full control and sensing of dissolved oxygen levels. By making the system 
compatible with common substrates such as microscope slides and multitier plates, it enables 
research staff to use standard laboratory equipment such as standard microscopes and 
multitier plate readers. 
 Furthermore, the microfluidic CF airways model permits to freely reconfigure 
connections between oxygen rich and oxygen depleted regions without bringing restrictions 
to the researcher in the design of experiments. It enables to mimic some different conditions 
and diseases in patients suffering from CF, such as clogging of the ostia in recurrent 
sinusitis
4, 75
 or the development of mucus plugs
76
 in the bronchioles. These experiments were 
not previously possible to perform in standard in vitro flow-cells models for biofilm studies. 





 Moreover, the use of this microfluidic system, instead of a CF airways animal model, 
is cheaper, safer and easier to handle for researchers. Importantly, it furthermore does not 
raise any ethical concerns, which is the case for the use of animal models in medical research. 
 We demonstrated the application of our microfluidic airway model for studying P. 
aeruginosa PAO1 under different oxygen levels in response to treatment with ciprofloxacin. 
We have in this way explicitly shown that the system is an asset in reliable and controllable 
biofilm evaluations for treatment with antibiotics at reduced oxygen concentrations. 
Importantly, such a system allows testing of very small volumes thereby minimizing the use 
of large amounts of expensive antimicrobials. PAO1 survival was shown to be highly 
dependent on the amount of oxygen available during the antimicrobial treatment. This 
corresponds very well with previous studies where it was shown that higher metabolic rate, in 




 We have shown that PAO1, under lowered oxygen concentrations, migrates towards 
higher oxygen concentrations even in nitrate supplemented media. Nitrate, which serves as 
final electron acceptor for anaerobic nitrate respiration (denitrification), does not seem to be 
favoured in the presence of oxygen.  This scenario can mimic the reinoculation of the lower 
respiratory tract, previously cleared by the antibiotic treatments, with bacteria from the 




 Next generation microfluidic systems should focus on in vivo-like 





stress factors, etc.) that would lead to more profound understanding of the bacterial role in CF 
pathology. 
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I. DETAILED DESIGN OF THE MICROFLUIDIC MODULES 
A. Multichannel peristaltic micropump 
The design of the multichannel peristaltic micropump was based on a previously 
reported system
1, 2
 with two major changes. In the new design (FIG. 1), the previously used 
poly(dimethylsiloxane) (PDMS) inlays were exchanged with thin-walled poly(vinyl chloride) 
(PVC) tubing with 0.63 mm internal diameter (medical grade, Thoma Fluid, Reichelt 
Chemietechnik GmbH + Co, Germany). The module (FIG. 2 a) was equipped with two 
separate micropumping units (FIG. 2 b). Each unit is capable of actuating up to 8 channels. In 
this way the capacity of each module is a total of 16 individual channels. The replacement of 
the PDMS inlays with PVC tubing allows us to skip the laborious process of the inlay 
moulding. Besides, PVC is a much more durable material than PDMS which makes the entire 
system more reliable. PVC is also known to be far more resistant to organic solvents and does 
not absorb hydrophobic agents from aqueous media as PDMS does. 
2 
 
FIG. 1 Exploded view of the multichannel peristaltic micropump. The type of material for each fabricated part is 
indicated in parenthesis, the acronyms stands for: SS – stainless steel, Al –aluminium, PEEK – poly(ether ether ketone), 






FIG. 2 Multichannel peristaltic micropump: (a) assembled micropumping unit, (b) module with two micropumping 
units facilitating 16 channels. 
B. Bubble trap module 
The array of bubble traps was designed according to previously reported work
3
. The 
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3 
and is equipped with a tapered opening on the top which serves as a vent. It can be closed or 






FIG. 3 Scheme of the bubble trap module: (a) image of the module, (b) cross-section of the bubble trap. 
 
C. Gas exchange module 
The gas exchange module allows oxygen saturation or desaturation of a desired 
culture media. The working principle of the module was communicated in our previous 
report
4
; here described briefly. It is based on the oxygen diffusion through gas permeable 
membranes made from PDMS. The culture media flows through the channels fabricated in 
PDMS. The channels were patterned with groves, similar as reported in our previous work
5
, 
in order to improve mixing of the media. The oxygen can diffuse from the culture media 
through the integrated membrane to the channel filled with oxygen scavenging liquid. The 
scavenger (sodium sulphite) reacts with the available oxygen. In the case, where the channels 
are filled with atmospheric air, the media is ensured to be saturated with oxygen. The PDMS 
inlays are enclosed in low gas permeability scaffold, made form PC, in order to separate the 















FIG. 4 Scheme of the gas exchange module: (a) exploded view of the module, (b) top view for on the module 
layers.  
D. Culture chambers module 
The culture chambers were designed to implement three different oxygen saturation 
environments (FIG. 5). The module consists of 8 chambers that can be interconnected by 
detachable PVC tubing. The volume of each chamber is 4.2 µl and the area for cells 
attachment equals to 12.7 mm
2
. Each chamber has additional tapered openings: one near its 
inlet and the other near its outlet (FIG. 6). The opening near the inlet of the chamber is used 
as the inoculation site. It can be opened and closed with a plug in the same manner as the 
vents in the bubble trap module. Instead of plugs, these openings can be equipped with 
fittings and tubing in order to interconnect two chambers with different oxygen 
environments.  
(a) (b) 
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channels for oxygen  
scavenger or 
atmospheric air 
PDMS inlays with 
channels for culture 
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PC slab with inlets 
and outlets 
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chambers for PDMS 
inlays 
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FIG. 5 The scheme of the cell culture chamber module facilitating different oxygen environments. 
 
 
FIG. 6 Cell culture chamber module: (a) scheme of the module with plugs and tubing interconnecting different 
chambers (for clarity of the image, only two interconnections are shown), (b) cross-section of the fitting and tubing. 
E. Check microvalve 
The working principle of the designed check microvalve was based on a previous 
report
6
. An array of 28 check microvalves was fabricated in 1 mm thick fluoroelastomer 
(FIG. 7 a), the same material that was used to fabricate the seals. The microvalves are 
clamped in-between the microfluidic modules and the platform. Each microvalve has a 
chamber with a 150 µm thick membrane (FIG. 7 b). In the membrane there are two holes 
with Φ = 500 µm spaced 1.59 mm from each other (centre to centre). Such spacing is large 
enough to cover the holes of the microfluidic modules when the membrane is in a relaxed 
PVC tubing 




state. Membrane deflection is only possible inward the chamber thereby only allowing media 
flow in one direction (FIG. 7 b). 
The purpose of the microvalve is to stop the backflow from the outlet tubing while 
allowing the user to inoculate the system using standard laboratory micropipettes. The 
membrane thickness, as well as the size and spacing between the holes, was optimised in 
order to get the opening pressure low enough enabling the use of a micropipette (typically 
below 1 kPa). 
 
 
FIG. 7 Check microvalve: (a) scheme of the module with 28 independent microvalves, (b) the working principle of 
the valve 
F. Modular platform 
The platform was designed to comply with the microplate footprint standards
7, 8
. This 
allows the device to be used together with a broad range of commonly used laboratory 
equipment such as microtitre plate readers and microscopes. The platform can be equipped 
with up to 4 modules with a microscope slide size (76x26 mm). Modules can be serially 
interconnected by 28 independent channels at the long edges of a module. Additionally, each 
module has 8 inlets/outlets at each of the short edges. The platform has 28 independent inlets 














FIG. 8 (A) Microfluidic modular platform, (B) gasket used to seal the modules with the platform 
Modules are attached to the platform by screws and nuts (FIG. 9) and all the 
microfluidic connections between the modules and platform are sealed by gaskets made from 
fluoroelastomer (FIG. 8 b).  
 
 
FIG. 9 Exploded view of the microfluidic platform with modules 
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ABSTRACT 
In this paper we report a microfluidic model to simulate the bronchi of a cystic fibrosis (CF) patient. The biochip is com-
prised of two cell culture chambers separated by a membrane. On top of the membrane an alginate hydrogel is formed in or-
der to simulate the thick mucus layer spotted in a CF bronchi. In the bottom chamber a monolayer of epithelial cells are cul-
tured to simulate the bronchi tissue. By inoculating the pseudomonas aeruginosa PAO1 strain to the hydrogel layer one can 
simulate bacterial infections commonly subjected to the CF patient, and the system can be applied for the studies on antibi-
otic treatment of bacterial infection related to CF. 
 
KEYWORDS: cystic fibrosis, bronchi, model, microfluidic, microfabrication  
 
INTRODUCTION 
Here we report work towards a microfluidic system that simulates the cystic fibrosis (CF) bronchi and the impact of the 
mucus layer on the treatment of bacterial infections. The classical way of studying CF related bacterial infections, primarily 
Pseudomonas aeruginosa, is by growing them in flow-cell systems [1,2]. In these flow cells bacteria are capable of forming 
biofilm, as in the airways, and can then be monitored using confocal microscopy [3]. However, the bacteria in CF patient 
bronchi are not subjected to a constant flow of nutrients as in flow-cell based systems. Instead they embed in the mucus that 
covers the bronchi epithelia through which the nutrients and metabolites are diffusing (Figure 1A). Moreover, the content of 
the mucus highly affects bacterial attachment and biofilm growth. Consequently, the biological response for biofilm drug 
treatments can be altered by changes in the mucus [4]. 
 
THEORY 
While the human primary bronchi have a relatively large lumen diameter (order of magnitude of centimetres), the respira-
tory bronchioles are about 1 mm in diameter. Therefore, in order to be able to mimic it as closely as possible to the in vivo 
conditions, a microfluidic system is required. The presented microfluidic model of the CF bronchi consists of two chambers 
separated by a microporous membrane (Figure 1B). The membrane is the underlying support for a hydrogel, which mimics 
the mucus layer in the CF bronchi. The chamber below the membrane simulates the artery and supplies the media with nutri-
ents and transports the metabolites. These compounds are provided further to the top chamber by diffusion through the mem-
brane and hydrogel. On the bottom side of the membrane epithelial cells are cultured while on the top part of the hydrogel the 
bacteria cells are inoculated. In order to simulate antibiotic treatment, the media in the bottom channel can be supplemented 
with drugs. This supplementation can be performed in cycles, which would mimic drug dosage to CF patients. The introduc-
tion of the human sub-bronchial gland cell line (Calu-3) without the layer of hydrogel can simulate the normal bronchi while 
the same system but with the hydrogel can simulate the bronchi of CF patients. 
 
 
Figure 1: (A) Bronchi of the healthy individual and CF patient. (B) The microfluidic model of CF epithelia. 
 
EXPERIMENTAL 
The biochip (Figure 2) was fabricated in polycarbonate (PC) by micromilling (Mini-Mill/3PRO, Minitech Machinery 
Corp., USA). The PC membrane with 0.45 µm pores was inserted between the milled parts and bonded (tetrahydrofuran va-
pours assisted bonding, 3.5 MPa, 50°C). 
A B 
The hydrogel layer was formed by introduction of 0.3% sodium alginate to the top chamber and 0.1 M CaCl2 solution to 
the bottom chamber. The thickness of the hydrogel was controlled by focusing the sodium alginate stream with PBS (Figure 
3). In order to visualise the hydrogel thickness, the sodium alginate was stained with 6-aminofluorescien according to the re-
ceipt by Strand et al. [5]. 
The biochip was thoroughly washed with PBS followed by cell culture media (DMEM, 10% FBS). Calu-3 cells with a 
density of 5·105 cells/ml were seeded on the membrane in the bottom chamber. 
The inoculum (OD600 = 0.01) of  the P. aeuruginosa PAO1 strain tagged with GFP was introduced into the upper cham-
ber to mimic the bronchi infection (Figure 5). The culture was performed for 3 days in the incubator (5% CO2, 37°C) 




Figure 2: (A) The 3D model of the biochip consist from 3 layers. (B) Fabricated and bonded biochip. 
 
RESULTS AND DISCUSSION 
The obtained thickness of the hydrogel layer in the top chamber was 270±20 µm (Figure 4). The focusing buffer was ac-
tively pushing the sodium alginate through the membrane, therefore a thin (below 100 µm) layer of hydrogel was formed on 




Figure 3: Numerical simulation of the formation of hydro-
gel layer in the top chamber. The thickness of the layer can be 
controlled by changing  the ratio between the sodium alginate 
and focusing buffer flow rates. 
 
Figure 4: Confocal image of the hydrogel formed 
in the biochip. Green fluorescence  represents calcium 
alginate and the gap between is the porous PC mem-
brane. The alginate was stained according to [5]. 
 
The Calu-3 cells were cultured in the bottom chamber of the system. After reaching the 70% of confluency (3rd day of 
culture) the P. aeruginosa PAO1 strain was inoculated to the upper chamber. The bacteria were allow to form biofilm in the 
hydrogel for 3 days (Figure 5A). The Calu-3 cells were stained with live/dead stain (Calcein AM/PI) in order to visualise the 
viable and necrotic epithelia (Figure 5B). 
The future application of the presented CF bronchi model lies in simulation of antibiotic treatment of CF related bacterial 
infection. The simulation of the treatment can be performed by supplementation of the culture media with drugs. The results 




Figure 5: (A) Confocal image of the P. aeruginosa PAO1 strain tagged with the GFP growing in the hydrogel. 




We have successfully designed and fabricated a microfluidic biochip which can be used as a model of the CF bronchi. 
The co-culture of the Calu-3 cells and P. aeruginosa PAO1 strain using the constructed biochip was shown. By alternating 
the thickness of the hydrogel layer, the presented model can be used in the future for comparative studies of the antibiotic 
treatment of bacterial infections in normal and CF patients. This system is a significant advancement in the mimicking of the 
airways function on the chip reported earlier [6]. 
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Abstract 
Here we present our work on a microfluidic device that mimics the bronchi in people suffering 
from cystic fibrosis. To imitate the mucus of the diseased bronchi, a 200 µm thick hydrogel is formed 
in a controlled manner on the top of a microporous membrane. This membrane is also the support 
for the attachment of the epithelial cells, to mimic the bronchial tissue. In the hydrogel, P. 
aeruginosa are inoculated to recreate the scenario of bacterial infections. Compared to flow- or 
static cell culture systems our microdevice allows better imitation of the nutrient supply through the 
bronchial bio-layers.   
Eventually, nutrient driven development of bacterial growth and the viability of the epithelial 






Many severe infections in humans affect the airways. Different types of pneumonia are 
major causes of morbidity and mortality in patients with various immuno compromising conditions. 
Ineffective anti-microbial therapies often fail to remove the infecting microbes. One of the most 
severe genetic diseases affecting the human airways, is cystic fibrosis (CF) [1]. 
CF patients suffer from a genetic defect in the CFTR (Cystic Fibrosis Transmembrane 
Regulator) gene that hinders the salt transport over the cell membranes [2]. This leads to high salt 
concentration in the epithelia and low concentration in the mucus, which stops water from 
rehydrating it [3]. The mucociliary clearance mechanism is impaired and results in frequent 
infections in the CF airways with increased risk of pneumonia[4]. Since the bacteria can infect the 
airways unhindered and thrive in the CF mucus, the immune system tries to eradicate the increasing 
infecting populations. The success of the immunological battery is highly reduced since the bacteria 
are embedded in mucus and more or less recalcitrant to the attacks [5]. Instead the lung tissue is 
gradually damaged by the ongoing immunological exposure [6], eventually leading to massive 
pulmonary deficiency and death.  
Several works exist on the mimicking of the human airways using microsystems: some focused 
on the reproduction of the mechanical function of the alveoli [7-9] while others were more oriented 
on the regulation of mucin production by NCI-h292 epithelial cells [10]. Huh et al. [7] proposed 
recently a model of the vacuoles in the lung. In this work the phagocytosis of planktonic Escherichia 
coli cells by neutrophils on the epithelial surface was shown.However, according to the author’s best 
knowledge there is no system that mimics the bacterial habitats in the CF bronchi.  
 
Microfluidic model of the cystic fibrosis bronchi 
 
The classical way of studying CF related bacterial infections, primarily Pseudomonas 
aeruginosa, is by growing them in static systems [11] or in flow systems [12-14]. In the static culture 
systems, the amount of nutrients provided to the cells is decreasing in time as the consequence of 
bacterial consumption. Consequently, in such a system the media have to be renewed regularly but 
render a system with higher throughput than the flow cell culture. In the flow cells, nutrients and 
waste are constantly being exchanged to the biofilm forming bacteria. However, the bacteria in CF 
bronchi are not subjected to a constant flow of nutrients. Instead they are embedded in the mucus 
that covers the bronchi epithelia through which the nutrients and metabolites are diffusing (Fig. 1).  
The human primary bronchi have relatively large lumen diameter (in the order of 
centimeters), whereas the respiratory bronchioles can be smaller than 1 mm in diameter [15]. 
Therefore, in order to respect this order of dimension a microfluidic system is required, which is the 




Fig. 1.  The bronchus of a CF patient: Cross section and microfluidic dynamics of the CF bronchi 
Materials and methods  
Design and procedure 
The in vitro CF bronchus consists of a chamber divided into two parts (bottom chamber - top 
chamber) by a porous membrane (Fig. 2). The membrane is used as a solid support for a hydrogel on 
top and for attachment of epithelial cells beneath. The hydrogel mimics the mucus residing inside 
the bronchi and epithelial cells the bronchial epithelial tissue. In the top chamber, bacteria can be 
inoculated to simulate a bacterial infection taking place in chronically infected CF patients [16]. The 
bottom chamber mimics an artery, provides media with nutrients and transportation of the 
metabolites. These compounds are supplied further to the top chamber by diffusion through the 









The immitation of the in vitro bronchus model, as described above, followed a specific 
procedure: 
To ensure the sterility inside the device, the entire system was flushed for 30 minutes with 
70% ethanol and then flushed for another 30 minutes with 5% hydrogen peroxide (Sigma Aldrich 
A/S, Denmark).  
The hydrogel (calcium alginate) was formed by a chemical reaction on top of the membrane. 
Following the formation of the desired thickness of alginate gel, epithelial cells were injected in the 
bottom chamber as described below in the “Epithelial cell culturing” section. Here the cells were 
allowed to adhere to the membrane as the device was orientated in an upside down position (top 
chamber down and bottom chamber up) for 24 hours. Once the bronchial cells reached a confluence 
of 90% (the 2nd day after seeding), bacteria were inoculated in the top chamber to recreate the 
scenario of a bacterial infection. 
Fabrication of the microfluidic chip 
The main feature of the chip is the chamber in the center where the CF bronchus is mimicked. 
It has an elliptic shape with a perigee of 2 mm, an apogee of 21 mm and a thickness of 2 mm. This 
shape enables to easily remove the bubbles that may get inside the device. The membrane dividing 
the chamber is a hydrophilic poly(tetrafluoroethylene) (PTFE) membrane (BCGM 000 10, Millipore 
A/S, Denmark). It is 50 µm thick with pores of 0.4 µm diameter. Two inlets and two outlets of 0.5 mm 
in diameter are connected to the upper chamber by a 1 mm thick and 0.5 mm wide channels, the 
same for the bottom chamber (Fig. 3). The different inlets are used to inject different solutions (see 
the “Hydrogel formation” section). In practice only one of the outlets from each channel is useful but 












Fig. 3 Top left: Picture of the microfabricated device. Top right: Exploded view of the microfluidic chip.  
Bottom: Sketches of the top and the side and view of the two assembled parts of the microfluidic chip. 
 
Each chamber with inlets, outlets and channels (except for the porous membrane) were 
fabricated by micromilling (Mini-Mill/3PRO, Minitech Machinery Corp., USA) in two polycarbonate 
(PC) slides (Nordisk Plast A/S, Denmark). Each of the slides has the dimensions of a microscope slide 
(76x26 mm) with a thickness of 3 mm.  
The polycarbonate constituting the cover of the chamber was milled down to 0.5mm in 
thickness to allow the use of high magnification microscope objectives for bacteria observation 
within the culture chamber (top chamber). Both sides of the PTFE membrane were exposed to air 
plasma (70 W, 6 mbar) for 30 s to later facilitate the attachment of the epithelial cells. The PC slides 
were exposed to tetrahydrofuran (THF) vapors for 5 min. Eventually, the PTFE membrane was 
inserted between the two polycarbonate slides followed by thermal bonding (using bonding press 











A 100 mM CaCl2 solution (Sigma-Aldrich Denmark A/S) was used to cross-link a 0.5% (w/v) 
solution of sodium alginate (Sigma-Aldrich Denmark A/S) in order to form the calcium alginate 
hydrogel. A phosphate buffer saline (PBS) solution (Sigma-Aldrich Denmark A/S) was used as buffer. 
The hydrogel formation within the chamber was performed in the following order (Fig. 4): 
1. Perfusion of both chambers with the PBS solution for 6 min at a flow rate of 10 ml·h-1. This 
ensures that all chemicals previously used for sterilization are washed out. 
2. Sodium alginate is perfused through the top chamber at a flow rate of 5 ml·h-1. In the 
bottom chamber PBS is kept at the same flow rate of 5 ml·h-1. This procedure is carried out 
for 6 min. 
3. The flow of PBS in the bottom chamber is then exchanged with a solution of CaCl2 at a 
flow rate of 5 ml·h-1 for 10 min. In this way, calcium ions can diffuse through the 
membrane to cross-link with the sodium alginate to form the gel.  
4. After the 10 min, the flow of sodium alginate in the top chamber is exchanged with a flow 
of PBS at 5 ml·h-1 for 10 min to remove weakly cross-linked alginate. The diffusion of 
calcium ions going on strengthens the hydrogel.  




Fig. 4. Process for the hydrogel formation. 
In order to determine the thickness of the hydrogel, experiments with stained sodium alginate 
were conducted. Aminofluorescein was covalently bound to the α-L-guluronate residues constituting 
the alginate by following a particular staining technique [17]. However, no stained alginate was used 
in the system while cell culturing was performed inside the device. 
Epithelial cell culturing  
Calu-3 cells (Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark) were 
cultured in 25 cm² tissue culture flasks (Sarstedt Inc., USA) with DMEM (Dubelcco’s Modified Eagle 
Medium) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) , 50 µg·ml-1 of Gentamicin and 
100 U·ml-1/100 µg·ml-1 of Penicillin/Streptomycin. The media was changed every second day. Once 
the cells reached a stage of 90% confluence they were passaged by using Trypsin-EDTA solution for 
10 min at 37°C. 
From the harvested cells a concentration of 8·105 cells·ml-1 was prepared for seeding inside 
the chip using a syringe. Cells were inoculated in the bottom chamber where the cells were allowed 
to adhere to the membrane. This was done by placing the device in an upside down position (top 
chamber down and bottom chamber up) for 24 hours in a cell culture incubator (5% CO2, 37°C) 
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with a continuous media flow of 0.3 ml·h-1 for both chambers until a cell confluence of about 90% 
was obtained.  
Calu-3 viability was checked by using a 40 nM concentration of Calcein AM to stain living cells 
and a 1.5 µM concentration of Propidium Iodide (PI) to stain dead cells. Calcein and PI respectively 
stain the cells with a green and red fluorescence as shown in Fig. 6. 
All chemicals, unless stated otherwise, were purchased from Sigma-Aldrich Denmark A/S. 
Bacteria cell culture 
The P. aeruginosa laboratory strain PAO1 was used in all experiments involving bacterial 
cultivation or co-cultivation [18]. PAO1 was grown at 37°C in shaken conditions overnight in Luria 
Bertani (LB) media. Preparation for inoculation was done by diluting to an OD600 of 0.01 in 0.9% NaCl. 
500 µL was inoculated in the top chamber and the cells were allowed to attach without any media 
flow delivered through the system for an incubation period of 1 hour. Following the incubation, the 
flow was resumed at 0.3 ml·h-1 in DMEM media with 10% of FBS without antibiotics. 
PAO1 was expressing the green fluorescent protein (GFP) tagged by the miniTn7 insertion 
method [19].  
 
Microscopy and data analysis 
A confocal laser scanning microscope (CLSM) (Leica TCS SP5 from Leica Microsystems A/S, 
Denmark) was used to acquire images of cells and hydrogel. Detectors and filters were set for 
monitoring Calcein-, GFP- and PI fluorescence. Images of Calu-3 cells and hydrogels were performed 
with a 10x/0.3 air objective. Bacteria were imaged with a 63x/0.70 air objective. 
In order to evaluate the thickness of the hydrogel, the pixels with an intensity higher than 25% 
of the maximum intensity value were taken into consideration. 
All the pictures were treated and analyzed by using the Imaris 7.1.1 software package 
(BITPLANE AG, Zürich, Switzerland).  
Results 
Hydrogel layer 
The thickness of the hydrogel layer depends on the time in which the Ca2+ ions are able to 
diffuse into the top chamber. The longer they can diffuse, the further up they are able to cross-link 
the alginate in the top chamber. Thus, controlling the time of diffusion allows better control of the 
gel thickness that one wants to achieve. A thickness of about 200 µm was chosen for imitation of the 
mucus layer. To obtain this specific thickness, 10 min of diffusion were required during the 3rd step of 
the protocol of “Hydrogel formation” section (Fig. 4). Confocal imaging revealed that the formed 
hydrogel was 230 µm (± 20 µm) thick (Fig. 5A). 
During the optimization of the hydrogel formation, several experiments allowed the 
determination of a diffusion time range: 5 min of Ca2+ diffusion lead to an approximate hydrogel 





   
Fig. 5. A. Stained hydrogel characterized by CLSM B. 100 µm thick hydrogel obtained after 5 min of Ca
2+
 diffusion. C. Top 
chamber completely filled after 15 min of Ca
2+
 diffusion. 
Co-culture of the Calu-3 epithelial cells and the P. aeruginosa PAO1 
strain 
The growth of the Calu-3 cells was successfully performed inside the microfluidic device. The 
cells reached a confluence of about 90% in 2 days (out of the 24 hours needed for attachment). To 
check the viability the cells were stained with Calcein AM and PI. Confocal microscopy revealed that 
less than 1% of the cells were necrotic after 3 days of culturing (Fig. 6). This resembles normal Calu-3 
culturing viability in a regular tissue culture flask (data not shown).   
 
 
Fig. 6. Viability of the epithelial layer after 3 days of culture. 
 
PA01 formed biofilm on top and inside the hydrogel layer (Fig. 7). Because the pores in the 
calcium alginate are much bigger (raging from tens to hundreds of microns) [20] than the size of 
bacteria, single bacteria could easily get inside and start forming microcolonies. 
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Fig. 7. 3D visualization of PA01-GFP embedded in the calcium alginate matrix at day 5. 
Discussion 
We demonstrated a fast and easy way to integrate the PTFE porous membrane. No specific 
setup needs to be used or optimized if we compare to in situ membrane integration [21]. No 
alignment or specific treatment was required for this membrane in regards to the bonding step. The 
surface treatment of polycarbonate parts using THF vapors and the thinness of the membrane (50 
µm) enabled strong and durable bonding, across the membrane, between the PC slides. 
The term “hydrogel thickness” used here includes the membrane size, the thickness of the gel 
below and above the membrane. The thickness below the membrane is though negligible (< 2 µm). 
Indeed because of the low diffusion coefficient of the alginate [22] a very low amount of it diffuses 
beneath the membrane and transforms into calcium alginate. However, the alginate beneath did not 
affect the attachment and development of the Calu-3 cells. 
As mentioned in the introduction, there are two main ways to culture cells: the flow cell 
culture [12-14] and the static cell culture [11].  
However, these types of culture do not reflect the conditions in which bacteria can develop in 
niches of the human body as in the severe case of the CF airways. As explained in the microfluidic 
model of the CF bronchi, the nutrients are provided to the bacteria by diffusion across different bio-
layers from a cyclic flow (i.e. the blood stream). With this in mind, the proposed microfluidic system 
represents a significant step forward in the study of lung infections since such mimicry has not been 
reported in the literature yet. 
Moreover, this in vitro chip makes microscopy observation possible which is not the case when 
using in vivo models. In addition, there is a very strong pressure from public societies, states, 
international organizations and from the industry to replace, reduce and refine the research 
conducted with the use of animals [23, 24]. This strategy is known as the “3 Rs” principle [25, 26]. 
Therefore, our developed microfluidic system can play an important role in the replacement of 
animal models used for medical experiments related to for instance CF. 
The chip provides a new way to simulate bacterial infections in the airways. In the future, it 
can also provide a novel bio-mimetic approach regarding drug treatment. Antibiotics can be 
delivered in two different manners. One would be to use a gaseous form to be delivered to the 
upper chamber to reproduce treatment using spray antibiotics. On the other hand, a liquid form of 





The device offers great opportunities to improve the bio-mimicry. The biological resemblance 
between the mucus and the hydrogel can be enhanced by altering the composition of additives as 
mucins and DNA [27, 28]. Such improvement will offer a better model for studying the response of a 
biofilm community to drug treatments [29]. In addition, the chip could be coupled with our previous 
system [30] to recreate the different type of dissolved oxygen conditions inside the airways. Finally 
our device brings great promises in the mimicry of other human organs where the mucus is involved, 
e.g. the gut or the stomach.  
Summary & Conclusion 
In this paper, we have demonstrated the fabrication of a robust and reliable microfluidic 
device. This device enables the setup of an in vitro microfluidic chip based mimicry of an infected 
human CF bronchus. The recreation of the scenario leading infection of the bronchi is based on a 
new approach of bacteria culture to be closer to their in vivo growth: nutrients diffuse through 
different bio-layers to feed the bacteria embedded in the mucus-like matrix. 
Inside the system, the imitation of the CF bronchus was performed by incorporating Calu-3 
cells and a hydrogel, beneath and on top of a microporous membrane, respectively. The formation of 
the hydrogel was controlled in order to mimic a mucus layer as thick as 200 µm. Calu-3 cells, 
mimicking the epithelial tissue, were cultured for 3 days to reach 90% of confluence. A bacterial 
infection was simulated by inoculating P. aeruginosa PA01 in the hydrogel. The formation of 
bacterial microcolonies was observed 2 days later. Confocal microscopy allowed in vitro imaging of 
the different cells to assess of their growth and viability. 
For future experiments, such device can enable to simulate and observe the biofilm response 
to drug treatments taken by oral or intravenous ways. Also, mucin and DNA could be added in the 
hydrogel to study the impact of the mucus composition on the bacterial infection. 
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14 Concluding	  remarks	  and	  key	  findings	  
In	  vitro	  systems	  are	  essential	  for	  our	  possibility	  to	  gain	  insight	  into	  the	  expressed	  genetic	  makeup	  of	  microbes.	  The	  airways	  of	  cystic	  fibrosis	  patients,	   is	  a	  habitat	  in	   which	   inhaled	   micro-­‐organisms	   battle	   for	   survival	   against	   other	   micro-­‐organisms,	  defense	  mechanisms	  and	  treatments	  with	  antimicrobial	  compounds.	  
P.	   aeruginosa	   has	   persisted	   in	   the	   CF	   community	   for	   decades	   and	   has	   evolved	  into	  a	  successful	  colonizer	  of	  the	  CF	  airways.	  The	  environmental	  shifts	  contribute	  to	   the	  diversification	  of	   the	  bacteria	   as	   they	  adapt	   to	   the	   specific	  niches	  of	   the	  airways.	   The	   mucus	   of	   the	   CF	   lung	   in	   combination	   with	   the	   biofilm	   mode	   of	  growth	  drives	  adaptation	  to	  life	  in	  varying	  oxygen	  tensions.	  	  The	   airway	   environments	   and	   physiological	   differences	   between	   CF	  patients	  and	  healthy	  individuals	  have	  been	  the	  main	  inspiration	  for	  this	  thesis.	  	  	  	   The	  versatility	  of	  the	  flow	  cell	  system	  was	  demonstrated	  to	  comply	  with	  several	  microbial	  organisms	   (paper	   I).	   I	   successfully	  produced	  a	  visual	  method	  publication	  in	  order	  to	  simplify	  the	  understanding	  of	  the	  highly	  complex	  flow	  cell	  biofilm	  system.	  The	  flow	  cell	  system	  was	  adapted	  to	  support	  S.	  cerevisiae	  biofilm	  formation	   by	   using	   Polyvinyl	   coverslips.	   S.	   cerevisiae	   biofilm	   formation	   is	  normally	  observed	  on	  Poly-­‐styrene	  surfaces,	  this	  polymer	  does	  however	  have	  a	  tendency	   for	   high	   autofluorescence	   and	   does	   not	   conform	   with	   confocal	  microscopy	  [310].	  The	   flow	  cell	   system	  was	  shown	  to	  be	  a	  good	   in	  vitro	  model	  system	  for	  studying	  fungal	  biofilms	  with	  S.	  cerevisiae.	  Nonpathogenic	  S.	  cerevisiae	  strains	  can	  be	  used	  to	  found	  the	  genetic	  understanding	  for	  biofilm	  formation	  by	  pathogenic	   Candida	   species.	   Candida	   albicans	   and	   Aspergillus	   fumigatus	  infections	   frequently	   arise	   in	   hospitalized	   patients	   with	   biofilms	   located	   on	  medical	   devices	   and	   often	   isolates	   in	   sputum	   samples	   from	   CF	   patients	   [132,	  311].	  The	   flow	  cell	  system	  could	  contribute	  to	  the	  understanding	  of	  underlying	  molecular	   mechanisms	   of	   biofilm	   formation,	   resistance	   mechanisms,	   cell-­‐cell	  communication	   for	   Candida	   infections	   and	   interactions	   with	   CF	   associated	  bacterial	  pathogens	  [312].	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   In	   this	   thesis	   work,	   an	   immense	   amount	   of	   work	   has	   gone	   into	   the	  development	  and	  not	   least	  prototype	  testing	  that	  has	  been	  the	  groundwork	  for	  the	  presented	  systems.	  The	   initial	  approach	   in	  developing	   the	  new	  systems	   for	  investigating	   bacterial	   biofilms	   originated	   form	   my	   work	   with	   the	   flow	   cell	  systems	   (presented	   in	   paper	   I)	   and	   the	   knowledge	   of	   the	   generated	   oxygen	  niches	   in	   the	   CF	   airways.	   A	   microfluidic	   approach	   was	   employed	   to	   fabricate	  devices	   that	   would	   enable	   control	   of	   dissolved	   oxygen	   concentrations	   in	   the	  growth	   medium	   for	   microbial	   biofilm	   studies.	   The	   initial	   approach	   was	   to	  develop	   a	   microfluidic	   chip	   that	   would	   create	   a	   dissolved	   oxygen	   gradient	  through	  the	  entire	  growth	  chamber.	  The	  system	  was	  designed	  in	  a	  layer-­‐by-­‐layer	  fashion	   (paper	   II	   and	   III).	   The	   incorporation	   of	   a	   gas	   permeable	   membrane	  enabled	   the	   utilization	   of	   an	   oxygen	   scavenging	   liquid	   to	   generate	   the	   desired	  oxygen	  gradient	  in	  the	  growth	  chambers.	  The	  control	  of	  the	  oxygen	  environment	  was	  merely	  managed	  by	  the	  flow	  rate	  of	  the	  biofilm	  media.	  Oxygen	  sensing	  was	  enforced	  by	  incorporation	  of	  an	  oxygen	  sensitive	  sensor	  in	  a	  thin	  PDMS	  film	  on	  the	   cover	   glass.	   The	   oxygen	   photoluminescence	   lifetime	   measurements	   were	  done	   with	   a	   microtiter	   plate	   reader,	   as	   the	   chambers	   were	   mapped	   to	   the	  coordinates	   of	   a	   384	  well	  microtiter	   plate.	   The	   design	   of	   the	  microfluidic	   chip	  was	   intended	   to	   comply	   with	   most	   laboratory	   settings	   and	   equipment.	  Monitoring	  PAO1	  biofilm	  formation	  under	  the	  set	  growth	  conditions	  proved	  the	  systems	   functionality.	   PAO1	   responded	   to	   the	   low	   oxygen	   environment	   by	   a	  reduced	  number	  of	  attaching	  cells.	  As	  the	  culture	  media	  only	  supported	  growth	  with	  oxygen	  as	  electron	  acceptor,	  PAO1	  responded	  with	  an	   immense	  reduction	  in	  biomass	  compared	  to	  atmospheric	  saturated	  culture	  media.	  Analyzing	  biofilms	  formed	  in	  the	  system	  under	  lowered	  oxygen	  availability	  does	  however	  include	  a	  variable	   that	   needs	   to	   be	   taken	   into	   consideration,	   as	   the	   local	   nutrient	   levels	  also	  influence	  the	  biofilm	  formation.	  	  	   To	  create	  a	  system	  that	  could	  mimic	   the	   individual	  oxygen	  niches	  of	   the	  CF	   airways,	   a	   modular	   microfluidic	   system	   was	   developed	   (paper	   IV).	  Individually	  based	  functionalities	  to	  each	  module	  generates	  a	  united	  system	  that	  incorporate	   e.g.	   bubble	   traps,	   grow	   chambers,	   micro-­‐mixer	   and	   an	   oxygen	  scavenging	   module.	   As	   individual	   growth	   chambers	   are	   designed	   to	   be	  interconnected,	   the	   system	   enables	   documentation	   of	   migration	   patterns	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following	   antimicrobial	   treatment,	   as	   with	   the	   presented	   ciprofloxacin.	   The	  presented	   system	   is	   set	   for	   efficient	   evaluations	   of	   the	   effects	   of	   microbial	  responses	  and	  development	  in	  oxygen	  specific	  niches.	  The	  system	  operates	  with	  requirements	   of	   small	   volumes	   and	   thereby	   only	   consuming	   small	   amounts	   of	  the	   tested	   antimicrobials,	   which	   is	   highly	   desirable	   when	   expensive	  antimicrobial	  candidates	  are	  tested.	  Compared	  to	  the	  systems	  presented	  in	  paper	  II	  and	  III,	  the	  modular	  based	  system	  eradicates	  the	  variable	  of	  nutrition	  levels	  as	  each	   specific	   chamber	   only	   differs	   in	   oxygen	   concentrations.	   The	   inter-­‐connections	  of	   the	   system	  can	   resemble	   the	  believed	   scenario	  of	   reinfection	  of	  the	  lower	  airways	  from	  the	  sinuses	  following	  antibiotic	  treatments	  [133].	  	  	   The	   most	   significant	   CF	   defining	   consequences	   is	   the	   accumulation	   of	  viscous	  mucus	  in	  the	  airways	  of	  the	  patients,	  generating	  a	  3D	  environment	  that	  
in	  vivo	  would	  support	  antibiotic	  tolerance	  and	  evasion	  of	  the	  immune	  system.	  To	  mimic	   this	   phenomenon,	   a	   device	   to	   simulate	   the	   mucus	   covered	   bronchial	  epithelia	  was	  developed	  (paper	  V	  and	  VI).	  The	  system	  enables	  epithelial	  cells	  to	  be	  cultured	  on	  the	  integrated	  membrane	  separating	  the	  two	  chambers	  within	  the	  model	   chip.	   Furthermore,	   a	   mucus	   substitution	   matrix,	   in	   the	   shape	   of	   an	  alginate	   hydrogel,	   was	   successfully	   introduced	   and	   stirred	   to	   form	   on	   the	  “airway”	  side	  of	  the	  membrane.	  The	  system	  enables	  culturing	  of	  both	  epithelial	  and	  bacterial	  cells	  as	  they	  occur	  in	  the	  CF	  airways.	  	  	  	   The	   presented	   models	   can	   be	   considered	   as	   a	   giant	   leap	   forward	   in	  developing	   in	   vitro	  models	   for	   CF	   research	   that	   allow	  biofilm	   investigations	   in	  more	   CF	   relevant	   oxygen	   niches.	   A	   further	   development	   that	   would	   allow	   a	  modular	   based	   “bronchi	   chip”	   to	   be	   combined	   with	   the	   oxygen	   scavenging	  module,	  would	  be	  a	  substantial	  contribution	  the	  CF	  related	  biofilm	  research.	  	  The	  presented	  systems	  would	  desirably	  answer	  questions	  about	  adaptability	  to	  specific	  generated	  niche	  environments.	  An	  intriguing	  experimental	  setup	  would	  be	  more	   long-­‐term	  experiments	  with	  boosted	  antibiotic	   treatments	   to	  evaluate	  the	   phenotypic	   diversification	   in	   the	   different	   oxygen	   compartments	   and	  migration	  patterns.	  Furthermore,	   it	  would	  be	   interesting	   to	   investigate	  mucoid	  vs.	   non-­‐mucoid	   strains	   in	   the	   micro-­‐compartmental	   setups	   with	   possible	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introduction	   of	   white	   blood	   cells	   to	   evaluate	   their	   efficiency	   towards	   the	  different	  phenotypes.	  	   The	  developed	  systems	  can	  bring	  a	  substantial	  contribution	  to	  studies	  of	  a	  wide	   range	   of	   biofilm	   forming	   microbes.	   The	   bronchi	   chip	   is	   an	   interesting	  system	  that	  can	  be	  used	  to	  mimic	  other	  epithelial	  linings	  as	  the	  stomach	  and	  the	  gut.	   Another	   interesting	   setup	   would	   be	   a	   microfluidic	   interpretation	   of	   the	  stomach	   lining	   for	  Helicobacter	  pylori	   investigations	   to	  evaluate	   the	   interaction	  and	  the	  disruption	  of	  the	  gastric	  mucosal	  epithelium.	  	  	  	   The	  systems	  presented	  in	  this	  thesis	  have	  circumvented	  the	  problematic	  scenario	   of	   generation	   an	   observable	   and	   controllable	   oxygen	   environment.	   In	  future	   the	   development	   of	   microfluidic	   systems	   to	   mimic	   human	   tissues	   will	  probably	   in	   the	   future	   replace	  a	   large	  part	  of	   animal	   tests	   and	   lead	   to	   cheaper	  methods	  for	  drug	  screenings.	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